---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description. Covers Product description and Place of product in therapy. 301 evidence topics quoted from 149 sources."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description

<a id="product-information-and-disease-description"></a>

## 2 Product Information and Disease Description

<a id="heading-2.1"></a>

### 2.1 Product Description

<a id="heading-2.1.1"></a>

#### 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

##### Regulatory status: Submission planned; U.S. accelerated approval application planned if the AMPLITUDE interim analysis, with data expected in early 2027, is positive

> “Having completed enrollment in the interim analysis (IA) cohort of the AMPLITUDE pivotal study last year, Vertex has now completed full enrollment. Vertex remains on track to conduct the pre-planned IA for potential U.S. accelerated approval after the IA cohort reaches 48 weeks of treatment and to share data from the IA in early 2027.”

Source: [Vertex Pharmaceuticals third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000287/ex-991_q32026.htm)

> “We are on track to conduct the pre-planned interim analysis for potential U.S. accelerated approval once the interim analysis cohort has been treated for 48 weeks and to share data from the interim analysis in early 2027.”

Source: [Vertex Pharmaceuticals Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000291/vrtx-20260930.htm)

> “Vertex is on track to share data from the pre-planned interim analysis (IA) of AMPLITUDE in early 2027 once the IA cohort reaches 48 weeks of treatment. If positive, the data could form the basis for potential accelerated approval in the U.S.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

> “potential to file for accelerated approval in the U.S. if 48-week interim analysis data positive”
> “If positive, the IA will serve as the basis for Vertex to seek accelerated approval of inaxaplin in the U.S.”

Source: [Vertex Pharmaceuticals press release, kidney portfolio advancements (2025)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-key-advancements-across-kidney-portfolio)

<a id="topic-2.1.1-2"></a>

##### Launch

No evidence found.

<a id="topic-2.1.1-3"></a>

##### Authorisation status in the European Union: not authorised

| Field | Quoted record |
| --- | --- |
| Investigational medicinal product | “VX-147 film-coated tablet” |
| Active substance | “Inaxaplin” |
| Authorisation status | “Not authorised” |
| Medicine status in the EU | “No EU-wide authorisation listed” |

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

<a id="topic-2.1.1-4"></a>

##### Pivotal AMPLITUDE trial: full enrollment completed in 2026

> “We have completed full enrollment in the AMPLITUDE pivotal clinical trial evaluating inaxaplin.”

Source: [Vertex Pharmaceuticals Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000291/vrtx-20260930.htm)

> “Vertex has completed full enrollment in the Phase 2/3 AMPLITUDE study of inaxaplin in people with severe proteinuria and no other kidney disease-causing comorbidities.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="topic-2.1.1-5"></a>

##### Interim analysis timing: company guidance from January 2025 to November 2026

> “Vertex expects to complete enrollment in the interim analysis cohort in 2025 for potential accelerated approval in the U.S., once this cohort reaches 48 weeks of treatment.”

Source: [Vertex Pharmaceuticals press release, pipeline and business updates (2025)](https://news.vrtx.com/news-releases/news-release-details/vertex-provides-pipeline-and-business-updates-advance-upcoming-0)

> “In September, Vertex completed enrollment in the interim analysis cohort of the AMPLITUDE Phase 2/3 trial of inaxaplin in patients with primary AMKD and will conduct the pre-planned interim analysis once this cohort reaches 48 weeks of treatment. Vertex expects to share data from the interim analysis in late 2026 or early 2027.”

Source: [Vertex Pharmaceuticals press release, pipeline and business updates (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-provides-pipeline-and-business-updates-advance-upcoming-1)

> “Vertex remains on track to conduct the pre-planned IA for potential U.S. accelerated approval after the IA cohort reaches 48 weeks of treatment and to share data from the IA in early 2027.”

Source: [Vertex Pharmaceuticals third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000287/ex-991_q32026.htm)

<a id="topic-2.1.1-6"></a>

##### Interim analysis endpoints: company wording from March 2022 to September 2025

> “The study is also designed to have a pre-planned interim analysis at Week 48 evaluating eGFR slope in VX-147 versus placebo, supported by a percent change from baseline in proteinuria. If positive, the interim analysis may serve as the basis for Vertex to seek accelerated approval of VX-147 in the U.S. for patients with AMKD.”

Source: [Vertex Pharmaceuticals press release, pivotal development (2022)](https://news.vrtx.com/news-releases/news-release-details/vertex-advances-vx-147-pivotal-clinical-development-people-apol1)

> “The study is also designed to have a pre-planned interim analysis at Week 48 evaluating eGFR slope, supported by a percent change from baseline in UPCR in the inaxaplin arm versus placebo.”

Source: [Vertex Pharmaceuticals press release, Breakthrough Therapy and PRIME designations (2022)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-inaxaplin-vx-147-granted-breakthrough-therapy)

> “The trial has a pre-planned interim analysis at Week 48 evaluating proteinuria, as measured by the percent change from baseline in UPCR, and eGFR slope.”

Source: [Falk et al. (2022)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.20223311s1181c~design-of-a-phase-23-adaptive-trial-evaluating-inaxaplin-in)

> “The study is also designed to have a pre-planned interim analysis at Week 48 evaluating eGFR slope, supported by a percent change from baseline in proteinuria in the inaxaplin arm versus placebo. If positive, the interim analysis may serve as the basis for Vertex to seek accelerated approval of inaxaplin in the U.S. for patients with AMKD.”

Source: [Vertex Pharmaceuticals press release, phase 3 advancement (2024)](https://news.vrtx.com/news-releases/news-release-details/vertex-advances-inaxaplin-vx-147-phase-3-portion-adaptive-phase)

> “The AMPLITUDE study is designed with an interim analysis at Week 48 in a pre-specified number of patients to assess percent change from baseline in proteinuria and eGFR slope in the inaxaplin arm versus placebo.”

Source: [Vertex Pharmaceuticals press release, kidney portfolio advancements (2025)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-key-advancements-across-kidney-portfolio)

<a id="topic-2.1.1-7"></a>

##### Interim analysis endpoints: registered primary endpoints

> “Part A: Percent change in UPCR evaluated from baseline at Week 48 (assessed at the IA) • eGFR slope (with ≥48 weeks of eGFR data assessed at the IA and at least 2 years of eGFR data assessed at the final analysis)”

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

> “Part A: Percent Change From Baseline in Urine Protein to Creatinine Ratio (UPCR) at Week 48 (Assessed at the Week 48 Interim Analysis)”

Source: [ClinicalTrials.gov NCT05312879](https://clinicaltrials.gov/study/NCT05312879)

<a id="topic-2.1.1-8"></a>

##### Interim analysis endpoint agreed with the FDA: eGFR slope

> “We are very pleased to have concluded our discussions with the FDA, enabling us to initiate the pivotal development program evaluating VX-147 in the broad patient population with AMKD and to have a clear path forward for potential accelerated approval in the U.S.”

Source: [Vertex Pharmaceuticals press release, pivotal development (2022)](https://news.vrtx.com/news-releases/news-release-details/vertex-advances-vx-147-pivotal-clinical-development-people-apol1)

> “A win would be a statistically significant result on the GFR slope. And I say that because, of course, we are going to measure proteinuria and GFR. But our agreement with the FDA, on what would be acceptable for accelerated approval is GFR.”
> “And at the same time, the FDA and our agreement is indeed with GFR. So, given that, we are focused on GFR.”

Source: [Vertex Pharmaceuticals earnings call transcript (2026)](https://www.webull.com/news/15858478693325824)

<a id="topic-2.1.1-9"></a>

##### Breakthrough Therapy designation for APOL1-mediated FSGS, June 2022

> “Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has granted inaxaplin (VX-147) Breakthrough Therapy Designation for APOL1-mediated focal segmental glomerulosclerosis (FSGS) and the European Medicines Agency (EMA) has granted inaxaplin Priority Medicines (PRIME) designation for APOL1-mediated chronic kidney disease (AMKD).”
> “The Breakthrough Therapy Designation was granted based on the Phase 2 clinical study of inaxaplin in patients with APOL1-mediated FSGS, a form of AMKD.”

Source: [Vertex Pharmaceuticals press release, Breakthrough Therapy and PRIME designations (2022)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-inaxaplin-vx-147-granted-breakthrough-therapy)

> “The FDA has granted Breakthrough Therapy designation to inaxaplin, and the European Medicines Agency (EMA) has granted PRIME designation.”

Source: [Vertex Pharmaceuticals third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000287/ex-991_q32026.htm)

<a id="topic-2.1.1-10"></a>

##### PRIME designation for AMKD, May 2022

> “PRIME designation was granted based on clinical proof-of-concept data from Vertex’s Phase 2 study of inaxaplin in APOL1-mediated FSGS. Inaxaplin is only the second nephrology product to be granted PRIME designation.”

Source: [Vertex Pharmaceuticals press release, Breakthrough Therapy and PRIME designations (2022)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-inaxaplin-vx-147-granted-breakthrough-therapy)

> “In the PRIME scheme (EMA priority medicines) since 19 May 2022”

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

<a id="topic-2.1.1-11"></a>

##### Rare Pediatric Disease designation for APOL1-mediated FSGS

> “The U.S. Food and Drug Administration (FDA) has granted inaxaplin Rare Pediatric Disease Designation (RPD) and Breakthrough Therapy Designation (BTD) for APOL1-mediated focal segmental glomerulosclerosis (FSGS). The European Medicines Agency (EMA) has also granted inaxaplin Priority Medicines (PRIME) and Orphan Drug designations for AMKD.”

Source: [Vertex Pharmaceuticals press release, phase 3 advancement (2024)](https://news.vrtx.com/news-releases/news-release-details/vertex-advances-inaxaplin-vx-147-phase-3-portion-adaptive-phase)

<a id="topic-2.1.1-12"></a>

##### EU orphan designation EU/3/22/2697, October 2022

> “This medicine was designated as an orphan medicine for the treatment of apolipoprotein L1-mediated kidney disease in the European Union on 11 October 2022.”

Source: [EMA orphan designation EU/3/22/2697 (2022)](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2697)

| Field | Quoted record |
| --- | --- |
| Active substance | “Inaxaplin” |
| Intended use | “Treatment of apolipoprotein L1-mediated kidney disease” |
| Orphan designation status | “Positive” |
| EU designation number | “EU/3/22/2697” |
| Date of designation | “11/10/2022” |
| Sponsor | “Vertex Pharmaceuticals (Ireland) Limited” |

Source: [EMA orphan designation EU/3/22/2697 (2022)](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2697)

<a id="topic-2.1.1-13"></a>

##### EU paediatric investigation plan EMEA-003368-PIP01-22, agreed October 2023

| Field | Quoted record |
| --- | --- |
| Active substance | “Inaxaplin” |
| Decision number | “P/0430/2023” |
| PIP number | “EMEA-003368-PIP01-22” |
| Pharmaceutical form | “Film-coated tablet” |
| Condition | “Treatment of apolipoprotein L1 (APOL1)-mediated kidney disease” |
| Route of administration | “Oral use” |
| Decision date | “27/10/2023” |

Source: [EMA paediatric investigation plan EMEA-003368-PIP01-22 (2023)](https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003368-pip01-22)

> “EMA decision of 27 October 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for inaxaplin”

Source: [EMA paediatric investigation plan EMEA-003368-PIP01-22 (2023)](https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003368-pip01-22)

<a id="topic-2.1.1-14"></a>

##### FDA orphan drug and Fast Track designations

No evidence found.

<a id="topic-2.1.1-15"></a>

##### First-in-human study, June 2019 to January 2020

> “The first-in-human study of inaxaplin (Study VX18-147-001 or Study 1) evaluated single ascending doses of 7.5 mg up to 50 mg and multiple ascending doses of 15 mg once daily, 15 mg twice daily, or 45 mg once daily in healthy participants.”
> “Study 1 was conducted at two sites in the United States (Madison, WI and Dallas, TX) between June 2019 and January 2020.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-2.1.1-16"></a>

##### Phase 2a proof-of-concept results, December 2021

> “Based on these results, Vertex plans to advance VX-147 into pivotal development in APOL1-mediated kidney disease, including FSGS, in Q1 2022.”

Source: [Vertex Pharmaceuticals press release, phase 2 results (2021)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2-study-vx-147-apol1)

<a id="topic-2.1.1-17"></a>

##### Pivotal phase 2/3 trial initiated, March 2022

> “Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company has advanced VX-147 into pivotal development for people living with proteinuric kidney disease mediated by two mutations in the APOL1 gene (AMKD), which affects approximately 100,000 people in the U.S. and Europe.”
> “The pivotal study will open for enrollment later this month.”

Source: [Vertex Pharmaceuticals press release, pivotal development (2022)](https://news.vrtx.com/news-releases/news-release-details/vertex-advances-vx-147-pivotal-clinical-development-people-apol1)

<a id="topic-2.1.1-18"></a>

##### Phase 3 portion and adolescent expansion, April 2024

> “Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that inaxaplin (VX-147) has advanced into the Phase 3 portion of the global Phase 2/3 pivotal clinical trial in APOL1-mediated kidney disease (AMKD), where a 45 mg once daily oral dose will be compared to placebo, on top of standard of care.”
> “In addition, the trial has been expanded to include adolescents with AMKD ages 10 to 17 years.”

Source: [Vertex Pharmaceuticals press release, phase 3 advancement (2024)](https://news.vrtx.com/news-releases/news-release-details/vertex-advances-inaxaplin-vx-147-phase-3-portion-adaptive-phase)

<a id="topic-2.1.1-19"></a>

##### Interim analysis cohort enrolled, September 2025

> “Vertex also announced today enrollment completion of the IA cohort of AMPLITUDE, a global Phase 2/3 clinical trial designed to assess the impact of inaxaplin on kidney function and proteinuria for people living with AMKD.”

Source: [Vertex Pharmaceuticals press release, kidney portfolio advancements (2025)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-key-advancements-across-kidney-portfolio)

<a id="topic-2.1.1-20"></a>

##### Phase 2b AMPLIFIED results, September 2026

> “Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from the Phase 2b AMPLIFIED study of inaxaplin in people with APOL1-mediated kidney disease (AMKD) and modest proteinuria and in people with AMKD and type 2 diabetes.”
> “We look forward to discussing the AMPLIFIED results with regulators in the context of the AMPLITUDE pivotal study.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="heading-2.1.2"></a>

#### 2.1.2 Product Information

<a id="heading-2.1.2.1"></a>

##### 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

###### Generic name, chemical name, and identifiers

| Field | Quoted record |
| --- | --- |
| International nonproprietary name (Latin) | “inaxaplinum” |
| International nonproprietary name (English) | “inaxaplin” |
| Chemical name | “3-[5,7-difluoro-2-(4-fluorophenyl)-1H-indol-3-yl]-N- [(3S,4R)-4-hydroxy-2-oxopyrrolidin-3-yl]propanamide” |
| Functional description | “apolipoprotein L1 (APOL1) function inhibitor” |
| Molecular formula | “C21H18F3N3O3” |
| CAS registry number | “2446816-88-0” |
| INN list | “Proposed INN: List 125” |

Source: [WHO Drug Information (2021)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-%28inn%29/pl125.pdf)

<a id="topic-2.1.2.1-2"></a>

###### Development codes: VX-147 and IXP

> “the U.S. Food and Drug Administration (FDA) has granted inaxaplin (VX-147) Breakthrough Therapy Designation for APOL1-mediated focal segmental glomerulosclerosis (FSGS)”

Source: [Vertex Pharmaceuticals press release, Breakthrough Therapy and PRIME designations (2022)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-inaxaplin-vx-147-granted-breakthrough-therapy)

> “Other Names: IXP VX-147”

Source: [ClinicalTrials.gov NCT06794996](https://clinicaltrials.gov/study/NCT06794996)

<a id="topic-2.1.2.1-3"></a>

###### Brand name

No evidence found.

<a id="topic-2.1.2.1-4"></a>

###### Manufacturer: Vertex Pharmaceuticals

> “Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from the Phase 2b AMPLIFIED study of inaxaplin in people with APOL1-mediated kidney disease (AMKD) and modest proteinuria and in people with AMKD and type 2 diabetes.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

> “We are developing inaxaplin, a small molecule inhibitor of APOL1 as a potential first-in-class treatment for APOL1-mediated kidney disease”

Source: [Vertex Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/vrtx-20251231.htm)

| Field | Quoted record |
| --- | --- |
| Sponsor | “Vertex Pharmaceuticals Inc.” |
| Marketing authorisation holder of the investigational product | “VERTEX PHARMACEUTICALS, INCORPORATED” |

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

<a id="topic-2.1.2.1-5"></a>

###### Therapeutic class: oral small molecule inhibitor of APOL1

> “Vertex has discovered and advanced multiple oral, small molecule inhibitors of APOL1 function, including inaxaplin, pioneering a new class of medicines that targets the underlying cause of this genetic kidney disease.”

Source: [Vertex Pharmaceuticals third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000287/ex-991_q32026.htm)

> “Inaxaplin is a first-in-class, investigational small molecule inhibitor of APOL1 aimed at addressing the underlying cause of AMKD.”

Source: [Vertex Pharmaceuticals press release, kidney portfolio advancements (2025)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-key-advancements-across-kidney-portfolio)

> “Vertex is developing inaxaplin, a potential first-in-class, investigational, oral small molecule inhibitor of APOL1, with the goal of targeting the underlying cause of AMKD.”

Source: [Vertex Pharmaceuticals press release, ASN Kidney Week (2024)](https://news.vrtx.com/news-releases/news-release-details/vertex-provides-updates-multiple-kidney-programs-american)

> “This medicine belongs to the class of apolipoprotein L1 inhibitors.”
> “Inaxaplin is an inhibitor of the apolipoprotein L1 protein (APOL1).”

Source: [EMA orphan designation EU/3/22/2697 (2022)](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2697)

<a id="heading-2.1.2.2"></a>

##### 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

###### Investigational dosage form: 45 mg film-coated tablet for oral use

| Field | Quoted record |
| --- | --- |
| Product | “VX-147 film-coated tablet” |
| Pharmaceutical form | “FILM-COATED TABLET” |
| Route of administration | “ORAL USE” |
| Maximum daily dose | “45 mg milligram(s)” |
| Maximum total dose | “4860 mg milligram(s)” |
| Maximum duration of treatment | “108 week(s)” |
| Placebo | “VX-147, Coated Placebo Tablet” |

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

> “Inaxaplin is being evaluated as a 45 mg once-daily oral dose compared to placebo, on top of standard of care.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="topic-2.1.2.2-2"></a>

###### Tablets in the AMPLITUDE and AMPLIFIED trials

> “Drug: VX-147 Tablets for oral administration.”
> “Drug: Placebo Tablets for oral administration.”

Source: [ClinicalTrials.gov NCT05312879](https://clinicaltrials.gov/study/NCT05312879)

> “Drug: Inaxaplin Tablets for Oral Administration.”

Source: [ClinicalTrials.gov NCT06794996](https://clinicaltrials.gov/study/NCT06794996)

<a id="topic-2.1.2.2-3"></a>

###### Pediatric acceptability of the tablet formulation

> “Part A: Acceptability Tablet Formulation of VX-147 in Pediatric Participants using the Convenience Domain of the Treatment Satisfaction Questionnaire for Medication (TSQM) Version 1.4”

Source: [ClinicalTrials.gov NCT05312879](https://clinicaltrials.gov/study/NCT05312879)

<a id="topic-2.1.2.2-4"></a>

###### Tablet formulation development: relative bioavailability and food effect study

> “The purpose of the study is to evaluate the relative bioavailability (BA) and the effect of food on the pharmacokinetics (PK), and the safety and tolerability of VX-147 test tablet formulation.”

Source: [ClinicalTrials.gov NCT05955872](https://clinicaltrials.gov/study/NCT05955872)

<a id="topic-2.1.2.2-5"></a>

###### Commercial strengths and package sizes

No evidence found.

<a id="heading-2.1.2.3"></a>

##### 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

Not applicable.

<a id="heading-2.1.2.4"></a>

##### 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

<a id="topic-2.1.2.4-1"></a>

###### AHFS classification

No evidence found.

<a id="topic-2.1.2.4-2"></a>

###### WHO INN functional description: apolipoprotein L1 function inhibitor

> “apolipoprotein L1 (APOL1) function inhibitor”

Source: [WHO Drug Information (2021)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-%28inn%29/pl125.pdf)

<a id="topic-2.1.2.4-3"></a>

###### EMA classification: apolipoprotein L1 inhibitors

> “This medicine belongs to the class of apolipoprotein L1 inhibitors.”

Source: [EMA orphan designation EU/3/22/2697 (2022)](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2697)

| Field | Quoted record |
| --- | --- |
| Therapeutic area | “Uro-nephrology” |

Source: [EMA paediatric investigation plan EMEA-003368-PIP01-22 (2023)](https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003368-pip01-22)

<a id="heading-2.1.2.5"></a>

##### 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

###### Population of the pivotal AMPLITUDE trial: primary AMKD with severe proteinuria and no kidney disease-causing comorbidities

> “Vertex has completed full enrollment in the Phase 2/3 AMPLITUDE study of inaxaplin in people with severe proteinuria and no other kidney disease-causing comorbidities.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

> “The phase 2/3 randomized, placebo-controlled AMPLITUDE trial is evaluating the effects of IXP on preserving kidney function and reducing proteinuria in non-diabetic persons with AMKD and severe proteinuria (UPCR ≥0.7 to <10g/g).”

Source: [Chertow et al. (2025b)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.20252q319dky~inaxaplin-for-a-broad-population-with-apol1-mediated-kidney)

> “In September, Vertex completed enrollment in the interim analysis cohort of the AMPLITUDE Phase 2/3 trial of inaxaplin in patients with primary AMKD”

Source: [Vertex Pharmaceuticals press release, pipeline and business updates (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-provides-pipeline-and-business-updates-advance-upcoming-1)

<a id="topic-2.1.2.5-2"></a>

###### Indication named for a potential accelerated approval: patients with AMKD

> “If positive, the interim analysis may serve as the basis for Vertex to seek accelerated approval of inaxaplin in the U.S. for patients with AMKD.”

Source: [Vertex Pharmaceuticals press release, phase 3 advancement (2024)](https://news.vrtx.com/news-releases/news-release-details/vertex-advances-inaxaplin-vx-147-phase-3-portion-adaptive-phase)

<a id="topic-2.1.2.5-3"></a>

###### Age range in AMPLITUDE: 10 to 65 years

> “Ages Eligible for Study 10 Years to 65 Years (Child, Adult, Older Adult )”

Source: [ClinicalTrials.gov NCT05312879](https://clinicaltrials.gov/study/NCT05312879)

> “In addition, the trial has been expanded to include adolescents with AMKD ages 10 to 17 years.”

Source: [Vertex Pharmaceuticals press release, phase 3 advancement (2024)](https://news.vrtx.com/news-releases/news-release-details/vertex-advances-inaxaplin-vx-147-phase-3-portion-adaptive-phase)

<a id="topic-2.1.2.5-4"></a>

###### Indications named in regulatory designations: APOL1-mediated FSGS (FDA) and AMKD (EMA)

> “The U.S. Food and Drug Administration (FDA) has granted inaxaplin Rare Pediatric Disease Designation (RPD) and Breakthrough Therapy Designation (BTD) for APOL1-mediated focal segmental glomerulosclerosis (FSGS). The European Medicines Agency (EMA) has also granted inaxaplin Priority Medicines (PRIME) and Orphan Drug designations for AMKD.”

Source: [Vertex Pharmaceuticals press release, phase 3 advancement (2024)](https://news.vrtx.com/news-releases/news-release-details/vertex-advances-inaxaplin-vx-147-phase-3-portion-adaptive-phase)

| Field | Quoted record |
| --- | --- |
| Intended use | “Treatment of apolipoprotein L1-mediated kidney disease” |

Source: [EMA orphan designation EU/3/22/2697 (2022)](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2697)

<a id="topic-2.1.2.5-5"></a>

###### Indication expansion studied in AMPLIFIED: AMKD with modest proteinuria or with type 2 diabetes

> “Our serial innovation strategy in AMKD focuses on indication expansion: evaluating inaxaplin in new populations of people with AMKD not included in the AMPLITUDE clinical trial.”
> “evaluates inaxaplin as a treatment for people with AMKD with moderate proteinuria, or with AMKD and type 2 diabetes, two populations that are not being studied in the AMPLITUDE trial.”

Source: [Vertex Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/vrtx-20251231.htm)

> “Vertex plans to initiate AMPLIFIED, a Phase 2b open-label study of inaxaplin in patients with AMKD and diabetes or other co-morbidities currently not eligible for the AMPLITUDE Phase 2/3 pivotal trial, expanding the estimated potentially eligible population from 150,000 to 250,000 patients.”

Source: [Vertex Pharmaceuticals press release, pipeline and business updates (2025)](https://news.vrtx.com/news-releases/news-release-details/vertex-provides-pipeline-and-business-updates-advance-upcoming-0)

> “An FDA label covering the two arms in Amplified would add about 100,000 patients to the target population.”

Source: [Fierce Biotech (2026)](https://www.fiercebiotech.com/biotech/vertexs-midstage-data-amplify-kidney-disease-market-opportunity)

> “AMPLIFIED is a phase 2, open-label study evaluating the efficacy of IXP to reduce proteinuria in 45 participants (ages 18-67yrs) with proteinuric AMKD who have none (Cohort 1,n=15) or one of the following significant comorbidities: type 2 diabetes mellitus (Cohort 2,n=15), sickle-cell disease (Cohort 3,n=5), human immunodeficiency virus (Cohort 3,n=5), or lupus nephritis (Cohort 3,n=5).”

Source: [Chertow et al. (2025b)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.20252q319dky~inaxaplin-for-a-broad-population-with-apol1-mediated-kidney)

<a id="heading-2.1.2.6"></a>

##### 2.1.2.6 Pharmacology

<a id="heading-2.1.2.6.1"></a>

###### 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

###### Pharmacologic class: APOL1 function inhibitor

> “apolipoprotein L1 (APOL1) function inhibitor”

Source: [WHO Drug Information (2021)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-%28inn%29/pl125.pdf)

> “Vertex has discovered and advanced multiple oral, small molecule inhibitors of APOL1 function, including inaxaplin, pioneering a new class of medicines that targets the underlying cause of this genetic kidney disease.”

Source: [Vertex Pharmaceuticals third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000287/ex-991_q32026.htm)

<a id="topic-2.1.2.6.1-2"></a>

###### Oral small-molecule inhibitor of APOL1 channel function

> “The underlying genetic cause of AMKD is a toxic gain-of-function in the APOL1 gene (G1 or G2) thought to enhance APOL1 channel function and damage glomerular cells (e.g., podocytes and endothelial cells) in response to an inflammatory trigger; the resulting cellular damage disrupts the glomerular filtration barrier, resulting in proteinuria, and often leads to accelerated loss of kidney function”
> “Based on the mechanism of disease, targeted inhibition of APOL1 should inhibit glomerular damage, reduce proteinuria, and ultimately slow the progression of kidney disease.”
> “Inaxaplin (previously known as VX-147) is an oral, small molecule inhibitor of APOL1 channel function that has been shown to reduce proteinuria in patients with AMKD in a phase 2a proof-of-concept study”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-2.1.2.6.1-3"></a>

###### Direct binding to APOL1 and inhibition of APOL1-mediated ion flux in cell models

> “Our in vitro and in vivo studies showed that inaxaplin bound directly to the APOL1 protein, inhibited APOL1 channel function, and reduced proteinuria in a transgenic mouse model of APOL1-mediated kidney disease.”
> “In this cell model, thallium flux was minimal in the absence of APOL1 expression, and APOL1-mediated thallium flux was nearly eliminated by the administration of inaxaplin (Figure 1B).”
> “Inaxaplin bound directly to APOL1 protein, as shown by a microscale thermophoresis binding assay (Figure 1C).”
> “We hypothesized that the ion-channel function of APOL1 responsible for trypanosome lysis is also the function that is relevant to kidney disease.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-2.1.2.6.1-4"></a>

###### Potency against APOL1 G0, G1, and G2 in channel, trypanolysis, and cell death assays

> “we determined VX-147 potently inhibited the APOL1 ion channel with IC50 values of 2.3 nM for G0, 1.3 nM for APOL1 G1, and 1.1 nM for APOL1 G2 (Fig. 3A).”
> “We found that VX-147 prevented APOL1-mediated T.b.b. death with essentially equivalent potencies to ion channel inhibition, with EC50 values of 2.0 nM for APOL1 G0, 2.1 nM for APOL1 G1, and 1.2 nM for APOL1 G2 (Fig. 3B).”
> “We saw complete inhibition of APOL1-dependent cell death using VX-147 with EC50 values of 4.3 nM for APOL1 G0, 2.0 nM for APOL1 G1, and 2.2 nM for APOL1 G2 (Fig. 3C).”

Source: [Zimmerman et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11696124/)

<a id="topic-2.1.2.6.1-5"></a>

###### Selectivity: off-target profiling

> “VX-147 was previously shown to bind directly to purified, recombinant APOL1 and broad profiling across a large panel of potential off-targets did not identify any significant activity, indicating that the mechanism of action is due to direct inhibition of the APOL1 ion channel”

Source: [Zimmerman et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11696124/)

<a id="topic-2.1.2.6.1-6"></a>

###### Rationale for limited on-target risk of APOL1 inhibition

> “We reasoned an APOL1 ion channel inhibitor would be likely to have limited on-target safety risk, because there is a published report of an individual with no detectable APOL1 protein expression due to homozygous truncation mutations.”
> “This individual was healthy except for a sensitivity to trypanosome infection”

Source: [Zimmerman et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11696124/)

<a id="topic-2.1.2.6.1-7"></a>

###### Potassium efflux as the proximal driver of APOL1-mediated cell death

> “We demonstrate that efflux of K+, and not influx of Na+, is responsible for APOL1-mediated cell death in our recombinant cell system.”

Source: [Zimmerman et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11696124/)

<a id="topic-2.1.2.6.1-8"></a>

###### Reversal of sodium import, potassium efflux, and downstream injury: independent study

> “In HEK293 cells, we demonstrated that G1-mediated Na+ import/K+ efflux triggered activation of GPCR/IP3–mediated calcium release from the ER, impaired mitochondrial ATP production, and impaired translation, which were all reversed by VX-147.”
> “Our study provides the first detailed biochemical mechanism, to our knowledge, that explains how VX-147 protects kidney cells.”
> “Based on these results, we conclude that the cytoprotective effects of VX-147 are not due to a decrease in G1 protein expression or translocation to the PM.”

Source: [Datta et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10904047/)

<a id="topic-2.1.2.6.1-9"></a>

###### Blockade of APOL1-dependent calcium influx: independent study

> “Furthermore, we observed that both the M1 (N264K) variant and APOL1 inhibitor, Inaxaplin, exerted protective effects on cell viability by blocking the APOL1-dependent intracellular Ca2+ influx.”

Source: [Adebayo et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13743002/)

<a id="heading-2.1.2.6.2"></a>

###### 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

###### Prevention of proteinuria in an interferon gamma-induced APOL1 G2 transgenic mouse model

> “In an APOL1 G2-homozygous transgenic mouse model, the injection of interferon gamma resulted in heavy proteinuria; in contrast, no proteinuria was seen when control Friend leukemia virus B (FVB) mice were exposed to interferon gamma.”
> “The prophylactic administration of inaxaplin (3 mg per kilogram three times daily) or vehicle for 3 days, with the first dose given on day 1 approximately 1.5 hours before the interferon gamma injection, significantly reduced the area under the curve for the mean urinary albumin-to-creatinine ratio in interferon gamma–injected G2-homozygous mice by an average of 74.1% (Figure 1D and Fig. S3).”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

> “The potency of VX-147 was consistent across the in vitro functional assays described above (EC50 of approximately 2nM).”
> “Oral administration of VX-147 reduced proteinuria in IFNγ-induced APOL1 G2Hom mice by 74.1%.”

Source: [Zimmerman et al. (2021)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.20213210s1419a~small-molecule-apol1-inhibitors-block-apol1-pore-function)

<a id="topic-2.1.2.6.2-2"></a>

###### Reversal of established proteinuria and eGFR decline with a close structural analog

> “Compound 3 had a rapid effect at lowering the UACR (Fig. 4A and Supplementary Fig. 13).”
> “Analysis of the UACR AUC following compound intervention revealed a 97% reduction over the 8 days of compound administration (Fig. 4B).”
> “In transgenic APOL1 mouse models, we used Compound 3, a close analog of VX-147 with comparable potency and selectivity, to show that blockage of the APOL1 channel can both prevent and reverse APOL1-dependent proteinuria as well as preserve glomerular integrity.”

Source: [Zimmerman et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11696124/)

> “Therapeutic intervention with Compound 3 at both intervention timepoints dramatically reduced proteinuria.”
> “Furthermore, therapeutic intervention with Compound 3 preserved the eGFR when administered early, and reversed eGFR decline back to near baseline level at a later timepoint of intervention.”

Source: [Blasio et al. (2024)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.2024502b9s3w~small-molecule-apol1-channel-inhibitor-reduces-proteinuria)

<a id="topic-2.1.2.6.2-3"></a>

###### Podocyte injury and proteinuria in APOL1 G1 transgenic mice: independent study

> “Within 48 hours, IFN-γ–treated mice developed significant proteinuria, which was almost completely attenuated with cotreatment with VX-147 (Figure 10, A and C).”
> “Importantly, these injury phenotypes were prevented by VX-147 treatment.”

Source: [Datta et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10904047/)

<a id="topic-2.1.2.6.2-4"></a>

###### Preeclampsia phenotype in pregnant APOL1 G2/G2 transgenic mice

> “Furthermore, inaxaplin restored BP (93.49± 6.60 vs. 106.38± 5.50 mmHg; n=7-9; p<0.01) and fetal weight (1.051 ± 0.097 vs. 0.607 ± 0.169 g; n=10; p<0.01) and reduced albuminuria by 57.9±7.5% (n=5; p<0.01) in pregnant G2/G2 females.”

Source: [Rao et al. (2025)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.2025kkecj205~inaxaplin-vx-147-mitigates-apol1-mediated-preeclampsia)

<a id="topic-2.1.2.6.2-5"></a>

###### Projected inhibition of APOL1 ion flux at 15 mg and 45 mg once daily

> “Based on an exposure-response model, the exposures from the 15 mg dose are expected to result in approximately 90% inhibition in the in vitro ion flux model.”
> “Based on the exposure-response model referenced above, exposures from this dose are expected to result in over 96% inhibition in the in vitro ion flux model.”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="topic-2.1.2.6.2-6"></a>

###### Onset and offset of proteinuria reduction in participants with APOL1-mediated FSGS

> “The treatment response from baseline was rapid and approximately linear, with a decrease seen by day 15; proteinuria continued to decrease through week 13 (Figure 2B).”
> “As compared with the baseline reduction in proteinuria that was observed at the end of part A of the study, in the exploratory part B of the study (in which data from nine participants were assessed), the mean urinary protein-to-creatinine ratio increased from −47.6% to −30.1% at week 4.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-2.1.2.6.2-7"></a>

###### Electrocardiographic effects in healthy adults

> “There was no evidence of effects of inaxaplin on ECG parameters.”
> “There were no participants with a maximum QT interval corrected by Fridericia’s formula (QTcF; calculated from ECG assessments) interval >480 msec.”
> “No participants in the SAD or MAD cohorts had a QTcF interval increase >60 msec.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-2.1.2.6.2-8"></a>

###### Serum creatinine, lipids, and leukocyte counts in healthy adults

> “Specifically, mean serum creatinine concentrations, serum lipid profile (i.e., total cholesterol, HDL cholesterol, LDL cholesterol, and triglyceride concentrations), and leukocyte counts were similar between the inaxaplin and placebo groups for all timepoints.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="heading-2.1.2.6.3"></a>

###### 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

###### Dose proportionality, half-life, and renal clearance in healthy adults

> “The PK of inaxaplin was generally dose proportional, and the variability in PK parameters was generally low and did not appear to change across the dose range (online Table S1).”
> “Half-life was consistent across both studies ranging from approximately 13.3 to 22.9 h, which supports once daily dosing (online Table S1).”
> “Renal clearance was a minor excretion pathway for inaxaplin”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-2.1.2.6.3-2"></a>

###### Steady-state exposure at 45 mg once daily and exposure margin at 120 mg once daily

> “Preliminary PK analysis demonstrated that the mean (CV%) AUC0-24h,ss achieved at this dose was 50.1 (27.5%) µg*h/mL, providing an approximately 3.8-fold exposure margin over the 45 mg qd clinical dose with a mean (CV%) AUC0-24h,ss of 13.3 (21.5%) µg*h/mL (Study 001).”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="topic-2.1.2.6.3-3"></a>

###### Food effect in the first-in-human study

> “Removed the requirement to fast before and after dosing, based on data from Study VX18-147-001 showing no food effect.”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="topic-2.1.2.6.3-4"></a>

###### Relative bioavailability and food effect of a test tablet formulation

> “The purpose of the study is to evaluate the relative bioavailability (BA) and the effect of food on the pharmacokinetics (PK), and the safety and tolerability of VX-147 test tablet formulation.”
> “Participants will receive VX-147 reference tablet under fasted condition in Treatment Period 1, then VX-147 test tablet under fed condition in Treatment Period 2, and VX-147 test tablet under fasted condition in Treatment Period 3.”

Source: [ClinicalTrials.gov NCT05955872](https://clinicaltrials.gov/study/NCT05955872)

Additional sources: [ClinicalTrials.gov NCT04340362](https://clinicaltrials.gov/study/NCT04340362)

<a id="heading-2.1.2.7"></a>

##### 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

###### 2.1.2.7.1 Warnings and Precautions

Not applicable.

<a id="heading-2.1.2.8"></a>

##### 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

###### Renal impairment: minor renal elimination

> “Renal clearance is a minor elimination pathway; thus, no dose adjustment is anticipated for the intended patient population that is expected to include patients with renal function impairment.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-2.1.2.8-2"></a>

###### Renal impairment: single-dose study in severe renal impairment

> “The purpose of this study is to evaluate the pharmacokinetics and safety of a single dose of Inaxaplin (IXP) in participants with severe renal impairment and healthy participants with normal renal function.”
> “Stable renal function for at least 1 month prior to enrollment”

Source: [ClinicalTrials.gov NCT05865171](https://clinicaltrials.gov/study/NCT05865171)

<a id="topic-2.1.2.8-3"></a>

###### Renal function range enrolled in AMPLITUDE

> “Estimated glomerular filtration rate (eGFR) ≥25 to < 75 mL/min/1.73 m2 during the Screening Period”

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

<a id="topic-2.1.2.8-4"></a>

###### Hepatic impairment: single-dose study in mild or moderate hepatic impairment

> “The purpose of this study is to evaluate the pharmacokinetics, safety and tolerability of Inaxaplin (IXP) in participants with mild or moderate hepatic impairment and in matched healthy participants.”
> “Cohort 1 (mild impairment): defined as a Child-Pugh total score of 5 to 6 (Child-Pugh Class A)”
> “Cohort 3 (moderate impairment): defined as a Child-Pugh total score of 7 to 9 (Child-Pugh Class B)”

Source: [ClinicalTrials.gov NCT06529796](https://clinicaltrials.gov/study/NCT06529796)

<a id="topic-2.1.2.8-5"></a>

###### Hepatic laboratory exclusions in AMPLITUDE

> “Total bilirubin ≥1.5 × upper limit of normal (ULN)”
> “Aspartate transaminase (AST) or alanine transaminase (ALT) ≥2 × ULN”

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

<a id="topic-2.1.2.8-6"></a>

###### Pediatric population: adolescents added to the phase 3 portion of AMPLITUDE

> “In addition, the trial has been expanded to include adolescents with AMKD ages 10 to 17 years.”
> “The IDMC also recommended enrolling adolescents with AMKD ages 10 to 17 years in the Phase 3 portion of the study.”

Source: [Vertex Pharmaceuticals press release, phase 3 advancement (2024)](https://news.vrtx.com/news-releases/news-release-details/vertex-advances-inaxaplin-vx-147-phase-3-portion-adaptive-phase)

> “For Phase 3, subjects must be between the ages of 12 and 65 years at time of signing first ICF, inclusive.”
> “Pediatric subjects may be enrolled only after IDMC review of Phase 2 data is completed, the Phase 3 dose is selected, and a recommendation by the IDMC on the inclusion of pediatric subjects is made.”

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

<a id="topic-2.1.2.8-7"></a>

###### Pediatric population: acceptability of the tablet formulation

> “Part A: Acceptability Tablet Formulation of VX-147 in Pediatric Participants using the Convenience Domain of the Treatment Satisfaction Questionnaire for Medication (TSQM) Version 1.4”

Source: [ClinicalTrials.gov NCT05312879](https://clinicaltrials.gov/study/NCT05312879)

<a id="topic-2.1.2.8-8"></a>

###### Pediatric population: EU paediatric investigation plan

> “EMA decision of 27 October 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for inaxaplin, (EMEA-003368-PIP01-22)”

Source: [EMA paediatric investigation plan EMEA-003368-PIP01-22 (2023)](https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003368-pip01-22)

<a id="topic-2.1.2.8-9"></a>

###### Older adults: enrollment limit in AMPLITUDE

> “Up to approximately 15% of the total number of subjects planned for enrollment may be >61 to ≤65 years of age at time of signing first ICF, inclusive.”

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

<a id="topic-2.1.2.8-10"></a>

###### Pregnancy and childbearing potential: exclusion from the phase 1 studies

> “In both studies, we enrolled healthy men and women of non-childbearing potential who were at least 18 years of age with body weight of >50 kg and body mass index (BMI) 18.0 to 32.0 kg/m2.”
> “A limitation of these studies, like most phase 1 studies, is that participants were predominantly men (owing to exclusion of women of childbearing age).”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-2.1.2.8-11"></a>

###### Pregnancy and lactation: exclusion from AMPLITUDE

> “Pregnant or nursing female subjects. Females of childbearing potential must have a negative pregnancy test at screening (serum test) and Day 1 (urine test).”

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

<a id="topic-2.1.2.8-12"></a>

###### Contraception requirements in the phase 2a study

> “Methods of contraception must be in successful use from signing of consent, approximately 28 days before the first dose of study drug (unless otherwise noted), and until 90 days following the last dose of study drug.”
> “Male subjects must use a condom to avoid exposing a potential fetus to study drug via the seminal fluid.”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

Additional sources: [Hosey et al. (2026)](https://www.ajkd.org/article/S0272-6386%2826%2900494-4/pdf)

<a id="heading-2.1.2.9"></a>

##### 2.1.2.9 Drug/Drug, Drug/disease Interactions

<a id="heading-2.1.2.9.1"></a>

###### 2.1.2.9.1 Effects of Other Drugs on Inaxaplin

<a id="topic-2.1.2.9.1-1"></a>

###### CYP3A4 and P-glycoprotein substrate

> “In vitro studies indicated VX-147 is substrate for CYP3A4 and P-gp.”
> “Therefore, it is anticipated that drugs that inhibit or induce CYP3A4 and P-gp could have an impact on the PK of VX-147.”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="topic-2.1.2.9.1-2"></a>

###### Rifampin and itraconazole drug interaction study in healthy adults

> “was done to evaluate the effect of rifampin, a strong CYP3A and P-gp inducer, and itraconazole, a strong CYP3A4 and P-gp inhibitor, on single dose PK of VX-147”
> “DDI study in 28 healthy male and female subjects (14 subjects in the itraconazole group and 14 subjects in the rifampin group).”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="topic-2.1.2.9.1-3"></a>

###### Strong CYP3A and P-gp inducer: rifampin

> “Administration of rifampin resulted in a significant decrease in VX-147 exposure: AUC0-∞ GMR (90% CI) 0.154 (0.139, 0.170) and Cmax GMR (90% CI) 0.552 (0.498, 0.612) relative to VX-147 administration alone.”
> “These results indicate that strong CYP3A4 inducers have the potential to significantly decrease VX-147 exposure.”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="topic-2.1.2.9.1-4"></a>

###### Strong CYP3A4 and P-gp inhibitor: itraconazole; moderate CYP3A4 inhibitor: cyclosporine

> “Administration of itraconazole resulted in a smaller change (approximately 2-fold) compared to rifampin.”
> “VX-147 AUC0-∞ increased with a GMR (90% CI) of 1.98 (1.79, 2.19), while Cmax increased slightly, GMR of 1.14 (1.07, 1.20) compared to VX-147 administration alone.”
> “These results indicate that strong CYP3A4 inhibitors are unlikely to cause a significant increase (>2-fold) in VX-147 exposure, and that a moderate CYP3A4 inhibitor, such as cyclosporine, is expected to result in a less than 2-fold increase in AUC0-24h,ss.”
> “Hence, cyclosporine administration is anticipated to be safe if co-administered with a 45 mg qd dose of VX-147.”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="topic-2.1.2.9.1-5"></a>

###### Restricted medications and foods in the phase 2a study

| Restriction | Start | Stop |
| --- | --- | --- |
| CYP3A4 inhibitors or inducers | “None allowed within 14 days before the first dose of the study drug” | “Completion of Safety Follow-up Visit assessments” |
| Grapefruit and related fruits | “7 days before first dose of study drug” | “Until last PK sample is taken” |

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

> “Moderate and strong CYP3A4 inhibitors or inducers, including consumption of herbal medications (e.g., St. John’s Wort)”
> “Grapefruit, grapefruit juice, pomelos, orange marmalade, Seville/blood oranges”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="topic-2.1.2.9.1-6"></a>

###### QT-prolonging concomitant medications excluded from AMPLITUDE

> “Risk factors for Torsade de Pointes (e.g., familial long QT syndrome, chronic hypokalemia, heart failure) or concomitant medications that prolong the QT/QTc interval or any history of cardiac disorders”

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

<a id="heading-2.1.2.9.2"></a>

###### 2.1.2.9.2 Effects of Inaxaplin on Other Drugs

<a id="topic-2.1.2.9.2-1"></a>

###### Sensitive CYP3A4 substrate: midazolam

> “We assessed the potential of inaxaplin to either induce or inhibit CYP3A4 enzymes in Study 1 by measuring the effect of inaxaplin administration on serum concentrations of midazolam, a sensitive CYP3A4 substrate.”
> “There were no clinically significant PK drug-drug interactions between inaxaplin and midazolam (online Table S3).”
> “Inaxaplin is not a clinically significant inhibitor or inducer of CYP3A4.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-2.1.2.9.2-2"></a>

###### In vitro CYP3A4 induction and removal of the CYP3A substrate restriction

> “In vitro studies indicated VX-147 is a weak inducer of CYP3A4; however, in a previous clinical study (VX18-147-001; Study 001) an interaction with midazolam, a sensitive substrate of CY3A4, indicated that VX-147 has minimal inhibitory effect.”
> “Removed the study restriction for concomitant use of sensitive CYP3A substrates, based on Study VX18-147-001 data showing that VX-147 45 mg q24h does not result in clinically meaningful CYP3A inhibition or induction.”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="topic-2.1.2.9.2-3"></a>

###### Combined oral contraceptives: ethinyl estradiol and levonorgestrel

> “The study design was an open label, 2-period, fixed-sequence crossover study in 17 healthy female adult subjects.”
> “Steady-state plasma levels of EE and LN did not decrease in the presence of daily doses of 45 mg VX-147.”
> “There were minor (~20%) increases in AUC0-24h,ss of both EE and LN.”
> “Based on these results the magnitude of these interactions are not deemed clinically significant; therefore, coadministration of VX-147 and combined oral contraceptives containing EE and LN is unlikely to result in contraceptive failure.”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="heading-2.1.2.10"></a>

##### 2.1.2.10 Dosing and Administration

<a id="heading-2.1.2.10.1"></a>

###### 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

###### Phase 3 dose: 45 mg once daily selected by the independent data monitoring committee

> “An Independent Data Monitoring Committee (IDMC) reviewed blinded and unblinded Phase 2 safety and efficacy data from the Phase 2/3 pivotal trial, which evaluated two different doses of inaxaplin compared to placebo for 12 weeks of treatment in patients ages 18 to 65 years and recommended the selection of a single inaxaplin dose of 45 mg once daily in the Phase 3 portion of the Phase 2/3 study.”

Source: [Vertex Pharmaceuticals press release, phase 3 advancement (2024)](https://news.vrtx.com/news-releases/news-release-details/vertex-advances-inaxaplin-vx-147-phase-3-portion-adaptive-phase)

<a id="topic-2.1.2.10.1-2"></a>

###### Doses compared in the phase 2 portion of AMPLITUDE: 15 mg and 45 mg once daily

> “The safety and efficacy of inaxaplin at 15 mg once daily and 45 mg once daily (which is in the lower range of doses explored in these phase 1 studies) is currently being evaluated in a randomized, double-blind, placebo-controlled, phase 2/3 adaptive trial in adults with AMKD (ClinicalTrials.gov number, NCT05312879).”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

> “participants will be randomized to receive 1 of 2 daily doses of IXP or placebo for 12wks.”

Source: [Falk et al. (2022)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.20223311s1181c~design-of-a-phase-23-adaptive-trial-evaluating-inaxaplin-in)

<a id="topic-2.1.2.10.1-3"></a>

###### AMPLIFIED: 45 mg once daily

> “In this study, inaxaplin was evaluated as a 45 mg once-daily dose on top of optimized standard of care.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="topic-2.1.2.10.1-4"></a>

###### Phase 2a regimen: 15 mg once daily for 2 weeks, then 45 mg once daily for 11 weeks

> “received inaxaplin treatment for 13 weeks (15 mg once daily for 2 weeks, followed by 45 mg once daily for 11 weeks) (Fig. S2).”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-2.1.2.10.1-5"></a>

###### Rationale for the phase 2a doses

> “The administration of once daily doses of 15 mg and 45 mg were selected on the totality of clinical safety, tolerability, and PK from the FIH study (Study 001); as well as toxicology and non-clinical pharmacodynamic (PD) data.”
> “A high dose of 45 mg once daily is selected to maximize the probability of reduction in proteinuria over the 11-week dosing period.”
> “No dose modifications are allowed.”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="topic-2.1.2.10.1-6"></a>

###### Doses evaluated in healthy adults

> “Inaxaplin is safe and well tolerated at single doses up to 165 mg and multiple doses up to 120 mg daily for 14 days.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-2.1.2.10.1-7"></a>

###### Maximum daily dose, total dose, and treatment duration in the EU trial record

| Field | Quoted record |
| --- | --- |
| Maximum daily dose | “45 mg milligram(s)” |
| Maximum total dose | “4860 mg milligram(s)” |
| Maximum duration of treatment | “108 week(s)” |

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

<a id="heading-2.1.2.10.2"></a>

###### 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

###### Oral film-coated tablet

| Field | Quoted record |
| --- | --- |
| Investigational medicinal product | “VX-147 film-coated tablet” |
| Pharmaceutical form | “FILM-COATED TABLET” |
| Route of administration | “ORAL USE” |

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

> “Tablets for oral administration.”

Source: [ClinicalTrials.gov NCT05312879](https://clinicaltrials.gov/study/NCT05312879)

<a id="topic-2.1.2.10.2-2"></a>

###### Administration instructions in the phase 2a study

> “VX-147 will be administered as 15 mg tablets, orally, as shown in Table 3-2.”
> “Study drug will be taken at approximately the same time on each dosing occasion.”
> “Study drug may be taken with or without food.”
> “Subjects will swallow the study drug whole, with a full glass of water and will not chew it before swallowing.”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="topic-2.1.2.10.2-3"></a>

###### Missed doses in the phase 2a study

> “If a subject misses a dose and recalls the missed dose within 6 hours, the subject should take his/her dose according to the guidance above.”
> “If more than 6 hours have elapsed after his/her usual dosing time, the subject should skip that dose and resume his/her normal schedule for the following dose.”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="heading-2.1.2.11"></a>

##### 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

###### Vertex-sponsored no-cost APOL1 genetic testing: Labcorp program

> “Each patient that meets the eligibility criteria will receive one Labcorp APOL1 Genotype Test and will have access to genetic results counseling included in the program at no cost to the patient.”
> “No patients, providers, and/or third-party payers (including commercial health plans and government health care programs) will be billed for the APOL1 testing covered under the program.”
> “This test is sponsored by Vertex and should only be ordered on eligible patients. Eligible patients include those of African ancestry who may self-identify as Black, African American, African or Afro-Caribbean, a diagnosis of chronic kidney disease, no history of kidney transplant, do not have diabetes and must not be currently treated with dialysis.”
> “This program is subject to change or discontinuation without notice.”

Source: [Labcorp](https://www.labcorp.com/tests/407154/apol1-genotyping)

<a id="topic-2.1.2.11-2"></a>

###### Vertex-sponsored no-cost APOL1 genetic testing: Natera Renasight program

> “Vertex Pharmaceuticals is sponsoring a no-cost Renasight™ renal genetic testing for eligible”
> “patients of African ancestry diagnosed with chronic kidney disease”
> “The Sponsored Renasight™ Genetic Testing Program is funded by Vertex Pharmaceuticals Incorporated.”
> “Healthcare providers must also confirm patient eligibility criteria for the sponsored Renasight™ Genetic Testing Program and complete a signed attestation form for each patient.”

Source: [Natera](https://www.natera.com/info/vertex-sponsored-page-program-overview/how-to-order/)

<a id="topic-2.1.2.11-3"></a>

###### Vertex-sponsored no-cost APOL1 genetic testing: Arkana Laboratories program

> “Vertex Pharmaceuticals is sponsoring the No Cost to Patient APOL1 Genotyping Program”
> “Vertex Pharmaceuticals will cover the cost of genetic counseling for eligible”
> “Metis Genetics is working with Arkana Laboratories and Vertex Pharmaceuticals to provide pre-test genetic counseling to eligible”
> “Absence of diabetes mellitus”
> “Not currently on dialysis and no history of kidney transplant”

Source: [Arkana Laboratories](https://www.arkanalabs.com/services/apol1/no-cost-to-patient-apol1-testing-patient/)

<a id="topic-2.1.2.11-4"></a>

###### Vertex-sponsored genotyping study for clinical trial referral

> “Our genotyping study is enrolling up to 4000 participants of recent African ancestry with FSGS or nondiabetic kidney disease and UPCR ≥0.5 g/g. One blood sample is collected to verify APOL1 genotype by polymerase chain reaction to describe the genetic prevalence of AMKD and inform eligibility for clinical trials.”
> “The genotyping study interim analysis included 2866 participants of whom 674 (23.5%) have 2 APOL1 variants; 164 of the 674 (24.3%) participants are from Europe.”

Source: [Chertow et al. (2025a)](https://doi.org/10.1093/ndt/gfaf116.0477)

<a id="topic-2.1.2.11-5"></a>

###### Genotype assay required for trial eligibility

> “Subject has an APOL1 genotype of G1/G1, G2/G2, or G1/G2 obtained with a Vertex designated investigational clinical study assay.”

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

> “Participant has an APOL1 genotype of G1/G1, G2/G2, or G1/G2 obtained with a Vertex designated investigational clinical study assay”

Source: [ClinicalTrials.gov NCT06794996](https://clinicaltrials.gov/study/NCT06794996)

<a id="topic-2.1.2.11-6"></a>

###### Companion diagnostic

No evidence found.

<a id="topic-2.1.2.11-7"></a>

###### Specialty pharmacy or distribution network

No evidence found.

<a id="heading-2.1.2.12"></a>

##### 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

###### Required background ACE inhibitor or ARB in AMPLITUDE

> “On a stable, maximum tolerated labeled dose (at least 4 weeks before screening) of an angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB), but not both concomitantly, unless documented to be intolerant to ACE inhibitor/ARB.”

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

<a id="topic-2.1.2.12-2"></a>

###### Permitted concomitant kidney therapies in AMPLITUDE at a stable dose

> “Subjects taking sodium glucose co transporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor agonist (GLP 1a), mineralocorticoid receptor antagonists (MRAs), endothelin antagonists, sparsentan, or permitted immunosuppressants (prednisone ≤10 mg or steroid equivalent, mycophenolate, tacrolimus, cyclosporine, or azathioprine) must have been on a stable dose for 4 weeks before screening.”

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

<a id="topic-2.1.2.12-3"></a>

###### Excluded concomitant medications in AMPLITUDE: QT-prolonging drugs

> “Risk factors for Torsade de Pointes (e.g., familial long QT syndrome, chronic hypokalemia, heart failure) or concomitant medications that prolong the QT/QTc interval or any history of cardiac disorders”

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

<a id="topic-2.1.2.12-4"></a>

###### Inaxaplin added to standard of care in AMPLITUDE

> “Inaxaplin is being evaluated as a 45 mg once-daily oral dose compared to placebo, on top of standard of care.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="topic-2.1.2.12-5"></a>

###### Background therapy in AMPLIFIED: optimized standard of care

> “In this study, inaxaplin was evaluated as a 45 mg once-daily dose on top of optimized standard of care.”
> “These patients were already well treated with foundational chronic kidney disease therapies and treatment with inaxaplin led to additional reductions in proteinuria.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="topic-2.1.2.12-6"></a>

###### Background therapy in the phase 2a study: stable standard-care medications

> “Participants were required to continue taking stable doses of standard-care medications from at least 28 days before commencing inaxaplin through follow-up. Such medications could include, but were not limited to, systemic glucocorticoids (prednisone at a dose of ≤10 mg per day or equivalent), immunosuppressants (tacrolimus, cyclosporine, or mycophenolate mofetil), and renin–angiotensin–aldosterone inhibitors.”
> “As a condition of participation in the study, we prohibited travel during the study to countries where African sleeping sickness (African trypanosomiasis) is endemic.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

> “Patients were on a stable standard-of-care regimen, which could include an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin II receptor blocker (ARB), immunosuppressants and/or low doses of corticosteroids.”
> “Results were consistent regardless of baseline proteinuria or background therapy.”

Source: [Vertex Pharmaceuticals press release, phase 2 results (2021)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2-study-vx-147-apol1)

<a id="heading-2.1.2.13"></a>

##### 2.1.2.13 Effect of Inaxaplin on Quality Measures

<a id="topic-2.1.2.13-1"></a>

###### HEDIS Kidney Health Evaluation for Patients With Diabetes (KED)

> “The percentage of persons 18–85 years of age with diabetes (type 1 or type 2) who received a kidney health evaluation”
> “The eGFR test evaluates kidney function; the uACR test evaluates kidney damage.”

Source: [NCQA](https://www.ncqa.org/report-cards/health-plans/state-of-health-care-quality-report/measures-list/kidney-health-evaluation-for-patients-with-diabetes-ked/)

<a id="topic-2.1.2.13-2"></a>

###### Product-specific effect on quality measures

No evidence found.

<a id="heading-2.1.2.14"></a>

##### 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

###### APOL1-directed and other investigational therapies for AMKD: review table

| Trial | Therapeutic | Phase | Mechanism studied |
| --- | --- | --- | --- |
| AMPLITUDE | “Inaxaplin” | “Phase 3” | “APOL1 channel function inhibition” |
| JUSTICE | “Baricitinib” | “Phase 2” | “Janus kinase STAT pathway” |
| NCT04269031 | “AZD2373” | “Phase 1” | “Antisense oligonucleotide therapy to reduce APOL1 mRNA formation” |
| NCT05324410 | “VX-840” | “Phase 1” | “APOL1 channel blocker” |
| Not named | “MZE829” | “Phase 1” | “APOL1 small molecule inhibitor” |

Source: [Srinivasan et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12361766/)

> “Antisense oligonucleotide therapy is in phase 1 trials because of studies in mice showing a dose-dependent reduction in liver and kidney APOL1 mRNA.”
> “a recent small molecule inhibitor, MZE829, attempts to phenocopy this protective variant in a phase 1 study.”

Source: [Srinivasan et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12361766/)

<a id="topic-2.1.2.14-2"></a>

###### MZE829 (Maze Therapeutics): oral dual-mechanism APOL1 inhibitor, phase 2 HORIZON interim results

> “today announced positive topline data from the Phase 2 HORIZON trial of MZE829, an oral, small molecule, dual-mechanism APOL1 inhibitor, in patients with broad APOL1-mediated kidney disease (AMKD).”
> “The HORIZON study is a Phase 2, open-label basket design trial that enrolled patients with broad AMKD carrying the APOL1 high risk genotype, including diabetic and non-diabetic patients and non-diabetic patients with severe focal segmental glomerulosclerosis (FSGS).”
> “For this topline analysis, 15 patients were enrolled in the HORIZON study and all were included in a safety and tolerability analysis. Twelve patients were evaluated for efficacy, i.e., uACR reduction, based on meeting the per protocol compliance threshold.”
> “Across all evaluated patients, a mean reduction in proteinuria from baseline of 35.6% was observed and 50% of patients achieved at least a 30% reduction in uACR.”
> “In FSGS patients, treatment with MZE829 led to a mean reduction in uACR of 61.8%. In patients with AMKD without diabetes, treatment with MZE829 resulted in a clinically meaningful mean reduction in uACR of 48.6%. In patients with AMKD with diabetes, five patients were evaluable per protocol for efficacy, with two patients achieving at least a 30% reduction in uACR.”
> “No serious adverse events (AEs) or severe treatment-related adverse events (TRAEs) were observed.”

Source: [Maze Therapeutics press release, MZE829 phase 2 topline data (2026)](https://mazetx.gcs-web.com/news-releases/news-release-details/maze-therapeutics-announces-positive-topline-data-phase-2)

<a id="topic-2.1.2.14-3"></a>

###### MZE829: HORIZON enrollment completed and pivotal trial planned for the first half of 2027

> “Enrollment for the Phase 2 HORIZON trial evaluating MZE829 in more than 50 patients in a broad AMKD population is complete and exceeded the target enrollment range of 10-15 patients per cohort as previously guided.”
> “In early 2027, Maze expects to announce the final data from HORIZON which is designed to evaluate the potential of MZE829 to treat each of three AMKD patient subgroups: AMKD without diabetes, AMKD with diabetes and AMKD with focal segmental glomerulosclerosis (FSGS).”
> “Subject to regulatory feedback, Maze plans to initiate a pivotal trial in the first half of 2027.”

Source: [Maze Therapeutics third quarter 2026 results (2026)](https://mazetx.gcs-web.com/news-releases/news-release-details/maze-therapeutics-reports-third-quarter-2026-financial-results)

<a id="topic-2.1.2.14-4"></a>

###### MZE829: HORIZON registry record

> “An open-label Phase 2 study is designed to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with Proteinuric Chronic Kidney Disease and the APOL1 High Risk Genotype.”

Source: [ClinicalTrials.gov NCT06830629](https://clinicaltrials.gov/study/NCT06830629)

<a id="topic-2.1.2.14-5"></a>

###### Competitive positioning of inaxaplin and MZE829

> “Inaxaplin, a small-molecule inhibitor of APOL1 channel function, could compete with Maze Therapeutics’ MZE829.”

Source: [Fierce Biotech (2026)](https://www.fiercebiotech.com/biotech/vertexs-midstage-data-amplify-kidney-disease-market-opportunity)

<a id="topic-2.1.2.14-6"></a>

###### AZD2373 (AstraZeneca): subcutaneous APOL1-directed therapy, phase 2b APPRECIATE trial

> “The purpose of this study is to assess the efficacy and safety of AZD2373 in participants diagnosed with APOL1-Mediated Kidney Disease (AMKD) who are homozygotes or compound heterozygotes for APOL1 high-risk genotypes (G1 and G2). The primary hypothesis to be evaluated is that AZD2373, compared with placebo, will result in a greater reduction in UACR as assessed by the relative change from Baseline in UACR at Week 30.”
> “Part A (n = 96) will have a 1:1:1 randomization of participants to subgroups receiving weekly subcutaneous injections of 50 mg AZD2373, 150 mg AZD2373, and placebo.”

Source: [ClinicalTrials.gov NCT06824987](https://clinicaltrials.gov/study/NCT06824987)

| Field | Quoted record |
| --- | --- |
| Sponsor | “AstraZeneca” |
| Status | “Active, not recruiting” |
| Enrollment (actual) | “63” |
| Primary completion (estimated) | “2027-10-04” |

Source: [ClinicalTrials.gov NCT06824987](https://clinicaltrials.gov/study/NCT06824987)

<a id="topic-2.1.2.14-7"></a>

###### AZD2373: APOL1 genotyping clinical trial assay used to select participants

> “The individuals who are identified as being homozygous or compound heterozygous for the APOL1 high-risk genotypes are candidates for enrolment onto an pharmaceutical company-sponsored, Phase 2b clinical trial which is investigating the safety and efficacy of a synthetic antisense oligonucleotide (ASO) for the treatment of APOL1-mediated kidney disease (AMKD).”

Source: [ClinicalTrials.gov NCT06839833](https://clinicaltrials.gov/study/NCT06839833)

<a id="topic-2.1.2.14-8"></a>

###### AZD2373: phase 1 studies in healthy participants of African ancestry

> “following subcutaneous (SC) administration of single ascending doses (SAD) of AZD2373 in healthy male subjects of African ancestry.”

Source: [ClinicalTrials.gov NCT04269031](https://clinicaltrials.gov/study/NCT04269031)

> “following subcutaneous (SC) administration of multiple ascending doses (MAD) of AZD2373 in healthy male participants of sub-Saharan West African ancestry.”

Source: [ClinicalTrials.gov NCT05351047](https://clinicaltrials.gov/study/NCT05351047)

<a id="topic-2.1.2.14-9"></a>

###### VX-840 and other Vertex APOL1 inhibitors

> “The purpose of this study is to evaluate the safety, tolerability, and PK of single and multiple ascending doses of VX-840 in healthy participants.”

Source: [ClinicalTrials.gov NCT05324410](https://clinicaltrials.gov/study/NCT05324410)

> “Consistent with the company’s serial innovation strategy, Vertex will also continue to investigate additional small molecule APOL1 inhibitors in the clinic.”

Source: [Vertex Pharmaceuticals press release, phase 2 results (2021)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2-study-vx-147-apol1)

> “Vertex has discovered and advanced multiple oral, small molecule inhibitors of APOL1 function, including inaxaplin, pioneering a new class of medicines that targets the underlying cause of this genetic kidney disease.”

Source: [Vertex Pharmaceuticals third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000287/ex-991_q32026.htm)

<a id="topic-2.1.2.14-10"></a>

###### Approved therapies directed at the cause of AMKD

> “There are no therapies currently approved for AMKD.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

Additional sources: [Limb et al. (2024)](https://doi.org/10.1681/ASN.2024mr2v3twq); [Hopper et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42480070/); [Dogra et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42709370/)

<a id="heading-2.2"></a>

### 2.2 Place of Product in Therapy

<a id="heading-2.2.1"></a>

#### 2.2.1 Disease Description

<a id="heading-2.2.1.1"></a>

##### 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

###### Disease definition: nondiabetic kidney disease in a person with two APOL1 risk variants

> “AMKD is diagnosed when an individual with a high-risk APOL1 genotype develops nondiabetic kidney disease. There is no established glomerular filtration rate (GFR) cutoff to diagnose AMKD. Proteinuria (urine albumin to creatinine ratio >30 mg/g) is often present but is not a requirement for the diagnosis of AMKD.”

Source: [Hopper and Olabisi (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11462457/)

> “APOL1-associated nephropathy reflects a spectrum of kidney diseases caused by APOL1 risk variants. It can be superimposed on other forms of kidney disease, but often, it presents as glomerulosclerosis with accompanying tubulointerstitial and vascular changes.”

Source: [Freedman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8425659/)

> “AMKD is a rapidly progressing, proteinuric kidney disease caused by two variants in the APOL1 gene. It occurs in people of African ancestry.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="topic-2.2.1.1-2"></a>

###### Terminology: APOL1 kidney disease at the 2024 KDIGO Controversies Conference, and ICD-10-CM codes

> “The terms APOL1-mediated or -associated kidney disease lacked universal support largely because APOL1 high-risk genotypes are probabilistic—not deterministic—risk factors for developing kidney disease, and most people with high-risk APOL1 genotypes do not develop clinically apparent kidney disease.”
> “The term APOL1 kidney disease received the highest support for describing kidney pathologies associated with the G1 and G2 variants.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

> “New International Classification of Disease-10th Edition-Clinical Modification codes for APOL1-mediated kidney disease (AMKD) and family history of AMKD in the United States provide great hope to the millions of people with recent African ancestry and chronic kidney disease worldwide. In the past, vague diagnosis codes forced misclassification of many such patients, especially nondiabetic persons of African ancestry.”

Source: [Freedman et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41577386/)

<a id="topic-2.2.1.1-3"></a>

###### Genetic cause: G1 and G2 variants with a recessive two-risk-allele genotype

> “In people of African ancestry, 2 apolipoprotein L1 gene (APOL1) variants have been identified as causing increased risk of progressive chronic kidney disease (CKD) compared with non–high-risk APOL1 variants.”
> “The risk variants, labelled G1 (2 amino acid substitutions) and G2 (2 deletions), confer resistance to infection from certain subspecies of the trypanosome parasite. Combinations of 2 risk variants (G1/G1, G2/G2, or G1/G2) are referred to as high-risk genotypes for the development or progression of CKD, and they are associated with a spectrum of kidney diseases of both continuous and categorical disease phenotypes (Figure 1).”
> “There is emerging evidence that a single risk allele (G1/G0 or G2/G0) may also confer risk.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

> “The risk of kidney disease associated with the APOL1 G1 and G2 alleles follows a recessive inheritance pattern. Individuals who are heterozygous for a G1 or G2 variant (G1/G0 or G2/G0) are resistant to African sleeping sickness but do not have increased risk of kidney disease.”

Source: [Hopper and Olabisi (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11462457/)

> “Genetic risk factors include two independent coding variants in the APOL1 gene, G1 and G2, which are found almost exclusively in people with recent West sub-Saharan African ancestry.”

Source: [Freedman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8425659/)

<a id="topic-2.2.1.1-4"></a>

###### Evolutionary origin: positive selection for resistance to African trypanosomiasis

> “The two APOL1 variants are common in African chromosomes but absent from European chromosomes and both reside within haplotypes that harbor signatures of positive selection. ApoL1 is a serum factor that lyses trypanosomes. In vitro assays revealed that only the kidney disease-associated ApoL1 variants lysed Trypanosoma brucei rhodesiense.”

Source: [Genovese et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2980843/)

> “The G1 and G2 variants of the APOL1 gene restored immune protection against the novel T brucei strains and underwent positive selection in West Africa.”

Source: [Hopper and Olabisi (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11462457/)

> “These high-risk APOL1 variants are hypothesized to have evolved more than 10,000 years ago and rose to a high frequency in Africa because they provided protection against lethal African sleeping sickness due to Trypanosoma brucei rhodesiense and gambiense infections.”

Source: [Gbadegesin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11735277/)

<a id="topic-2.2.1.1-5"></a>

###### Phenotype spectrum: FSGS, hypertension-attributed kidney disease, HIVAN, COVAN, lupus nephritis, and sickle cell nephropathy

> “APOL1 high-risk genotypes have been associated with several kidney diseases, including FSGS, HIV-associated nephropathy, hypertension-attributed ESKD, lupus nephritis, and sickle cell disease nephropathy.”

Source: [Freedman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8425659/)

> “As discussed above, high-risk APOL1 genotypes have been associated with a spectrum of kidney disease phenotypes: vascular disease (hypertension-attributed kidney failure), diseases of the podocyte, and infectious etiologies such as HIV- and COVID-associated nephropathy.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

> “APOL1 risk variants increase the risk of hypertension-attributed ESKD (H-ESKD; 7- to 11-fold), FSGS (17-fold), HIV-associated nephropathy (HIVAN; 29- to 89-fold), nondiabetic CKD (2- to 4-fold), and other kidney disease manifestations. APOL1 does not appear to affect risk for developing IgA nephropathy or diabetic nephropathy (but does have some influence on progression in patients with diabetes and proteinuric kidney disease).”

Source: [Friedman and Pollak (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7863644/)

> “Kidney diseases in the spectrum include FSGS with and without nephrotic-range proteinuria, HIV-associated nephropathy (HIVAN), interferon-associated FSGS, severe lupus nephritis (LN), sickle cell nephropathy, and solidified glomerulosclerosis with low-level proteinuria.”

Source: [Freedman et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6200346/)

<a id="topic-2.2.1.1-6"></a>

###### FSGS, hypertension-attributed ESKD, and HIVAN: odds ratios in the case-control studies

> “Here we show that in African-Americans, focal segmental glomerulosclerosis (FSGS) and hypertension-attributed end-stage kidney disease (H-ESKD) are associated with two independent sequence variants in the APOL1 gene on chromosome 22 [FSGS odds ratio = 10.5 (95% CI 6.0–18.4); H-ESKD odds ratio = 7.3 (95% CI 5.6–9.5)].”

Source: [Genovese et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2980843/)

> “In a recessive model, APOL1 variants conferred seventeenfold higher odds (95% CI 11 to 26) for focal segmental glomerulosclerosis (FSGS) and twenty-nine-fold higher odds (95% CI 13 to 68) for HIV-associated nephropathy (HIVAN).”

Source: [Kopp et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3231787/)

<a id="topic-2.2.1.1-7"></a>

###### COVID-19-associated collapsing glomerulopathy (COVAN)

> “This case series included six Black patients with COVID-19 (four men, two women), mean age 55 years.”
> “All six patients had an APOL1 high-risk genotype. Five patients needed dialysis (two of whom died); one partially recovered without dialysis.”

Source: [Wu et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7460910/)

> “The 23 patients with COVID-19–associated collapsing glomerulopathy were median age 57 years (range, 35–72), included 16 men, and were predominantly (91%) Black.”
> “Among 17 patients genotyped, 16 (94%) were high-risk APOL1.”

Source: [Kudose et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8806099/)

<a id="topic-2.2.1.1-8"></a>

###### Lupus nephritis: APOL1 and lupus nephritis-attributed ESKD

> “The G1/G2 risk alleles were strongly associated with SLE-ESRD, with 25% of cases and 12% of controls having 2 nephropathy alleles”
> “The age-, sex-, and admixture-adjusted population attributable risk for ESRD among patients with G1/G2 polymorphisms was 0.26, compared to 0.003 among European American patients. The mean time from SLE diagnosis to ESRD development was ~2 years earlier among individuals with APOL1 risk genotypes (P = 0.01).”

Source: [Freedman et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4002759/)

<a id="topic-2.2.1.1-9"></a>

###### Second hits and modifiers: interferon, viral infection, and the p.N264K variant

> “The two-hit hypothesis suggests that a high-risk APOL1 genotype could act as a first hit, but a second hit, such as modifier genes, HIV infection, SLE, or other comorbidity, may be required to initiate nephropathy.”

Source: [Freedman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8425659/)

> “Even among individuals with a high-risk genotype, having 2 APOL1 risk alleles does not necessarily lead to development of CKD.”
> “Nongenetic second hits resulting in glomerular disease include high interferon states, viral infections (HIV and COVID-19), exposure to alpha, beta, or gamma interferon, and APOL1 overexpression”
> “Expression of APOL1 is regulated by cytokines (mostly by interferon), inflammation, hypoxia/ischemia, viruses, and nucleic acids.”
> “The APOL1 p.N264K variant was recently found to genetically and almost completely negate the effect of G2 risk alleles to levels comparable to G0, and this observation has been replicated in subsequent studies, making APOL1 p.N264K the most robust genetic modifier of APOL1 G2 to date.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

> “Using human kidney organoids, primary endothelial cells, and patient samples, we demonstrate that IFN-γ induces pyroptotic angiopathy in combination with APOL1 expression.”

Source: [Juliar et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11216883/)

<a id="topic-2.2.1.1-10"></a>

###### Unpredictability of disease among genotype carriers

> “Despite the strong association between having a high-risk genotype and increased risk of kidney disease, it is not possible to predict which individuals with a high-risk genotype will develop CKD, idiopathic FSGS, hypertension-attributed kidney disease, HIV-1–associated nephropathy (HIVAN), or earlier failure of a kidney transplant from a donor with an APOL1 high-risk genotype.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

> “Although the majority of people with a high-risk APOL1 genotype will not develop CKD, we cannot currently predict who will be affected.”

Source: [Freedman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8425659/)

<a id="heading-2.2.1.2"></a>

##### 2.2.1.2 Epidemiology

<a id="heading-2.2.1.2.1"></a>

###### 2.2.1.2.1 Incidence of APOL1-mediated kidney disease

<a id="topic-2.2.1.2.1-1"></a>

###### United States, 2023: kidney failure by race in the US Renal Data System

> “Racial disparities persist: Kidney failure was over four times more common among Black people and twice as common among Hispanic people compared with White people in 2023.”

Source: [USRDS Annual Data Report, ESKD incidence and prevalence (2025)](https://usrds-adr.niddk.nih.gov/2025/end-stage-renal-disease/1-incidence-and-prevalence)

> “ESKD affects approximately 750,000 people in the United States and represents a major health disparity, with incidence approximately three-fold higher among Black people than among White people.”

Source: [Freedman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8425659/)

> “According to the United States Renal Data System 2020 Annual Data Report, 30% of patients with end-stage kidney disease (ESKD) in the US are Black individuals, although they comprise only 13% to 14% of the population.”

Source: [Hopper and Olabisi (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11462457/)

<a id="topic-2.2.1.2.1-2"></a>

###### Registry data: no AMKD diagnosis in the US Renal Data System

> “The lack of an AMKD diagnosis in the US Renal Data System and international registries has had profound effects on public health, confusing the epidemiology of kidney failure and delaying research for more accurate diagnoses and treatments.”

Source: [Freedman et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41577386/)

<a id="topic-2.2.1.2.1-3"></a>

###### Fraction of disease attributable to the high-risk genotype

> “Rates of many types of severe kidney disease are much higher in Black individuals than most other ethnic groups. Much of this disparity can now be attributed to genetic variants in the apoL1 (APOL1) gene found only in individuals with recent African ancestry.”

Source: [Friedman and Pollak (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7863644/)

> “The effect of carrying two APOL1 risk alleles explains 18% of FSGS and 35% of HIVAN; alternatively, eliminating this effect would reduce FSGS and HIVAN by 67%.”

Source: [Kopp et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3231787/)

> “indicating that APOL1 genotype alone does not account for the entirety of the excess incidence of CKD in the Black community.”

Source: [Freedman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8425659/)

<a id="topic-2.2.1.2.1-4"></a>

###### Penetrance: lifetime risk of CKD, kidney failure, FSGS, and HIVAN among genotype carriers

> “Studies in African American individuals indicate that approximately 15%–20% of individuals with 2 APOL1 risk alleles develop CKD”
> “Approximately 15% of individuals with an APOL1 high-risk genotype will develop kidney failure, and a smaller fraction will develop FSGS.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

> “Individuals with a high-risk APOL1 genotype have been estimated to have a 15% to 30% lifetime risk of developing ESKD.”
> “The basis of this variable penetrance is currently unknown.”

Source: [Hopper and Olabisi (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11462457/)

> “The lifetime risk of clinically significant kidney disease for individuals with two APOL1 risk alleles remains uncertain.”
> “Some estimates pose that the lifetime probability of developing ESKD for carriers of the high-risk genotype may be up to 15%, a number that requires refinement (51).”

Source: [Friedman and Pollak (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7863644/)

> “Individuals with two APOL1 risk alleles have an estimated 4% lifetime risk for developing FSGS, and untreated HIV-infected individuals have a 50% risk for developing HIVAN.”

Source: [Kopp et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3231787/)

<a id="topic-2.2.1.2.1-5"></a>

###### Atherosclerosis Risk in Communities study: incident CKD and ESKD in middle-aged Black adults

> “Carrying two risk alleles associated with a 1.49-fold increased risk of CKD (95% CI=1.02 to 2.17) and a 1.88-fold increased risk of ESRD (95% CI=1.20 to 2.93) compared with zero or one risk allele; associations persisted after adjusting for European ancestry.”
> “Among 3067 African-American participants free of CKD at baseline, 190 (6.2%) participants developed CKD. The overall incidence rate of CKD was 7.94 events/1000 person-years among participants carrying zero APOL1 risk alleles, 8.60 events/1000 person-years among participants carrying one risk allele, and 11.64 events/1000 person-years among participants carrying two risk alleles (Table 2)”
> “Among participants with follow-up for ESRD events through 2008, 114 (3.7%) participants experienced an ESRD event over a median follow-up of 19.7 years.”

Source: [Foster et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3752955/)

<a id="topic-2.2.1.2.1-6"></a>

###### Atherosclerosis Risk in Communities study: healthy middle-aged adults followed for 25 to 30 years

> “There were 5,075 Whites (86%), 701 Blacks carrying the low-risk APOL1 genotype (12%), and 110 Blacks carrying the high-risk APOL1 genotype (2%). The mean age at baseline was 53 ± 6 years.”
> “The odds of developing CKD stage 3a or worse were not different between low-risk and high-risk APOL1 group in both unadjusted and adjusted models (P = 0.26 and P = 0.39, respectively). At last follow-up, <5% developed ESKD, and 45% of individuals either died or reached ESKD with no difference in outcomes between the groups.”

Source: [Doshi et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11127222/)

<a id="topic-2.2.1.2.1-7"></a>

###### Jackson Heart Study: incident albuminuria, CKD, and ESKD

> “Of 2,300 participants, 41.3% had zero, 45.1% had 1, and 13.6% had 2 APOL1 risk variants.”
> “Compared with participants with zero APOL1 risk variants, those with 2 alleles had an increased risk for incident albuminuria (adjusted HR [aHR], 1.88; 95% CI, 1.04 to 3.40), ESKD (aHR, 9.05; 95% CI, 1.79 to 45.85), incident CKD (aHR, 1.65; 95% CI, 1.06 to 2.57)”

Source: [Young et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8664705/)

<a id="topic-2.2.1.2.1-8"></a>

###### CARDIA study: incident albuminuria in young adults

> “Mean age was 35 years, mean eGFRcys was 107 ml/min per 1.73 m2, and 13.2% of blacks had two APOL1 alleles. The incidence rate per 1000 person-years (95% confidence interval) for albuminuria over 15 years was 15.6 (10.6–22.1) for high-risk blacks, 7.8 (6.4–9.4) for low-risk blacks, and 3.9 (3.1–4.8) for whites. Compared with whites, the odds ratio (95% confidence interval) for incident albuminuria was 5.71 (3.64–8.94) for high-risk blacks and 2.32 (1.73–3.13) for low-risk blacks.”

Source: [Peralta et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4769203/)

<a id="topic-2.2.1.2.1-9"></a>

###### United States, 2008 to 2018: incidence of FSGS-attributed kidney failure in the US Renal Data System

> “The mean annual period prevalence and incidence rates of FSGS-attributed kidney failure from 2008 to 2018 were 87.6 and 7.5 per million in the US population, respectively.”
> “The majority were White (61.8%) or Black (32.6%).”

Source: [Bensink et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10831785/)

<a id="heading-2.2.1.2.2"></a>

###### 2.2.1.2.2 Prevalence of APOL1-mediated kidney disease

<a id="topic-2.2.1.2.2-1"></a>

###### United States: high-risk genotype frequency among Black Americans

> “Based on cohort and cross-sectional studies in the United States, the estimated allelic frequency among African Americans is 20%–22% for G1 and 13%–15% for G2, with approximately 10%–15% having an APOL1 high-risk genotype.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

> “Among Black individuals in the US, the G1 allele frequency is 22% and G2 allele frequency is 13%.”
> “Approximately 13% of Black individuals in the US (more than 5 million people) have a high-risk APOL1 genotype.”

Source: [Hopper and Olabisi (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11462457/)

> “In the MVP cohort, 15,604 (12.8%) had two APOL1 HR variants, of which 582 (0.5%) also had APOL1 p.N264K.”

Source: [Hung et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10631602/)

> “Allele frequencies of the G1 and G2 alleles were 22% and 13%, respectively (Table 1). Overall, 13.2% of the study sample carried two APOL1 risk alleles (G1/G1, G1/G2, or G2/G2), whereas 45.4% and 41.4% carried one (wild type [WT]/G1 or WT/G2) or zero (WT/WT) risk alleles, respectively.”

Source: [Foster et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3752955/)

<a id="topic-2.2.1.2.2-2"></a>

###### United States: estimated share of the Black population affected

> “Approximately 10%–15% of the Black population has a high-risk APOL1 genotype”
> “we can estimate that up to 3% of the Black population will be affected.”

Source: [Freedman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8425659/)

<a id="topic-2.2.1.2.2-3"></a>

###### West Africa and sub-Saharan Africa: high-risk genotype frequency

> “Frequencies of APOL1 high-risk genotypes are highest in West Africa, with up to 50% in Southeastern Nigeria, 37% in Central Ghana, and 25% in Southwestern Nigeria (Figure 3).”
> “Given that more than 100 million people in Sub-Saharan Africa may have 2 APOL1 high-risk alleles, the potential burden of APOL1 kidney disease in this region is catastrophically high.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

> “The Human Health and Heredity in Africa (H3Africa) Kidney Disease Research Network studied 8,355 participants from Ghana and Nigeria: 4,712 participants with CKD stages 2–5, 866 participants with biopsy proven glomerular diseases, and 2777 controls (eGFR ≥90 ml/min/1.73m2 without proteinuria).”
> “Overall, 43.0% and 29.7% participants carried 1 and 2 APOL1 risk variants, respectively (Table S4). The G1 haplotype was more frequent (40.7%) than the G2 haplotype (13.9%). The prevalence of APOL1 high-risk carriers was higher among persons with CKD compared to those without CKD (31.6% vs. 25.7%).”

Source: [Gbadegesin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11735277/)

> “In Africa, the APOL1 risk alleles are heavily concentrated in West Africa, and they are found at lower frequencies in eastern and southern Africa (15). For example, some groups within Nigeria or Ghana have combined risk variant allele frequencies that may exceed 50% (with high-risk genotypes of 25%), whereas individuals in Ethiopia, Sudan, and Somalia have very low probability of having two APOL1 risk variants.”

Source: [Friedman and Pollak (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7863644/)

<a id="topic-2.2.1.2.2-4"></a>

###### The Americas: high-risk genotype frequency in 111 populations

> “we found elevated frequencies of the APOL1 haplotype in African-American, sub-Saharan African, and Western African populations (11 to 32%). However, we also found other populations with elevated frequencies, including Jamaican, Barbadian, Grenadian, and Brazilian from Salvador (>10 to 22%); Trinidadian, Panamanian, Honduran, Haitian, Garifunan, and Palenque (>5 to 10%); and Guyanese, Dominican, Peruvian, Belizean, and Native American (1 to 5%).”

Source: [Nadkarni et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6482949/)

<a id="topic-2.2.1.2.2-5"></a>

###### Europe: high-risk genotype in unexplained kidney failure in the UK 100,000 Genomes Project

> “The study recruited 218 patients with uKF onset before age 50 years from the United Kingdom's 100,000 Genomes Project.”
> “Among individuals with recent African ancestry, high-risk APOL1 genotypes were significantly more common in those with uKF (52% vs 8.4% in those without uKF; P < 0.001).”

Source: [Sadeghi-Alavijeh et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40967557/)

> “Key areas of need include prevalence data for Black populations in the Caribbean, Brazil, the United Kingdom, Belgium, France, Sub-Saharan Africa, and any populations originating after dislocation by the diaspora (Table 1).”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

<a id="topic-2.2.1.2.2-6"></a>

###### High-risk genotype among Black patients with nondiabetic CKD, FSGS, and hypertension-attributed ESKD

> “The high-risk genotypes are found in approximately 16%–23% of Black people with nondiabetic CKD”

Source: [Freedman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8425659/)

> “40%–60% of those with primary FSGS have 2 APOL1 risk alleles.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

> “A high-risk APOL1 genotype is present in about 75% of Black patients with FSGS (1,33).”
> “Similarly, approximately 50% of Black patients with hypertension-attributable ESKD have a high-risk APOL1 genotype (1).”

Source: [Friedman and Pollak (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7863644/)

<a id="topic-2.2.1.2.2-7"></a>

###### High-risk genotype among people referred for APOL1 genotyping or kidney genetic testing

> “Our genotyping study is enrolling up to 4000 participants of recent African ancestry with FSGS or nondiabetic kidney disease and UPCR≥0.5g/g.”
> “The genotyping study interim analysis included 2866 participants of whom 674(23.5%) have 2 APOL1 variants; 36 of these participants enrolled in the completed Ph2 portion of AMPLITUDE.”

Source: [Chertow et al. (2024)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.20241x7qn0bv~amplitude-a-phase-23-adaptive-trial-of-inaxaplin-in)

> “Of 15,181 patients, 1035 (6.8%) had high-risk APOL1 genotypes.”
> “Considering APOL1 genotypes, 25.6% of patients in the genetic African ancestry cluster had high-risk APOL1 genotypes (n = 944), 39.5% were single risk allele carriers (n = 1453), and 34.8% had G0/G0 (n = 1281; Table 2 and Supplementary Figure S3).”

Source: [da Silva Francisco et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11403072/)

<a id="topic-2.2.1.2.2-8"></a>

###### United States, 2008 to 2018: prevalence of FSGS-attributed kidney failure in the US Renal Data System

> “The prevalence of FSGS-attributed kidney failure steadily increased over time from 76.5 per million US persons in 2008 to 96.0 per million in 2018 (Fig 2A)”

Source: [Bensink et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10831785/)

<a id="topic-2.2.1.2.2-9"></a>

###### Company estimates: Vertex Pharmaceuticals statements of the affected population in the United States and Europe, 2024 to 2026

> “Approximately 100,000 people in the U.S. and Europe have two APOL1 genetic variants and proteinuric kidney disease.”

Source: [Vertex Pharmaceuticals press release, phase 3 advancement (2024)](https://news.vrtx.com/news-releases/news-release-details/vertex-advances-inaxaplin-vx-147-phase-3-portion-adaptive-phase)

> “Vertex plans to initiate AMPLIFIED, a Phase 2b open-label study of inaxaplin in patients with AMKD and diabetes or other co-morbidities currently not eligible for the AMPLITUDE Phase 2/3 pivotal trial, expanding the estimated potentially eligible population from 150,000 to 250,000 patients.”

Source: [Vertex Pharmaceuticals press release, pipeline and business updates (2025)](https://news.vrtx.com/news-releases/news-release-details/vertex-provides-pipeline-and-business-updates-advance-upcoming-0)

> “AMKD affects an estimated patient population of approximately 250,000 in the U.S. and Europe, including AMKD patients with comorbidities.”

Source: [Vertex Pharmaceuticals press release, kidney portfolio advancements (2025)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-key-advancements-across-kidney-portfolio)

> “AMKD occurs in people with African ancestry, with an estimated patient population of approximately 150,000 people in the U.S. and Europe.”
> “In addition, we estimate that there are approximately 100,000 people with AMKD with comorbidities, such as type 2 diabetes, in the U.S. and Europe”

Source: [Vertex Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/vrtx-20251231.htm)

> “AMKD affects approximately 150,000 people in the U.S. and Europe.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="heading-2.2.1.3"></a>

##### 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

###### Penetrance: lifetime risk of kidney failure with a high-risk genotype

> “Even among individuals with a high-risk genotype, having 2 APOL1 risk alleles does not necessarily lead to development of CKD. Approximately 15% of individuals with an APOL1 high-risk genotype will develop kidney failure, and a smaller fraction will develop FSGS.”
> “Despite the strong association between having a high-risk genotype and increased risk of kidney disease, it is not possible to predict which individuals with a high-risk genotype will develop CKD, idiopathic FSGS, hypertension-attributed kidney disease, HIV-1–associated nephropathy (HIVAN), or earlier failure of a kidney transplant from a donor with an APOL1 high-risk genotype.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

> “Individuals with a high-risk APOL1 genotype have been estimated to have a 15% to 30% lifetime risk of developing ESKD.”
> “The basis of this variable penetrance is currently unknown.”

Source: [Hopper and Olabisi (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11462457/)

> “Among individuals with high-risk APOL1 genotypes, the lifetime risk of developing kidney failure is ∼15%, indicating that other genetic variants or nongenetic modifiers likely contribute substantially to an individual patient’s risk of progressive kidney disease.”

Source: [da Silva Francisco et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11403072/)

<a id="topic-2.2.1.3-2"></a>

###### Progression in established CKD: AASK and CRIC cohorts

> “In the AASK study, the primary outcome occurred in 58.1% of the patients in the APOL1 high-risk group and in 36.6% of those in the APOL1 low-risk group (hazard ratio in the high-risk group, 1.88; P<0.001). There was no interaction between APOL1 status and trial interventions or the presence of baseline proteinuria.”
> “Among the patients with diabetes, the eGFR slope (as measured in milliliters per minute per 1.73 m2 per year) was −1.5 among white patients, −2.7 among black patients in the APOL1 low-risk group, and −4.3 among black patients in the APOL1 high-risk group. Among the patients without diabetes, the corresponding eGFR slopes were −0.7, −1.0, and −2.9.”

Source: [Parsa et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3969022/)

<a id="topic-2.2.1.3-3"></a>

###### Trajectory of eGFR decline in hypertension-attributed CKD

> “Over a median follow-up of 9 years, 24.0% of participants experienced steady eGFR decline, 25.9% had an unsteady decline, 25.6% were steady and stable, and 24.6% were unsteady but stable.”
> “The APOL1 high–risk group was associated with a greater odds for the steady decline pattern than the APOL1 low–risk group (unadjusted odds ratio, 2.45; 95% confidence interval, 1.62 to 3.69). This association remained significant after adjusting for demographic factors, baseline eGFR, urine protein-to-creatinine ratio, treatment assignment, and follow-up time (adjusted odds ratio, 1.59; 95% confidence interval, 1.00 to 2.52).”

Source: [Tin et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4974891/)

> “Individuals with the high-risk genotypes were 1.72-fold more likely to develop incident proteinuria compared with those with the low-risk genotypes (95% confidence interval, 1.27 to 2.32), independent of age, sex, ancestry, baseline eGFR, baseline systolic BP, and randomized treatment groups. Although eGFR declined faster after the onset of proteinuria, this rate did not differ significantly by APOL1 risk status.”

Source: [Chen et al. (2017b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5672963/)

<a id="topic-2.2.1.3-4"></a>

###### Real-world progression in genetically confirmed AMKD

> “Almost half of patients in the US with APOL1-mediated kidney disease (AMKD) had progressed to stage 4 or 5 chronic kidney disease (CKD) by a mean age of 45.6 years”
> “In the pooled cohort with baseline eGFR below 90 mL/min/1.73 m2, the mean annual eGFR slope was –3.0 mL/min/1.73 m2 (95% CI, –3.3 to –2.7) in patients without diabetes and –4.2 mL/min/1.73 m2 (95% CI, –4.5 to –3.9) in patients with type 2 diabetes.”

Source: [AJMC (2026)](https://www.ajmc.com/view/real-world-amkd-data-highlight-quick-progression-unmet-needs)

<a id="topic-2.2.1.3-5"></a>

###### Age at kidney failure and time to dialysis: company and laboratory statements

> “People with AMKD progress to end stage kidney disease at a faster rate than those with other forms of chronic kidney disease and reach kidney failure at a median age of 45 years old.”

Source: [Vertex Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/vrtx-20251231.htm)

> “Compared with chronic kidney disease (CKD) patients of African ancestry with zero or one APOL1 risk variant, AMKD patients progress to dialysis nine to 12 years earlier and have a higher decline in the estimated glomerular filtration rate (eGFR).”

Source: [Labcorp](https://www.labcorp.com/tests/407154/apol1-genotyping)

<a id="topic-2.2.1.3-6"></a>

###### FSGS: faster progression to kidney failure

> “FSGS associated with two APOL1 risk alleles associated with earlier age of onset (P = 0.01) and faster progression to ESRD (P < 0.01) but similar sensitivity to steroids compared with other subjects.”
> “The hazard ratio for progression was 2.3 (95% CI 1.43, 4), and median survival was 5 yr for subjects with 2 APOL1 risks alleles, compared with 13 yr for subjects with 0 or 1 APOL1 risk allele.”

Source: [Kopp et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3231787/)

> “APOL1 risk status is associated with lower kidney function, more glomerulosclerosis and interstitial fibrosis, and greater propensity to progress to ESRD.”

Source: [Kopp et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4446865/)

<a id="topic-2.2.1.3-7"></a>

###### General population: incident CKD and kidney failure in ARIC

> “Carrying two risk alleles associated with a 1.49-fold increased risk of CKD (95% CI=1.02 to 2.17) and a 1.88-fold increased risk of ESRD (95% CI=1.20 to 2.93) compared with zero or one risk allele; associations persisted after adjusting for European ancestry. Among participants who developed CKD, those participants with two risk alleles were more likely to progress to ESRD than their counterparts with zero or one risk allele (HR=2.22, 95% CI=1.01 to 4.84).”

Source: [Foster et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3752955/)

> “Black race and APOL1 high-risk status were associated with faster eGFR decline (P<0.001 for each). However, we detected substantial overlap among the groups: median (10th–90th percentile) unadjusted eGFR decline was 1.5 (1.0–2.2) ml/min per 1.73 m2 per year for whites, 2.1 (1.4–3.1) ml/min per 1.73 m2 per year for blacks with APOL1 low-risk status, and 2.3 (1.5–3.5) ml/min per 1.73 m2 per year for blacks with APOL1 high-risk status.”

Source: [Grams et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5004654/)

<a id="topic-2.2.1.3-8"></a>

###### Young adults: incident albuminuria and eGFR decline in CARDIA

> “The incidence rate per 1000 person-years (95% confidence interval) for albuminuria over 15 years was 15.6 (10.6–22.1) for high-risk blacks, 7.8 (6.4–9.4) for low-risk blacks, and 3.9 (3.1–4.8) for whites.”
> “After adjustment, high-risk blacks had a 0.45% faster yearly eGFRcys decline over 9.3 years compared with whites.”

Source: [Peralta et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4769203/)

<a id="topic-2.2.1.3-9"></a>

###### Children with APOL1-associated glomerular disease

> “In the United States, children having a high-risk APOL1 genotype are reportedly at increased risk for early onset CKD.13,46 Findings suggest a common natural history for children with APOL1-associated glomerular disease, where children with high-risk genotypes have a more aggressive form of glomerular disease, which may relate to high rates of FSGS and prematurity.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

<a id="topic-2.2.1.3-10"></a>

###### Prognostic heterogeneity among high-risk genotype carriers with preserved eGFR

> “APRS achieved a time-dependent area under the receiver operating characteristic curve (tAUC) of 86.5%, outperforming the Kidney Failure Risk Equation (66.1%) and polygenic risk scores, with 10-year event rates of 62.5% versus 3.3% across risk quintiles.”

Source: [Li et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13190321/)

<a id="topic-2.2.1.3-11"></a>

###### COVID-19-associated collapsing glomerulopathy: short-term outcomes

> “At follow-up, 19 (86%) patients were alive, and 15 (68%) were dialysis free, including seven of 14 who initially required dialysis.”
> “Overall, 36% achieved partial remission of proteinuria, 32% had no remission, and 32% reached combined end points of ESKD or death.”

Source: [Kudose et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8806099/)

<a id="topic-2.2.1.3-12"></a>

###### Mortality: death before kidney failure and all-cause mortality by genotype

> “Over a median follow-up of 9 years, 77 patients (11.1%) died before reaching the composite renal outcome, 204 (29.4%) received a diagnosis of end-stage renal disease, and 288 (41.6%) reached the composite renal outcome (Table 2). APOL1 status was not significantly associated with death before a diagnosis of end-stage renal disease.”

Source: [Parsa et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3969022/)

> “Over a mean follow-up of 5.1 years, APOL1 high-risk Blacks had a 2.67-fold higher risk for ESRD compared with low-risk Blacks (95% confidence interval [CI] = 1.05–6.79) in models adjusted for age and sex. This association was no longer significant upon further adjustment for baseline eGFRCrCys and albuminuria (hazard ratio [HR] = 1.08; 95% CI = .39–2.96). Rate of hospitalizations and risks of mortality and incident CKD did not differ significantly by APOL1 genotype status.”

Source: [Chen et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7855571/)

> “In a recessive genetic model adjusted for demographics, comorbidities, and kidney measures, there were no significant associations between APOL1 kidney-risk genotypes and death or the composite outcome of incident cardiovascular disease, which included coronary heart disease, stroke, myocardial infarction, and heart failure.”

Source: [Grams et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6779370/)

<a id="topic-2.2.1.3-13"></a>

###### Kidney transplantation: allograft survival with kidneys from high-risk genotype donors

> “Twenty-two of 136 transplanted kidneys (16%) were from donors with two APOL1 nephropathy risk variants. Twenty five grafts failed; eight (32%) had two APOL1 risk variants.”
> “Kidneys from AA deceased donors harboring two APOL1 risk variants failed more rapidly after renal transplantation than those with zero or one risk variants.”

Source: [Reeves-Daniel et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3083491/)

> “Combined analysis of 1153 DDKTs from AA donors revealed donor APOL1 high-risk genotype (HR 2.05; p=3×10−4), older donor age (HR 1.18; p=0.05), and younger recipient age (HR 0.70; p=0.001) adversely impacted allograft survival.”
> “A competing risk analysis revealed that APOL1 impacted renal allograft survival, but not recipient survival.”

Source: [Freedman et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4684443/)

> “In the United States, living donors with APOL1 high-risk genotypes more often develop advanced CKD post donation,84 and receipt of deceased donor kidneys from APOL1 high-risk genotype donors are associated with more rapid graft failure.85–87 Results are mixed,88–90 but recipients with high-risk APOL1 genotypes may also have reduced graft survival.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

<a id="topic-2.2.1.3-14"></a>

###### Living kidney donors: kidney function after donation

> “Sixty-eight Black donors (15.3%) had APOL1 high-risk genotypes (G1/G1, G2/G2, or G1/G2). Home-based research study visits occurred a median (IQR) of 18.5 (16.9-20.5) years after donation.”
> “Black kidney donors with APOL1 high-risk genotypes had a higher risk of developing an eGFR of less than 45 mL/min/1.73 m2 than Black kidney donors without APOL1 high-risk genotypes (relative risk, 2.31; 95% CI, 1.16-4.61; P = .02) (after adjustment for predonation eGFR: relative risk, 1.91; 95% CI, 0.90-4.03; P = .09).”

Source: [Hsu et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42329639/)

> “At a median of 12 years after donation, donors with the APOL1 high-risk genotype had lower eGFR (57±18 versus 67±15 ml/min per 1.73 m2; P=0.02) and faster decline in eGFR after adjusting for predonation eGFR (1.19; 95% confidence interval, 0 to 2.3 versus 0.4; 95% confidence interval, 0.1 to 0.7 ml/min per 1.73 m2 per year, P=0.02). Two donors developed ESRD; both carried the APOL1 high-risk genotype.”

Source: [Doshi et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5875947/)

<a id="topic-2.2.1.3-15"></a>

###### APOLLO: prospective study of transplant outcomes by donor and recipient genotype

> “The National Institutes of Health (NIH)–sponsored APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) is prospectively assessing kidney allograft survival from donors with recent African ancestry based on donor and recipient APOL1 genotypes.”
> “The primary objective of APOLLO is determining whether the presence of APOL1 renal-risk genotypes in deceased-donors is associated with death-censored renal allograft survival.”
> “APOLLO aims to enroll all eligible kidney donors and kidney transplant recipients from U.S. transplant programs. This effort includes 260 academic and community-based programs with kidneys recovered from 58 OPOs (Figure 1).”

Source: [Freedman et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7056919/)

<a id="heading-2.2.1.4"></a>

##### 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

###### Normal function of APOL1: trypanolytic pore-forming protein

> “The APOL1 gene encodes an innate immune pore-forming protein that inserts into the trypanosome’s lysosomal membrane, inducing osmotic stress and ultimately lysing the trypanosome.”
> “The G1 and G2 variants of the APOL1 gene restored immune protection against the novel T brucei strains and underwent positive selection in West Africa.”

Source: [Hopper and Olabisi (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11462457/)

> “In vitro assays revealed that only the kidney disease-associated ApoL1 variants lysed Trypanosoma brucei rhodesiense.”

Source: [Genovese et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2980843/)

<a id="topic-2.2.1.4-2"></a>

###### Gain-of-function cation channel activity of the G1 and G2 variants

> “APOL1 protein can act as an ion channel (pore) in trypanosome and eukaryotic cells.26,49–51 The G1 and G2 variants of APOL1 alter the normal pore-forming function of the APOL1 protein, leading to increased pore activity.”
> “In cell-based models, G0 is generally nontoxic, whereas G1 and G2 express toxic, gain-of-function variants.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

> “Recent experimental evidence suggests that the G1 and G2 variants may cause kidney injury by increased transport of monovalent cations—similar to the mechanism by which G1 and G2 provide resistance to T brucei.”

Source: [Hopper and Olabisi (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11462457/)

> “In HEK293 cells, we demonstrated that G1-mediated Na+ import/K+ efflux triggered activation of GPCR/IP3–mediated calcium release from the ER, impaired mitochondrial ATP production, and impaired translation, which were all reversed by VX-147.”
> “Together, these results establish APOL1-mediated Na+/K+ transport as the proximal driver of APOL1-mediated kidney disease.”

Source: [Datta et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10904047/)

<a id="topic-2.2.1.4-3"></a>

###### Human genetic evidence: the p.N264K variant blocks pore function

> “A different APOL1 variant, p.N264K, reduced the risk of CKD and ESKD among carriers of APOL1 HR variants to levels comparable with individuals with APOL1 low-risk variants in an analysis of 121,492 participants of African ancestry from the Million Veteran Program (MVP). Functional genetic studies in cell models showed that APOL1 p.N264K blocked APOL1 pore-forming function and ion channel conduction and reduced toxicity of APOL1 HR mutations.”

Source: [Hung et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10631602/)

<a id="topic-2.2.1.4-4"></a>

###### Podocyte injury, proteinuria, and glomerulosclerosis

> “Risk genotypes overexpressed in podocytes play a crucial role in podocyte injury and correlate with disease severity.3,25 Although podocyte expression of G1/G2 APOL1 and engagement of downstream signaling mechanisms is necessary for glomerulosclerosis, there is a growing body of data for extra-podocyte roles of APOL1 risk variants.”
> “Currently, there are no models of the slowly progressive, low proteinuria, chronic disease that accounts for the vast majority of human APOL1 kidney disease.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

> “In AMKD, the kidney’s filtering units, known as the glomeruli, and within them the cells known as podocytes, are damaged, leading to leakage of protein into the urine, deterioration in kidney function, scarring, and, ultimately, end stage renal disease.”

Source: [Vertex Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/vrtx-20251231.htm)

<a id="topic-2.2.1.4-5"></a>

###### Interferon-induced APOL1 expression and second hits

> “Expression of APOL1 is regulated by cytokines (mostly by interferon), inflammation, hypoxia/ischemia, viruses, and nucleic acids.”
> “Nongenetic second hits resulting in glomerular disease include high interferon states, viral infections (HIV and COVID-19), exposure to alpha, beta, or gamma interferon, and APOL1 overexpression,3,6,20,22,68 with high interferon states having the strongest evidence.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

> “The most established systemic factors are viral infections (for example, HIV) and, more generally, systemic elevations in interferon levels. It is now apparent that APOL1 is expressed in an interferon-dependent manner55.”
> “Kidney disease has also been reported in individuals with APOL1 risk variants after receiving therapeutic interferon138.”

Source: [Daneshpajouhnejad et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8877744/)

> “Our results reveal that IFN-γ signaling simultaneously induces endothelial injury and primes renal cells for pyroptosis, suggesting a combinatorial mechanism for APOL1-mediated collapsing glomerulopathy, which can be targeted therapeutically.”

Source: [Juliar et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11216883/)

<a id="topic-2.2.1.4-6"></a>

###### Downstream cellular injury pathways in experimental models

> “Functions associated with G1 or G2 APOL1 overexpression in cells or mice include ion channel,26 actin cytoskeleton,51,60,61 or mitochondrial dysfunction62; endoplasmic reticulum stress3; reduction of global protein synthesis63,64; suPAR (soluble urokinase plasminogen activator receptor)-dependent activation of integrin65; activation of nucleotide sensors; and inflammation.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

> “Cell and mouse models implicate endolysosomal and mitochondrial dysfunction, altered ion channel activity, altered autophagy, and activation of protein kinase R in the pathogenesis of APOL1-associated kidney disease; however, the relevance of these injury pathways to human disease has not been resolved.”

Source: [Daneshpajouhnejad et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8877744/)

<a id="heading-2.2.1.5"></a>

##### 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

###### Diagnostic definition: high-risk genotype with nondiabetic kidney disease

> “AMKD is diagnosed when an individual with a high-risk APOL1 genotype develops nondiabetic kidney disease. There is no established glomerular filtration rate (GFR) cutoff to diagnose AMKD. Proteinuria (urine albumin to creatinine ratio >30 mg/g) is often present but is not a requirement for the diagnosis of AMKD.”

Source: [Hopper and Olabisi (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11462457/)

> “A definitive diagnosis of AMKD requires a genetic test for the presence of two APOL1 risk variants.”

Source: [Labcorp](https://www.labcorp.com/tests/407154/apol1-genotyping)

<a id="topic-2.2.1.5-2"></a>

###### Role of genotyping: definitive for risk alleles, not diagnostic of a specific disease

> “Genetic testing is definitive for the presence of APOL1 risk alleles, although the presence of risk alleles is not prognostic or diagnostic of any specific kidney diseases.”
> “However, for individuals, genotyping is an important clinical consideration given that the high-risk APOL1 genotypes are associated with significantly increased risk of CKD progression, and genotyping could inform risk stratification and frequency of follow-up.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

<a id="topic-2.2.1.5-3"></a>

###### Delphi consensus: patients in whom APOL1-associated nephropathy should be considered

> “A1. APOL1-associated nephropathy should be considered in all patients with kidney disease who have African ancestry, particularly when there is a family history of CKD”
> “A2. Regardless of ancestry, APOL1-associated nephropathy should be considered in all patients with kidney disease and a family member with a confirmed APOL1 high-risk genotype”
> “A3. Clinical factors that are relevant to considering APOL1-associated nephropathy include hypertension, nondiabetic nephropathy, and rapid progression of CKD”
> “A12. APOL1 testing is not common in routine clinical practice; it is carried out in only a few specialist centers, often as part of APOL1 research”

Source: [Freedman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8425659/)

<a id="topic-2.2.1.5-4"></a>

###### Delphi consensus: testing and kidney biopsy if a treatment becomes available

> “C3. If a treatment for APOL1-associated nephropathy becomes available, all patients suspected of having APOL1-associated nephropathy should be offered genetic testing with appropriate counseling”
> “C4. If a treatment for APOL1-associated nephropathy becomes available, all Black people (or those with sub-Saharan African ancestry) with CKD should be offered genetic testing with appropriate counseling”
> “C6. If a treatment for APOL1-associated nephropathy was available, a kidney biopsy should be performed to confirm the diagnosis in individuals with high-risk APOL1 genotypes”

Source: [Freedman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8425659/)

<a id="topic-2.2.1.5-5"></a>

###### Misclassification as hypertension-attributed CKD

> “Genetic testing for APOL1 in African ancestry patients with nephropathy is currently uncommon. As such, many patients with APOL1-associated nephropathy who present with subnephrotic proteinuria are misclassified as having unspecified CKD or hypertension-attributed CKD, although intensive BP control does not slow kidney disease progression.”

Source: [Freedman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8425659/)

> “Many with West African ancestry who have hypertension and kidney disease who were previously labeled as hypertensive nephropathy are now recognized to carry 2 APOL1 risk alleles and have APOL1-contributed kidney disease.”

Source: [Ames et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266825/)

<a id="topic-2.2.1.5-6"></a>

###### KDIGO Controversies Conference: principles for APOL1 testing

> “At population levels, there is insufficient evidence to guide recommendations for APOL1 routine testing or screening. There are no established treatments or treatment recommendations for APOL1 kidney disease, and APOL1 genotype results are not by themselves actionable for changing management.”
> “The individual has kidney disease OR is a prospective living kidney donor OR has a relative with an APOL1 high-risk genotype.”
> “Appropriately qualified counseling is available to support voluntary and informed decision-making about testing.”
> “In children with FSGS and CKD, APOL1 genotyping can inform prognosis, and early targeted testing for APOL1 genotype in infants and children could make possible early surveillance and intervention.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

<a id="topic-2.2.1.5-7"></a>

###### Screening of asymptomatic individuals

> “Screening of asymptomatic individuals in the US for high-risk APOL1 genotype is not currently recommended.”
> “However, individuals with recent West African heritage who have nondiabetic CKD, proteinuria, or a family history of kidney disease may be offered APOL1 screening. All individuals should receive genetic counseling before and after APOL1 genetic testing and be advised about potential for increased cost of health insurance that may be associated with detection of a high-risk APOL1 genotype.”

Source: [Hopper and Olabisi (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11462457/)

<a id="topic-2.2.1.5-8"></a>

###### KDIGO 2024 CKD guideline: genetic testing in evaluation of cause

| Test category | Examples | Comment |
| --- | --- | --- |
| Genetic testing | “APOL1, COL4A3, COL4A4, COL4A5, NPHS1, UMOD, HNF1B, PKD1, PKD2” | “Evolving as a tool for diagnosis, increased utilization is expected.” |

Source: [KDIGO (2024)](https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf)

> “Genetic testing is emerging as a valuable component for evaluation of cause.”

Source: [KDIGO (2024)](https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf)

<a id="topic-2.2.1.5-9"></a>

###### Genotype refinement: the p.N264K (M1) protective variant

> “Therefore, this variant, based on prior functional and current genetic data, counters the toxic effect of the G2 allele, allowing the reclassifying of APOL1 high-risk individuals as non-high-risk if they carry the p.N264K missense variant.”

Source: [Gupta et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10689833/)

> “Among individuals with CKD with APOL1-HR genotypes, M1 was 4 times more frequent in those whose CKD was not due to FSGS or SRNS. Importantly, electronic health record and biopsy review identified an alternative, non-APOL1 cause for CKD in nearly all APOL1-HR-M1 cases.”
> “Patients with CKD with an APOL1-HR genotype and M1 should be evaluated for an alternative and potentially treatable cause of their CKD.”

Source: [Martinelli et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12980251/)

> “Therefore, risk prediction solely based on presence of APOL1 risk variants without testing for the N264K variant is inadequate.”

Source: [Ames et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266825/)

<a id="topic-2.2.1.5-10"></a>

###### Mendelian kidney disease in patients with high-risk genotypes

> “Of 15,181 patients, 1035 (6.8%) had high-risk APOL1 genotypes. Among patients with recent genomic African ancestry, the prevalence of Mendelian kidney diseases was lower in those with high-risk APOL1 genotypes (9.6%; n = 91/944) compared with single risk APOL1 allele carriers (13.6%; n = 198/1453) and those with G0/G0 APOL1 genotypes (16.6%; n = 213/1281).”

Source: [da Silva Francisco et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11403072/)

<a id="topic-2.2.1.5-11"></a>

###### Unexplained kidney failure in the United Kingdom

> “Among individuals with recent African ancestry, high-risk APOL1 genotypes were significantly more common in those with uKF (52% vs 8.4% in those without uKF; P < 0.001).”

Source: [Sadeghi-Alavijeh et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40967557/)

<a id="topic-2.2.1.5-12"></a>

###### Living kidney donor evaluation

> “Among transplant centers in the United States, in 1 survey,93 one-half of centers offered APOL1 testing. The KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors94 suggests that APOL1 genotyping may be offered to donor candidates with Sub-Saharan African ancestry. The British Transplantation Society95 recommends offering APOL1 genotyping (which is publicly funded by the United Kingdom National Health Service) as part of the assessment and communication of donor risk early in the evaluation of all potential donors of African heritage under 60 years old.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

> “Therefore, in donors at high risk for APOL1 risk variants, genetic testing for APOL1 mutations may provide information for both the disease risk in the donor and allograft outcomes in the recipient.”

Source: [KDIGO (2021)](https://kdigo.org/wp-content/uploads/2017/02/KDIGO-Glomerular-Diseases-Guideline-2021-English.pdf)

> “Healthy living donors who self-identify as Black people or of sub-Saharan or West African ancestry, who are otherwise approved for donation, should be counseled regarding the risk of future kidney disease from APOL1 G1 and G2 variants and the protective role of the N264K APOL1 variant and should also offered the option of testing (Supplementary Information, Case 4).”

Source: [Ames et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266825/)

> “The study found that the APOL1 genotype is a risk factor for reduced kidney function postdonation. These results suggest that all Black individuals who are living donor candidates in the US should undergo APOL1 genotyping for better risk stratification.”

Source: [Hsu et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42329639/)

> “Key elements of consensus include the following: ask potential donors about African ancestry rather than race; make testing decisions only after discussion with donors; encourage disclosure of test results to blood relatives and organ recipients but do not require it; use test results to inform decision making, but never for unilateral decisions by transplant programs.”

Source: [McIntosh et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11020447/)

<a id="topic-2.2.1.5-13"></a>

###### Available tests: manufacturer-sponsored genotyping

> “This test is used for identification of APOL1 risk variants to aid the diagnosis and management of APOL1-mediated kidney disease (AMKD).”
> “Multiplex end-point TaqMan Polymerase Chain Reaction (PCR) allelic discrimination”
> “Each patient that meets the eligibility criteria will receive one Labcorp APOL1 Genotype Test and will have access to genetic results counseling included in the program at no cost to the patient.”

Source: [Labcorp](https://www.labcorp.com/tests/407154/apol1-genotyping)

> “Vertex Pharmaceuticals is sponsoring a no-cost Renasight™ renal genetic testing for eligible* patients of African ancestry diagnosed with chronic kidney disease”

Source: [Natera](https://www.natera.com/info/vertex-sponsored-page-program-overview/how-to-order/)

<a id="topic-2.2.1.5-14"></a>

###### Barriers to genetic testing

> “Barriers to widespread adoption of genetic testing include a lack of perceived benefit, lack of ease, difficulties in interpreting genetic variants, high cost, and the need for genetic counseling.”

Source: [Srinivasan et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12361766/)

Additional sources: [Mohan et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6756958/)

<a id="heading-2.2.1.6"></a>

##### 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

###### Symptom burden: often asymptomatic until advanced disease

> “AMKD occurs in people of African ancestry, specifically of sub-Saharan origin, and is characterized by two APOL1 risk variants, proteinuria, rapid progression, early disease onset, lack of symptoms and other factors such as hypertension or a family history of kidney disease.”

Source: [Labcorp](https://www.labcorp.com/tests/407154/apol1-genotyping)

> “In terms of the clinical presentation and course of APOL1 nephropathies, we do not know the extent to which the annual risk of incident kidney disease differs over the life course of these individuals; the extent to which APOL1 kidney disease first manifests as microalbuminuria, macroalbuminuria or reduced eGFR”

Source: [Daneshpajouhnejad et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8877744/)

<a id="topic-2.2.1.6-2"></a>

###### Urinary findings: variable proteinuria, from subnephrotic to nephrotic range

> “The typical traits of APOL1 kidney disease include recent (<10,000 years) African ancestry, variable proteinuria, interstitial fibrosis, and reduced kidney function.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

> “As such, many patients with APOL1-associated nephropathy who present with subnephrotic proteinuria are misclassified as having unspecified CKD or hypertension-attributed CKD”

Source: [Freedman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8425659/)

> “Proteinuria (urine albumin to creatinine ratio >30 mg/g) is often present but is not a requirement for the diagnosis of AMKD.”

Source: [Hopper and Olabisi (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11462457/)

<a id="topic-2.2.1.6-3"></a>

###### Cardiovascular signs: hypertension

> “Hypertension (88.9%), hyperlipidemia (42.3%), and chronic pulmonary disease (23.1%) were the most common comorbidities, and 45.7% of patients were in CKD stage 4 or 5.”

Source: [AJMC (2026)](https://www.ajmc.com/view/real-world-amkd-data-highlight-quick-progression-unmet-needs)

> “These variants, termed G1 and G2, are a frequent cause of kidney disease — termed APOL1 nephropathy — that typically manifests as focal segmental glomerulosclerosis and the clinical syndrome of hypertension and arterionephrosclerosis.”

Source: [Daneshpajouhnejad et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8877744/)

> “APOL1 risk alleles were associated under an additive model with systolic blood pressure (SBP) and age at diagnosis of hypertension, which was 2 to 5 years younger in the APOL1 variant allele homozygotes (Cox proportional hazards analysis, p value for combined meta-analysis [pcom] = 1.9 × 10−5).”
> “APOL1-associated estimated glomerular filtration rate decline was observed starting a decade later in life in the 30- to 39-year age range.”

Source: [Nadkarni et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5479565/)

> “Based on data from the United States, hypertension accelerates all forms of CKD progression,38 but it is not clear whether hypertension alone causes APOL1 kidney disease.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

<a id="topic-2.2.1.6-4"></a>

###### Kidney function: reduced eGFR at presentation

> “Among the 63% of patients with eGFR values recorded during the study period, the mean (SD) eGFR was 38 (29) mL/min/1.73 m2.”

Source: [AJMC (2026)](https://www.ajmc.com/view/real-world-amkd-data-highlight-quick-progression-unmet-needs)

> “Individuals with the APOL1 risk genotype tended to present at an older age and had significantly lower baseline eGFR, more segmental glomerulosclerosis and total glomerulosclerosis, and more tubular atrophy/interstitial fibrosis.”

Source: [Kopp et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4446865/)

<a id="topic-2.2.1.6-5"></a>

###### Age at onset: adolescence and early adulthood in APOL1-associated FSGS

> “As shown in Table 3, 70% of individuals with two APOL1 risk alleles experience onset of FSGS between the ages of 15 to 39 compared with 42% of carriers of 0 or 1 risk alleles (P = 0.0003, FET). Together these data support the idea that FSGS among APOL1 high-risk individuals is a distinct disease with earlier onset and tendency to present during the teenage years and early adulthood.”

Source: [Kopp et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3231787/)

<a id="topic-2.2.1.6-6"></a>

###### Acute presentation: acute kidney injury and nephrotic syndrome with collapsing glomerulopathy

> “All but one patient presented with AKI, 17 had nephrotic-range proteinuria, and six had nephrotic syndrome. Fourteen (61%) patients required dialysis at presentation. Among 17 patients genotyped, 16 (94%) were high-risk APOL1.”
> “Seventeen had nephrotic-range proteinuria when quantified, although only six had full nephrotic syndrome, largely due to the absence of edema.”
> “Seven had hematuria (defined as more than five red blood cells per high-power field; data available in n=21), and six had edema on physical examination.”

Source: [Kudose et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8806099/)

> “At biopsy day, mean serum creatinine was 6.5 mg/dl and mean urine protein-creatinine ratio was 11.5 g. Kidney biopsy specimens showed collapsing glomerulopathy, extensive foot process effacement, and focal/diffuse acute tubular injury.”
> “All six patients had an APOL1 high-risk genotype. Five patients needed dialysis (two of whom died); one partially recovered without dialysis.”

Source: [Wu et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7460910/)

<a id="topic-2.2.1.6-7"></a>

###### Histologic findings: FSGS, collapsing variant, and interstitial fibrosis

> “There were differences in renal histology, particularly more collapsing variants in those with the risk genotype (P=0.02), although this association was confounded by age.”

Source: [Kopp et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4446865/)

> “The presence of 2 APOL1 risk variants (G1/G1, G1/G2, and G2/G2), referred to as high-risk genotype, substantially increases the risk of certain kidney diseases like FSGS, collapsing glomerulopathy (HIV and COVID associated), and severe lupus nephritis.”

Source: [Ames et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266825/)

<a id="heading-2.2.1.7"></a>

##### 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

###### Kidney failure requiring dialysis or transplantation

> “Black individuals in the US with a high-risk APOL1 genotype are also more likely to develop hypertension-attributed ESKD, lupus nephritis–attributed ESKD, FSGS, and HIV-associated nephropathy compared with Black individuals who have a low-risk APOL1 genotype (Figure).”

Source: [Hopper and Olabisi (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11462457/)

> “Among blacks, the APOL1 high-risk genotype associated only with higher risk of ESRD in a fully adjusted analysis.”

Source: [Grams et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5004654/)

<a id="topic-2.2.1.7-2"></a>

###### Cardiovascular disease

> “A metanalysis showed no overall association between the presence of APOL1 risk variants and cardiovascular disease, suggesting that high-risk variants may not have a direct effect on cardiovascular disease independent from effects on kidney disease.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

> “There were also no significant associations between these variants and coronary heart disease, stroke, myocardial infarction, and heart failure when the conditions were considered individually. This study suggests that the APOL1 kidney-risk variants may not have a direct effect on cardiovascular disease separate from the effects of kidney disease itself.”

Source: [Grams et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6779370/)

> “There was no significant association between APOL1 genotypes and the composite CVD outcome in both unadjusted (HR=1.23; 95% CI: 0.83 to 1.81) and fully adjusted (HR=1.16; 95% CI: 0.77 to 1.76) models; however, in using an additive model, APOL1 high-risk variants were associated with increased cardiovascular mortality.”

Source: [Chen et al. (2017a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5570668/)

> “In those without diabetes mellitus, APOL1 high-risk genotypes associated with greater risk of incident composite CVD (hazard ratio, 1.67; 95% confidence interval, 1.12–2.47) compared with those with APOL1 low-risk genotypes in multivariable adjusted models. This latter association was driven by ischemic strokes (hazard ratio, 2.32; 95% confidence interval, 1.33–4.07), in particular, those related to small vessel disease (hazard ratio, 5.10; 95% confidence interval, 1.55–16.56).”

Source: [Gutiérrez et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6339526/)

<a id="topic-2.2.1.7-3"></a>

###### Preeclampsia and pregnancy outcomes

> “Fetal APOL1 genotype has been associated with maternal preeclampsia in preterm infants and with altered fetal growth in term infants.41 There is a clear health disparity in the prevalence and severity of preeclampsia in Black women compared with Hispanic or White women, apparently due at least in part to having an APOL1 high-risk genotype.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

> “Fetal APOL1 high-risk (HR) genotype was associated with preeclampsia, with odds ratios at EMC and UTHSC of 1.84 (95% CI 1.11, 2.93) and 1.92 (95% CI 1.05, 3.49), respectively. Maternal APOL1 HR genotype was not associated with preeclampsia. Mothers with the fetal APOL1 HR genotype had more cerebral or visual disturbances (63% versus 37%, p = 0.04).”

Source: [Reidy et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6128247/)

<a id="heading-2.2.1.8"></a>

##### 2.2.1.8 Burden of APOL1-mediated kidney disease

<a id="heading-2.2.1.8.1"></a>

###### 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

###### Health-related quality of life, anxiety, and depression in 78 adults and 29 children with primary FSGS and their care-partners

> “This study cross-sectionally surveyed patients with primary focal segmental glomerulosclerosis (FSGS) and their caregivers/care-partners, in terms of physical and mental health-related quality of life (HRQoL) and work productivity.”
> “78 adults and 29 children/adolescents with FSGS, with their care-partners/caregivers, were included. The median ages of adults and children/adolescents with FSGS were 44.5 and 12.0 years, respectively; 74.4% and 58.6% were female. Mean physical and mental SF-12 scores for adult patients were 41.9 (SD: 12.1) and 44.8 (10.2), respectively.”
> “Both SF-12 components for adult patients, the SF-12 mental component for care-partners, and all PedsQL item scores were worse compared to US general population estimates. Among adult patients, 28.2% reported at least moderate anxiety; 37.3% reported at least moderate depression. Compared to external controls, patients experienced significantly higher severity of anxiety (6.1 vs. 5.0) and depression (7.6 vs. 5.9; both p < 0.0001).”
> “Patients with FSGS and their care-partners experience impairments to mental/physical HRQoL and work productivity, underscoring the need for effective FSGS therapies and care-partner support.”

Source: [Szklarzewicz et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12182477/)

<a id="topic-2.2.1.8.1-2"></a>

###### Quality of life and health care costs in FSGS: review of three systematic literature reviews

> “This supplement explores the burden of FSGS from a clinical, humanistic, and economic perspective, informed by the results of 3 systematic literature reviews. FSGS is associated with poorer quality of life and high health care costs, and these outcomes are correlated with disease severity.”

Source: [Bensink et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/42101820/)

<a id="topic-2.2.1.8.1-3"></a>

###### PROMIS health-related quality of life in 478 children and 1115 adults with primary glomerular disease

> “We assessed the relationship between HRQOL and demographic and clinical variables in 478 children and 1115 adults at the time of enrollment into CureGN.”
> “Patient-reported edema consistently had the strongest and most robust association with each measured domain of HRQOL in multivariable analysis”
> “Female sex, weight (particularly obesity), and estimated glomerular filtration rate were also associated with some, but not all, domains of HRQOL. Primary diagnosis, disease duration, and exposure to immunosuppression were not associated with HRQOL after adjustment.”
> “There were substantial differences in racial distribution among the diagnoses, with black participants more likely to have FSGS and less likely to have IgAN or IgAV.”

Source: [Canetta et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6743723/)

<a id="topic-2.2.1.8.1-4"></a>

###### Racial and ethnic differences in health-related quality of life in glomerular disease

> “Black adults missed work or school most frequently due to kidney disease (30 vs. 16–23% in the other 3 groups, p = 0.04), and had the worst self-reported global physical health (median score 44.1 vs. 48.0–48.2, p < 0.001) and fatigue (53.8 vs. 48.5–51.1, p = 0.002), compared to other racial/ethnic groups.”
> “However, these findings were not statistically significant with adjustment for socioeconomic status and disease severity, both of which were strongly associated with HRQOL in adults.”
> “Among patients with glomerular disease enrolled in CureGN, the worse HRQOL reported by black adults was attributable to lower socioeconomic status and more severe glomerular disease.”

Source: [Krissberg et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8553235/)

<a id="topic-2.2.1.8.1-5"></a>

###### Health-related quality of life and outcomes in 3837 adults with CKD

> “Data from 3837 adult participants with mild to severe CKD enrolled in the prospective observational Chronic Renal Insufficiency Cohort and Hispanic Chronic Renal Insufficiency Cohort Studies were analyzed.”
> “Younger age, women, low education, diabetes, vascular disease, congestive heart failure, obesity, and lower eGFR were associated with low baseline health–related quality of life (P<0.05).”
> “Low health–related quality of life across several subscales was independently associated with a higher risk of incident cardiovascular events and death but not associated with CKD progression.”

Source: [Porter et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4934840/)

<a id="topic-2.2.1.8.1-6"></a>

###### Utility values by CKD treatment modality: meta-analysis of 190 studies

> “In total, 190 studies reporting 326 utilities from over 56,000 patients were analysed.”
> “Using time tradeoff as a referent instrument, kidney transplant recipients had a mean utility of 0.82 (95% CI: 0.74, 0.90).”
> “The researchers found that the highest average utility was for those who had renal transplantation, 0.82, followed by the pre-dialysis group (0.80), dialysis patients (0.71), and, finally, patients receiving conservative care (0.62).”
> “For patients with late-stage CKD, treatment with dialysis is associated with a significant decrement in quality of life compared to treatment with kidney transplantation.”

Source: [Wyld et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3439392/)

<a id="topic-2.2.1.8.1-7"></a>

###### Quality of life of caregivers of adults receiving maintenance dialysis: systematic review of 61 studies

> “61 studies were identified that included 5,367 caregivers from 21 countries and assessed the impact on caregivers using 70 different scales.”
> “Caregiver quality of life was poorer than in the general population, mostly comparable with caregivers of people with other chronic diseases, and often better than experienced by the dialysis patients cared for. Caregiver quality of life was comparable across dialysis modalities.”

Source: [Gilbertson et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30454885/)

<a id="topic-2.2.1.8.1-8"></a>

###### Patient-reported concern and worry after APOL1 genotyping in 200 Black adults

> “Among 200 participants enrolled with completed 3-month follow-up as of January 2025, 17.5% (35/200) carried an APOL1 high-risk genotype (2 RRVs). At baseline, concern about kidney conditions was common: 39% reported being extremely concerned, 34% very concerned, 12% somewhat concerned, 10% a little concerned, and 6% not concerned at all.”
> “APOL1 high-risk genotypes were more common in those with an increase, compared to a decrease, in kidney concern at follow-up (29% vs 11%; P = 0.02). Worry related to having an APOL1 high-risk genotype declined over time, from 14% at baseline to 8% at 3 months.”
> “Even among healthy individuals, such as living kidney donor candidates, APOL1 testing may evoke psychological distress and fear of kidney failure (7).”

Source: [Elsurer Afsar et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13438459/)

<a id="topic-2.2.1.8.1-9"></a>

###### Attitudes of African American living kidney donors toward APOL1 genetic testing

> “Twenty-three donors participated in semi-structured interviews. Most (96%) reported that transplant centers should routinely offer APOL1 genetic testing to all AA potential donors.”
> “Participants believed that potential donors would experience psychological distress from learning they have two gene variants and could harm their recipients.”

Source: [Gordon et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6252162/)

<a id="heading-2.2.1.8.2"></a>

###### 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

###### AMKD-specific health care resource utilization and cost studies

No evidence found.

<a id="topic-2.2.1.8.2-2"></a>

###### Treatment use among 1332 patients with genetically confirmed AMKD in the United States: conference poster report

> “Patients with evidence of diabetes, autosomal dominant polycystic kidney disease, or IgA nephropathy were excluded, leaving 1332 patients with a mean (SD) age of 45.6 (15.4) years.”
> “Hypertension (88.9%), hyperlipidemia (42.3%), and chronic pulmonary disease (23.1%) were the most common comorbidities, and 45.7% of patients were in CKD stage 4 or 5.”
> “Within the study period, 35.7% of patients had at least 1 administration or fill of a RAAS inhibitor, 35% of a calcium channel blocker, 27.9% of a beta blocker, 10.5% of an SGLT2 inhibitor, and 4.4% of a GLP-1 receptor agonist.”

Source: [AJMC (2026)](https://www.ajmc.com/view/real-world-amkd-data-highlight-quick-progression-unmet-needs)

<a id="topic-2.2.1.8.2-3"></a>

###### Medicare expenditures for people with kidney failure

> “Total Medicare costs for people with ESRD increased to an all-time high of $55.3 billion in 2023”
> “MA costs for people with ESRD ($27.7 billion) exceeded FFS costs ($24.4 billion) for the first time in 2023”
> “In 2023, PPPY costs for people with FFS Medicare coverage with ESRD who were not eligible for Medicaid were $68,202; costs for people with FFS who were dual-eligible for Medicaid were 49% higher, at $101,730.”
> “Inflation-adjusted PPPY costs for people with FFS coverage receiving in-center HD in 2023 were $15,377 higher than costs for beneficiaries on PD.”

Source: [USRDS Annual Data Report, ESRD expenditures (2025)](https://usrds-adr.niddk.nih.gov/2025/end-stage-renal-disease/9-healthcare-expenditures-for-persons-with-esrd)

<a id="topic-2.2.1.8.2-4"></a>

###### Medicare fee-for-service expenditures for people with CKD

> “The yearly cost per person with FFS coverage with CKD was $31,176 in 2023, which is about 15% less than it was in 2013”
> “Total costs for people who already had CKD increased over the last decade, reaching $104.3 billion in 2023.”
> “Inflation-adjusted PPPY costs for adults with Medicare FFS coverage with CKD as of January 1 of each year were consistently highest for those with stage 4-5 CKD, intermediate for those with stage 3 CKD, and lowest for those with stages 1-2 CKD.”

Source: [USRDS Annual Data Report, CKD expenditures (2025)](https://usrds-adr.niddk.nih.gov/2025/chronic-kidney-disease/6-healthcare-expenditures-for-persons-with-ckd)

<a id="topic-2.2.1.8.2-5"></a>

###### Per person per year Medicare fee-for-service spending among older adults with CKD, by race and CKD stage

| Older adults with CKD, 2023 | All CKD | Stages 1-2 | Stage 3 | Stages 4-5 |
| --- | --- | --- | --- | --- |
| All | “$30,141” | “$26,241” | “$29,176” | “$42,172” |
| White | “$29,525” | “$25,874” | “$28,696” | “$40,577” |
| Black | “$35,178” | “$27,820” | “$33,408” | “$49,197” |

Source: [USRDS Annual Data Report, CKD expenditures (2025)](https://usrds-adr.niddk.nih.gov/2025/chronic-kidney-disease/6-healthcare-expenditures-for-persons-with-ckd)

<a id="topic-2.2.1.8.2-6"></a>

###### Health care resource utilization and costs in 844 patients with FSGS and matched controls

> “Patients with FSGS (n = 844; first claim = index event) between April 2016 and December 2018 were matched on index date, age, sex, and race to non-FSGS controls (n = 1688).”
> “Mean total medical costs were higher in FSGS ($59,753 vs. $8431 PPPY; P < 0.0001), driven by outpatient costs. Nephrotic range proteinuria was associated with higher all-cause inpatient, outpatient, and prescription costs versus nonnephrotic patients (all P < 0.0001), resulting in higher total costs ($70,481 vs. $36,099 PPPY; P < 0.0001).”

Source: [Kalantar-Zadeh et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8484118/)

<a id="topic-2.2.1.8.2-7"></a>

###### Health care resource utilization and costs in FSGS by proteinuria and CKD stage: 9899 patients in a US claims and EHR database

> “In this descriptive, noninterventional, retrospective cohort study, 9899 patients were identified between January 2016 and December 2020 in Optum de-identified Market Clarity Data”
> “There was a consistent trend toward higher health care resource utilization and total costs with both chronic kidney disease progression (stage 1-5/kidney failure) and higher levels of proteinuria”
> “The observed prevalence of FSGS increased in the US and was highest among Black individuals. More advanced chronic kidney disease and higher levels of proteinuria were both associated with greater health care resource utilization and costs.”

Source: [Bensink et al. (2026a)](https://pubmed.ncbi.nlm.nih.gov/41222995/)

<a id="topic-2.2.1.8.2-8"></a>

###### Health care resource utilization and costs in FSGS-attributed kidney failure

> “The FSGS cohort and Medicare Coverage and 1-year Medicare Coverage subgroups included 25,699, 6,340, and 5,575 patients, respectively.”
> “In the Medicare Coverage and 1-year Medicare Coverage subgroups, 76.6% and 74.2% required inpatient admission, 69.9% and 67.3% visited the emergency room, and mean monthly health care costs were $6,752 and $5,575 in the year postindex, respectively.”
> “Drug costs may be underestimated because Medicare Part D coverage was not required; kidney acquisition costs were not available.”

Source: [Bensink et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10831785/)

<a id="topic-2.2.1.8.2-9"></a>

###### Health care resource utilization and costs in 2515 US veterans with FSGS

> “The study included 2,515 veterans with FSGS who were followed for an average of 8.9 years.”
> “Overall, 43.3% underwent dialysis and 5.8% had a kidney transplant.”
> “During the first year post-index, 40% had an inpatient admission and 33% visited the emergency room; mean total healthcare cost per patient in the analysis was $36,543.”

Source: [Goldschmidt et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11642916/)

<a id="heading-2.2.1.8.3"></a>

###### 2.2.1.8.3 Economic Impact of APOL1-mediated kidney disease on Families

<a id="topic-2.2.1.8.3-1"></a>

###### Work productivity of care-partners and caregivers of patients with FSGS

> “Additionally, 14–20% of care-partners and caregivers reported moderate to severe anxiety or depression. All employed groups reported high overall work impairment (15.0–30.6%), with adult patients and their care-partners reporting high FSGS-related activity impairment (37.8%; 17.3%, respectively), absenteeism (10.4%; 6.1%) and presenteeism (21.8%; 11.6%).”

Source: [Szklarzewicz et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12182477/)

<a id="topic-2.2.1.8.3-2"></a>

###### Work productivity and financial well-being of 674 caregivers of patients with CKD in seven countries, including the United States

> “A total of 1303 patients and 674 caregivers were recruited.”
> “Work productivity and activity impairment were greatest among dialysis patients, a trend also observed among caregivers for patients on dialysis.”
> “Caregivers for patients with CKD generally reported a higher degree of impairment than the matched general population for absenteeism (mean range 3.4–14.7% vs. 1.4–20.8%; difference: − 7.6% to 12.0%), presenteeism (mean range 28.7–41.3% vs. 8.5–19.8%; difference: 12.0–28.2%), work activities (mean range 22.5–33.6% vs. 7.8–19.1%; difference: 11.1–23.7%), non-work activities (mean range 34.5–49.8% vs. 11.2–21.0%; difference: 17.9–34.9%).”
> “The indirect burden of CKD extends beyond clinical costs to include significant financial and work productivity impacts on patients and caregivers, with greater challenges for patients on dialysis.”

Source: [Chadban et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12909312/)

<a id="topic-2.2.1.8.3-3"></a>

###### Loss of employer-sponsored health insurance after dialysis initiation in the United States

> “18,408 in-center hemodialysis and peritoneal dialysis patients employed full-time at the time of dialysis initiation, with employer-sponsored health insurance three months post-dialysis, followed for loss of employer-sponsored health insurance.”
> “Compared to patients receiving PD, patients receiving IHD without a fistula (HR, 1.26 [95% CI, 1.18–1.36]) and with a fistula (HR, 1.14 [95% CI, 1.05–1.24]) were more likely to lose employer-sponsored health insurance.”
> “Less than one quarter of working-age patients in the United States who began dialyzing between 1996 and 2013 were employed at dialysis initiation, and 38% of those employed six months prior to chronic dialysis were unemployed at dialysis start.”

Source: [Hirth et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13094777/)

<a id="topic-2.2.1.8.3-4"></a>

###### Direct and indirect costs to living kidney donors and their caregivers

> “We collected cost data in the 12 mo following donation from 182 LKDs participating in the multicenter prospective Kidney Donor Outcomes Cohort (KDOC) Study.”
> “LKDs missed 33 072 total work hours, 40% of which were unpaid and led to $302 175 in lost wages (mean $1660). Caregivers lost $68 655 in wages (mean $377). Although some donors received financial assistance, 89% had a net financial loss in the 12-mo period, with one-third (33%) reporting a loss exceeding $2500.”

Source: [Rodrigue et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26845630/)

<a id="topic-2.2.1.8.3-5"></a>

###### Family implications of APOL1 genetic testing

> “Established guidance on disclosure of genetic test results to family members (cascade testing) should be followed. This typically involves provision of support and resources to a patient for passing on information to the family (if they choose) who may then seek counseling and testing.”
> “What are the impacts on individuals, families, and communities of donating and not donating kidneys from individuals with high-risk APOL1 genotypes (economic, psychological, societal), including consequences of continuing dialysis?”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

> “Apolipoprotein L1 (APOL1) renal risk variants (RRVs) contribute to the increased risk of kidney disease among Black Americans, but use of genetic testing may be limited by patient concerns regarding clinical implications and effects on family.”

Source: [Elsurer Afsar et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13438459/)

<a id="topic-2.2.1.8.3-6"></a>

###### APOL1-specific family cost studies

No evidence found.

<a id="heading-2.2.1.8.4"></a>

###### 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

###### Genetic testing requirement for diagnosis

> “A definitive diagnosis of AMKD requires a genetic test for the presence of two APOL1 risk variants.”

Source: [Labcorp](https://www.labcorp.com/tests/407154/apol1-genotyping)

<a id="topic-2.2.1.8.4-2"></a>

###### Manufacturer-sponsored no-cost APOL1 genotyping: Labcorp program

> “Each patient that meets the eligibility criteria will receive one Labcorp APOL1 Genotype Test and will have access to genetic results counseling included in the program at no cost to the patient. No patients, providers, and/or third-party payers (including commercial health plans and government health care programs) will be billed for the APOL1 testing covered under the program.”
> “Eligible patients include those of African ancestry who may self-identify as Black, African American, African or Afro-Caribbean, a diagnosis of chronic kidney disease, no history of kidney transplant, do not have diabetes and must not be currently treated with dialysis.”
> “Labcorp and Vertex Pharmaceuticals reserve the right to rescind, revoke or amend the program for any reason without notice.”

Source: [Labcorp](https://www.labcorp.com/tests/407154/apol1-genotyping)

<a id="topic-2.2.1.8.4-3"></a>

###### Manufacturer-sponsored no-cost APOL1 genotyping: Natera program

> “Vertex Pharmaceuticals is sponsoring a no-cost Renasight™ renal genetic testing for eligible* patients of African ancestry diagnosed with chronic kidney disease”
> “Healthcare providers must also confirm patient eligibility criteria for the sponsored Renasight™ Genetic Testing Program and complete a signed attestation form for each patient.”
> “This program is subject to change or discontinuation without notice.”

Source: [Natera](https://www.natera.com/info/vertex-sponsored-page-program-overview/how-to-order/)

<a id="topic-2.2.1.8.4-4"></a>

###### Manufacturer-sponsored no-cost APOL1 genotyping and genetic counseling: Arkana Laboratories program

> “APOL1-risk variant testing is available at no cost to patients who meet all of the following criteria:”
> “Self-reported race as Black, African American, African, Afro-Caribbean, Hispanic, or Latino”
> “Absence of diabetes mellitus”
> “Not currently on dialysis and no history of kidney transplant”
> “Vertex Pharmaceuticals will cover the cost of genetic counseling for eligible* patients.”

Source: [Arkana Laboratories](https://www.arkanalabs.com/services/apol1/no-cost-to-patient-apol1-testing-patient/)

<a id="topic-2.2.1.8.4-5"></a>

###### Billing code for a commercial APOL1 genotyping test

> “Report 0355U only for Apolipoprotein L1 (APOL1) Renal Risk Variant Genotyping from Quest Diagnostics®.”
> “The variant analysis aids in risk evaluation for kidney transplant donors and recipients.”

Source: [AAPC](https://www.aapc.com/codes/cpt-codes/0355U)

<a id="topic-2.2.1.8.4-6"></a>

###### List price or Medicare payment rate for APOL1 genotyping

No evidence found.

<a id="topic-2.2.1.8.4-7"></a>

###### Cost of APOL1 genotyping of potential living kidney donors at one US center

> “Since May 2017, all potential AA living kidney donors at our center underwent APOL1 genotyping early in the donor evaluation process.”
> “One out of 26 potential donors had high-risk genotype and was therefore declined.”
> “A crude cost analysis utilizing our sample suggested probable cost-effectiveness of APOL1 genotyping as it can prevent earlier onset of chronic kidney disease in AA donors.”

Source: [Gudsoorkar et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31940609/)

<a id="topic-2.2.1.8.4-8"></a>

###### Cost as a barrier to genetic testing

> “Barriers to widespread adoption of genetic testing include a lack of perceived benefit, lack of ease, difficulties in interpreting genetic variants, high cost, and the need for genetic counseling.”
> “When offering genetic testing, physicians should counsel patients on risks and potential implications of testing, which may include out-of-pocket expenses, data privacy concerns, emotional distress, and the impact of a positive test result on life and disability insurance applications.”

Source: [Srinivasan et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12361766/)

> “Participants were apprehensive about insurance coverage and costs of APOL1 testing and feared that APOL1 genetic test results could discriminate against AAs.”

Source: [Gordon et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6252162/)

<a id="topic-2.2.1.8.4-9"></a>

###### Cost considerations for population, pediatric, and donor APOL1 testing

> “At population levels, evaluation of costs and potential benefits is important prior to investing in APOL1 testing.”
> “Yet unnecessary testing would be costly and potentially anxiety-provoking.”
> “recommends offering APOL1 genotyping (which is publicly funded by the United Kingdom National Health Service) as part of the assessment and communication of donor risk early in the evaluation of all potential donors of African heritage under 60 years old.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

<a id="topic-2.2.1.8.4-10"></a>

###### Equipment costs of current APOL1 genotyping methods

> “Current available genotyping methods rely on PCR and sequencing and are associated with high equipment costs, long turnaround times and bioinformatic data analysis, all of which can challenge their application in resource-limited settings or at the point-of-care.”

Source: [Greensmith et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11473833/)

> “Although APOL1 genotyping is typically performed using quantitative polymerase chain reaction or sequencing, these techniques require specialized technical expertise and costly equipment, resources that are often limited in sub-Saharan Africa.”

Source: [Adebayo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12822060/)

<a id="heading-2.2.2"></a>

#### 2.2.2 Approaches to Treatment

<a id="heading-2.2.2.1"></a>

##### 2.2.2.1 Current Treatment Options and Standard of Care

<a id="heading-2.2.2.1.1"></a>

###### 2.2.2.1.1 Renin-Angiotensin System Inhibitors and Blood Pressure Control

<a id="topic-2.2.2.1.1-1"></a>

###### Blood pressure target: KDIGO 2024 CKD guideline

> “Recommendation 3.4.1: We suggest that adults with high BP and CKD be treated with a target systolic blood pressure (SBP) of <120 mm Hg, when tolerated, using standardized office BP measurement (2B).”

Source: [KDIGO (2024)](https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf)

<a id="topic-2.2.2.1.1-2"></a>

###### Renin-angiotensin system inhibitor recommendations: KDIGO 2024 CKD guideline

> “Recommendation 3.6.1: We recommend starting renin-angiotensin-system inhibitors (RASi) (angiotensin-converting enzyme inhibitor [ACEi] or angiotensin II receptor blocker [ARB]) for people with CKD and severely increased albuminuria (G1–G4, A3) without diabetes (1B).”
> “Recommendation 3.6.2: We suggest starting RASi (ACEi or ARB) for people with CKD and moderately increased albuminuria (G1–G4, A2) without diabetes (2C).”
> “Recommendation 3.6.3: We recommend starting RASi (ACEi or ARB) for people with CKD and moderately-to-severely increased albuminuria (G1–G4, A2 and A3) with diabetes (1B).”
> “Recommendation 3.6.4: We recommend avoiding any combination of ACEi, ARB, and direct renin inhibitor (DRI) therapy in people with CKD, with or without diabetes (1B).”
> “Practice Point 3.6.1: RASi (ACEi or ARB) should be administered using the highest approved dose that is tolerated to achieve the benefits described because the proven benefits were achieved in trials using these doses.”

Source: [KDIGO (2024)](https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf)

<a id="topic-2.2.2.1.1-3"></a>

###### Supportive treatment for FSGS: KDIGO 2021 glomerular diseases guideline

> “Adult patients with FSGS should receive the necessary supportive treatment as advised for all patients with persistent proteinuria (Chapter 1), including the use of RAS blockade, optimal BP control, and dietary salt restriction.”

Source: [KDIGO (2021)](https://kdigo.org/wp-content/uploads/2017/02/KDIGO-Glomerular-Diseases-Guideline-2021-English.pdf)

<a id="topic-2.2.2.1.1-4"></a>

###### Blood pressure control after a high-risk APOL1 genotype is confirmed: Delphi consensus

> “After a patient with CKD is confirmed to have a high-risk APOL1 genotype, the clinician should:”
> “Inform the patient about other modifiable risk factors and renoprotective measures (lifestyle changes, BP control)”

Source: [Freedman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8425659/)

<a id="topic-2.2.2.1.1-5"></a>

###### Blood pressure goal and ACE inhibitor effects by APOL1 genotype in AASK

> “In the AASK study, the primary outcome occurred in 58.1% of the patients in the APOL1 high-risk group and in 36.6% of those in the APOL1 low-risk group (hazard ratio in the high-risk group, 1.88; P<0.001). There was no interaction between APOL1 status and trial interventions or the presence of baseline proteinuria.”
> “there was no significant interaction between APOL1 status and the randomized blood-pressure goal with respect to the progression of chronic kidney disease (P = 0.72 for interaction)”
> “The lack of significant interaction between APOL1 and treatment with an ACE inhibitor suggests that patients in the APOL1 high-risk group still benefit from this class of drugs.”

Source: [Parsa et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3969022/)

<a id="topic-2.2.2.1.1-6"></a>

###### Strict blood pressure control and mortality by APOL1 genotype in AASK

> “This included 682 participants with known APOL1 genotype (157 with high-risk genotype) previously assigned to either strict (mean arterial pressure [MAP] 92 mm Hg or less) versus usual blood pressure control (MAP 102-107 mm Hg) during the trial.”
> “In the APOL1 high-risk group, risk of death was 42% lower comparing strict versus usual blood pressure control (0.58 [0.35-0.97]). In the APOL1 low-risk group, risk of death comparing strict versus usual blood pressure control was not significantly different (1.09 [0.84-1.43]).”

Source: [Ku et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5237400/)

<a id="topic-2.2.2.1.1-7"></a>

###### Real-world use of RAAS inhibitors, SGLT2 inhibitors, and other drug classes in AMKD

> “Within the study period, 35.7% of patients had at least 1 administration or fill of a RAAS inhibitor, 35% of a calcium channel blocker, 27.9% of a beta blocker, 10.5% of an SGLT2 inhibitor, and 4.4% of a GLP-1 receptor agonist.”

Source: [AJMC (2026)](https://www.ajmc.com/view/real-world-amkd-data-highlight-quick-progression-unmet-needs)

<a id="heading-2.2.2.1.2"></a>

###### 2.2.2.1.2 Sodium-Glucose Cotransporter-2 Inhibitors

<a id="topic-2.2.2.1.2-1"></a>

###### SGLT2 inhibitor recommendations: KDIGO 2024 CKD guideline

> “However, in the present guideline, we offer a more general 1A recommendation for adults with CKD.”
> “Recommendation 3.7.2: We recommend treating adults with CKD with an SGLT2i for the following (1A):”
> “Recommendation 3.7.3: We suggest treating adults with eGFR 20 to 45 ml/min per 1.73 m2 with urine ACR <200 mg/g (<20 mg/mmol) with an SGLT2i (2B).”
> “Practice Point 3.7.3: SGLT2i initiation or use does not necessitate alteration of frequency of CKD monitoring and the reversible decrease in eGFR on initiation is generally not an indication to discontinue therapy.”

Source: [KDIGO (2024)](https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf)

<a id="topic-2.2.2.1.2-2"></a>

###### Dapagliflozin in biopsy-confirmed FSGS: DAPA-CKD prespecified analysis

> “Of 104 participants with biopsy-confirmed FSGS, 45 were randomized to dapagliflozin and 59 to placebo.”
> “The primary outcome occurred in 4 (8.9%) and 7 (11.9%) participants randomized to dapagliflozin and placebo, respectively [hazard ratio 0.62, 95% confidence interval (95% CI) 0.17, 2.17].”
> “Thereafter, mean rates of chronic eGFR decline with dapagliflozin and placebo were −1.9 (−3.0, −0.9) and −4.0 (−4.9, −3.0) mL/min/1.73 m2/year, respectively (difference 2.0, 95% CI 0.6 to 3.5, mL/min/1.73 m2/year).”
> “With respect to limitations, the DAPA-CKD study was not specifically designed to test our hypothesis in patients with FSGS, and the relatively small sample size of this subgroup limited the precision of estimates of treatment effects on the study endpoints.”

Source: [Wheeler et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9395378/)

<a id="topic-2.2.2.1.2-3"></a>

###### No SGLT2 inhibitor data specific to APOL1 kidney disease

> “Of note, much of the data on CKD progression due to APOL1 variants came before the widespread use of sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dual angiotensin and endothelin receptor antagonists, and it is unclear whether such therapies influence disease development or progression.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

> “In the current review, we highlight the potential reasons for exploring the use of SGLT2i in APOL1-KD. Future studies are warranted to explore if SGLT2i use can provide protection in APOL1-KD.”

Source: [Afsar et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40038200/)

<a id="heading-2.2.2.1.3"></a>

###### 2.2.2.1.3 Nonsteroidal Mineralocorticoid Receptor Antagonists

<a id="topic-2.2.2.1.3-1"></a>

###### Nonsteroidal MRA recommendation in type 2 diabetes and CKD: KDIGO 2024 CKD guideline

> “Recommendation 3.8.1: We suggest a nonsteroidal mineralocorticoid receptor antagonist with proven kidney or cardiovascular benefit for adults with T2D, an eGFR >25 ml/min per 1.73 m2, normal serum potassium concentration, and albuminuria (>30 mg/g [>3 mg/mmol]) despite maximum tolerated dose of RAS inhibitor (RASi) (2A).”
> “Practice Point 3.8.1: Nonsteroidal MRA are most appropriate for adults with T2D who are at high risk of CKD progression and cardiovascular events, as demonstrated by persistent albuminuria despite other standard-of-care therapies.”

Source: [KDIGO (2024)](https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf)

<a id="topic-2.2.2.1.3-2"></a>

###### Finerenone in nondiabetic CKD due to glomerular diseases: FIND-CKD prespecified subgroup

> “Of 1584 participants, 903 (57.0%) had investigator-reported glomerular disease, including 416 (46.1%) with immunoglobulin A nephropathy, 215 (23.8%) with focal segmental glomerulosclerosis, and 90 (10.0%) with membranous nephropathy.”
> “The total eGFR slope up to 32 months was -3.50 mL/min/1.73 m2 per year with finerenone and -4.23 mL/min/1.73 m2 per year with placebo (0.73 mL/min/1.73 m2 per year difference; 95% CI, 0.22-1.24).”
> “In this exploratory analysis, treatment with finerenone slowed kidney function decline, reduced albuminuria, and lowered the risk of kidney failure or substantial loss of kidney function in patients with glomerular diseases.”

Source: [Neuen et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42246414/)

<a id="topic-2.2.2.1.3-3"></a>

###### AMKD with type 2 diabetes

> “evaluates inaxaplin as a treatment for people with AMKD with moderate proteinuria, or with AMKD and type 2 diabetes, two populations that are not being studied in the AMPLITUDE trial.”

Source: [Vertex Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/vrtx-20251231.htm)

> “The authors noted that earlier longitudinal studies of proteinuric AMKD were limited by sample size and did not include patients with type 2 diabetes, who made up 65% of this cohort.”

Source: [AJMC (2026)](https://www.ajmc.com/view/real-world-amkd-data-highlight-quick-progression-unmet-needs)

<a id="heading-2.2.2.1.4"></a>

###### 2.2.2.1.4 Glucocorticoids and Calcineurin Inhibitors

<a id="topic-2.2.2.1.4-1"></a>

###### Immunosuppression in primary and secondary FSGS: KDIGO 2021 glomerular diseases guideline

> “Practice Point 6.2.1.1: Immunosuppression should not be used in adults with FSGS of undetermined cause (FSGS-UC), or in those with secondary FSGS.”
> “Recommendation 6.2.2.1: We recommend that high-dose oral glucocorticoids be used as the first-line immunosuppressive treatment for primary FSGS (1D).”
> “Practice Point 6.2.2.2: Initial high-dose glucocorticoids should be continued until complete remission is achieved, or as tolerated by patients up to a maximum of 16 weeks, whichever is earlier.”
> “Recommendation 6.3.1.1: For adults with steroid-resistant primary FSGS, we recommend that cyclosporine or tacrolimus be given for”
> “rather than continuing with glucocorticoid monotherapy or not treating (1C).”
> “Practice Point 6.3.3.1: Adults with steroid-resistant primary FSGS who respond to CNI treatment should receive CNIs for a minimum of 12 months to minimize the risk of relapses (Figure 55).”
> “There is no evidence or a priori rationale justifying the use of glucocorticoids or other immunosuppressive drugs in this population, and the potential for harm of such treatment is clear.”

Source: [KDIGO (2021)](https://kdigo.org/wp-content/uploads/2017/02/KDIGO-Glomerular-Diseases-Guideline-2021-English.pdf)

<a id="topic-2.2.2.1.4-2"></a>

###### Treatment resistance in genetic forms of FSGS: KDIGO 2021 glomerular diseases guideline

> “Although the majority of adults with primary FSGS respond to immunosuppression, treatment resistance is a common feature in genetic forms of FSGS, and in particular, resistance to glucocorticoid therapy is a consistent finding in all forms of genetic FSGS.”
> “Moreover, the discovery of genetic variants in this group should prompt a discussion on discontinuing further immunosuppression treatment.”

Source: [KDIGO (2021)](https://kdigo.org/wp-content/uploads/2017/02/KDIGO-Glomerular-Diseases-Guideline-2021-English.pdf)

<a id="topic-2.2.2.1.4-3"></a>

###### Response to cyclosporine or mycophenolate mofetil with dexamethasone by APOL1 genotype: FSGS Clinical Trial

> “The FSGS Clinical Trial involved 138 children and young adults who were randomized to cyclosporin or mycophenolate mofetil plus pulse oral dexamethasone with a primary outcome of proteinuria remission.”
> “APOL1 risk genotype did not affect response to either treatment regimen. Individuals with the risk genotype were more likely to progress to ESRD (P<0.01).”
> “At present, however, there are no data that would indicate that aggressive treatment with available agents retards progressive kidney function loss in these high-risk individuals.”

Source: [Kopp et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4446865/)

<a id="topic-2.2.2.1.4-4"></a>

###### Limits of glucocorticoids and calcineurin inhibitors in FSGS: review of burden

> “Until recently, no medicines had been approved by the FDA or European Medicines Agency, with management focused on supportive care and proteinuria reduction.”
> “Available treatments, such as glucocorticoids or calcineurin inhibitors, are limited in efficacy and safety.”

Source: [Bensink et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/42101820/)

<a id="topic-2.2.2.1.4-5"></a>

###### Role of conventional immunosuppression in APOL1 kidney disease as a research question

> “Is there a role for conventional treatment of FSGS and other glomerular diseases (calcineurin inhibitors, cytotoxic agents) in patients with APOL1 high-risk genotypes?”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

<a id="heading-2.2.2.1.5"></a>

###### 2.2.2.1.5 Dual Endothelin Angiotensin Receptor Antagonists

<a id="topic-2.2.2.1.5-1"></a>

###### Sparsentan indication, dosing, and REMS

> “To reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome (1.2, 12.1, 14.2).”
> “FILSPARI is only available through a restricted distribution program called the FILSPARI Risk Evaluation and Mitigation Strategies (REMS) because of the risk of hepatotoxicity (5.2):”
> “Prior to initiating treatment with FILSPARI, discontinue use of renin-angiotensin-aldosterone system (RAAS) inhibitors and endothelin receptor antagonists (ERAs) (2.1, 4, 7.1).”
> “Greater than 50 kg: Initiate treatment with FILSPARI at 400 mg orally once daily. After 14 days, increase to 800 mg once daily, as tolerated (2.4).”

Source: [FDA FILSPARI prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/216403s006lbl.pdf)

<a id="topic-2.2.2.1.5-2"></a>

###### Sparsentan versus irbesartan in FSGS: DUPLEX results in the label

> “At baseline, the mean age of trial participants was 42 years (range 9 to 75 years); 54% were male; 73% were White, 13% Asian, 7% Black or African American, and 7% were other, multiple or unknown.”
> “The primary efficacy endpoint at the final analysis was not statistically significant.”
> “In the subgroup of patients without nephrotic syndrome, the percent UPCR reduction at Week 108 from baseline was 48% in patients randomized to FILSPARI compared to 27% in patients randomized to irbesartan.”
> “In contrast, there was no difference between treatment arms in UPCR reduction from baseline to Week 108 in the subgroup of patients with nephrotic syndrome.”

Source: [FDA FILSPARI prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/216403s006lbl.pdf)

<a id="topic-2.2.2.1.5-3"></a>

###### Sparsentan versus irbesartan in FSGS: DUPLEX primary publication

> “At 36 weeks, the percentage of patients with partial remission of proteinuria was 42.0% in the sparsentan group and 26.0% in the irbesartan group (P = 0.009), a response that was sustained through 108 weeks.”
> “Among patients with FSGS, there were no significant between-group differences in eGFR slope at 108 weeks, despite a greater reduction in proteinuria with sparsentan than with irbesartan.”

Source: [Rheault et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37921461/)

<a id="topic-2.2.2.1.5-4"></a>

###### Sparsentan in participants with APOL1 high-risk genotypes: DUPLEX post hoc analysis

> “Finally, 14 patients (4%) had two APOL1 high-risk alleles, nine in the sparsentan and five in the irbesartan groups.”
> “Sparsentan treatment resulted in profound (approximately 50%) sustained reduction of UPCR in the patients with APOL1 high-risk genotypes, although the treatment effect versus irbesartan was not sustained during the second year of the treatment period (Figure 1C).”
> “CR occurred exclusively in sparsentan-treated patients among those with podocyte gene variants (8% versus 0%), in 18% versus 7% of patients with COL4A3–5 gene variants, and in 33% versus 20% of patients with APOL1 high-risk genotypes.”
> “Owing to the small sample size in each genetic subgroup, the result has limited analytic power”

Source: [Yee et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13065193/)

| Subgroup | Sparsentan, time-averaged change from baseline in UPCR, % (95% CI) | Irbesartan, time-averaged change from baseline in UPCR, % (95% CI) | Relative change, % (95% CI) | P value |
| --- | --- | --- | --- | --- |
| APOL1 high-risk genotypes | “−54.3 (−76.6 to −10.9)” | “−33.8 (−71.2 to 52.2)” | “−27.3 (−78.1 to 141.2)” | “0.57” |

Source: [Yee et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13065193/)

<a id="heading-2.2.2.1.6"></a>

###### 2.2.2.1.6 Antiretroviral Therapy for HIV-associated Nephropathy

<a id="topic-2.2.2.1.6-1"></a>

###### Antiretroviral therapy recommendation: KDIGO 2021 glomerular diseases guideline

> “Recommendation 7.2.3.3.1: We recommend that antiretroviral therapy be initiated in all patients with HIV and CKD, especially biopsy-proven HIV-associated nephropathy (HIVAN), regardless of CD4 count, adjusted to the degree of kidney function (1C).”
> “The quality of the evidence is low, with no RCTs for guidance in patients with HIVAN.”
> “In multivariate analysis, HIVAN risk was reduced by 60% by use of HAART, and no patient developed HIVAN when HAART had been initiated prior to the development of acquired immune deficiency syndrome (AIDS).”
> “Practice Point 7.2.3.3.1: A decision for the use of glucocorticoids as an adjunct therapy for HIVAN must be made on a case-by-case basis, as the risks and benefits long-term are uncertain.”
> “Whether APOL1 risk alleles should be assessed routinely in patients of west African ancestry with HIVAN remains uncertain.”

Source: [KDIGO (2021)](https://kdigo.org/wp-content/uploads/2017/02/KDIGO-Glomerular-Diseases-Guideline-2021-English.pdf)

<a id="topic-2.2.2.1.6-2"></a>

###### Antiretroviral therapy and HIVAN: KDIGO Controversies Conference on kidney disease in HIV

> “The classic kidney disease of HIV infection, HIV-associated nephropathy (HIVAN), has become less common with widespread use of antiretroviral therapy (ART); however, there has been a simultaneous increase in the prevalence of other kidney diseases.”
> “Evidence from observational studies strongly supports the beneficial effect of early ART initiation on the risk of classic HIVAN.”
> “Given the overwhelming benefit on survival, ART is recommended for all HIV-positive individuals.”

Source: [Swanepoel et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5983378/)

<a id="topic-2.2.2.1.6-3"></a>

###### Lifetime risk of HIVAN without antiretroviral therapy by APOL1 genotype

> “We estimate the lifetime incidence for HIVAN of 50% among HIV-infected African Americans with two APOL1 risk alleles who are not receiving antiviral therapy.”

Source: [Kopp et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3231787/)

<a id="topic-2.2.2.1.6-4"></a>

###### Kidney function after proteinuria onset in people with HIV and high-risk APOL1 genotypes

> “Event-free survival 5 years after proteinuria onset was 53.8% among participants with diabetes and 70.2% among those without diabetes, a difference that was not statistically significant (P = .37).”

Source: [AJMC (2026)](https://www.ajmc.com/view/real-world-amkd-data-highlight-quick-progression-unmet-needs)

<a id="heading-2.2.2.1.7"></a>

###### 2.2.2.1.7 Dialysis

<a id="topic-2.2.2.1.7-1"></a>

###### Timing of dialysis initiation: KDIGO 2024 CKD guideline

> “Practice Point 5.4.1: Initiate dialysis based on a composite assessment of a person’s symptoms, signs, QoL, preferences, level of GFR, and laboratory abnormalities.”
> “This often but not invariably occurs in the GFR range between 5 and 10 ml/min per 1.73 m2.”
> “Practice Point 5.5.1: Inform people with CKD about the options for KRT and comprehensive conservative care.”

Source: [KDIGO (2024)](https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf)

<a id="topic-2.2.2.1.7-2"></a>

###### Initial kidney replacement therapy modality and age at treatment start in the United States

> “Although in-center HD remained the most common initial ESKD treatment modality in 2023 (81.7%), there was a shift toward PD over the last decade. The percentage starting PD reached an all-time high of 14.1% in 2023. Preemptive kidney transplant also reached a new high, though it remained only 3.8% in 2023.”
> “Black, Hispanic, Native American, and Native American and Other Pacific Islander people started treatment for ESKD at a younger age (median 59-62 years) than White and Asian people (median 66-68 years).”

Source: [USRDS Annual Data Report, ESKD incidence and prevalence (2025)](https://usrds-adr.niddk.nih.gov/2025/end-stage-renal-disease/1-incidence-and-prevalence)

<a id="topic-2.2.2.1.7-3"></a>

###### Age at hemodialysis initiation by APOL1 genotype

> “African Americans carrying two copies of the G1 risk allele initiated chronic hemodialysis at a mean age of 49.0 ± 14.9 years, which was significantly younger than both subjects with one copy of the G1 allele (55.9 ± 16.7 years; P = 0.014) and subjects without either risk allele (61.8 ± 17.1 years; P = 6.2 × 10−7).”

Source: [Kanji et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3231784/)

> “People with AMKD progress to end stage kidney disease at a faster rate than those with other forms of chronic kidney disease and reach kidney failure at a median age of 45 years old.”

Source: [Vertex Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/vrtx-20251231.htm)

<a id="heading-2.2.2.1.8"></a>

###### 2.2.2.1.8 Kidney Transplantation

<a id="topic-2.2.2.1.8-1"></a>

###### Preemptive transplantation: KDIGO 2024 CKD guideline

> “Practice Point 5.4.3: Consider planning for preemptive kidney transplantation and/or dialysis access in adults when the GFR is <15–20 ml/min per 1.73 m2 or risk of KRT is >40% over 2 years.”
> “Practice Point 5.4.5: Pursue living or deceased donor preemptive kidney transplantation as the treatment of choice for children in whom there is evidence of progressive and irreversible CKD.”

Source: [KDIGO (2024)](https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf)

<a id="topic-2.2.2.1.8-2"></a>

###### Transplant access for Black people with kidney failure in the United States

> “The rate of deceased donor kidney transplant among Black people with ESRD consistently exceeded that of White people after implementation of changes to the kidney allocation system in 2021 (KAS250) (Figure 7.1b).”
> “Rates of living donor kidney transplant remained about four times higher among White as among Black people with ESRD and about twice as high among White as among Hispanic people in 2024 (Figure 7.1b).”

Source: [USRDS Annual Data Report, kidney transplant (2025)](https://usrds-adr.niddk.nih.gov/2025/end-stage-renal-disease/7-kidney-transplant)

<a id="topic-2.2.2.1.8-3"></a>

###### Allograft survival of kidneys from deceased donors with two APOL1 risk variants

> “Combined analysis of 1153 DDKTs from AA donors revealed donor APOL1 high-risk genotype (HR 2.05; p=3×10−4), older donor age (HR 1.18; p=0.05), and younger recipient age (HR 0.70; p=0.001) adversely impacted allograft survival.”
> “A competing risk analysis revealed that APOL1 impacted renal allograft survival, but not recipient survival.”

Source: [Freedman et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4684443/)

<a id="topic-2.2.2.1.8-4"></a>

###### Allograft survival by recipient APOL1 genotype

> “Recipients carrying two APOL1 RA demonstrated lower graft survival compared to recipients with only one or none of APOL1 RA at 1-year posttransplant independently of other donor and recipient characteristics (Adjusted HR 3.2 [95% CI 1.0–10.4, p-value 0.05]). There was no significant difference in overall survival or graft survival after 3 years posttransplantation.”

Source: [Roy et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11184510/)

<a id="topic-2.2.2.1.8-5"></a>

###### Kidney function after living donation by APOL1 genotype: APOLLO

> “Sixty-eight Black donors (15.3%) had APOL1 high-risk genotypes (G1/G1, G2/G2, or G1/G2).”
> “Black kidney donors with APOL1 high-risk genotypes had a higher risk of developing an eGFR of less than 45 mL/min/1.73 m2 than Black kidney donors without APOL1 high-risk genotypes (relative risk, 2.31; 95% CI, 1.16-4.61; P = .02) (after adjustment for predonation eGFR: relative risk, 1.91; 95% CI, 0.90-4.03; P = .09).”

Source: [Hsu et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42329639/)

<a id="topic-2.2.2.1.8-6"></a>

###### FSGS recurrence and donor APOL1 testing: KDIGO 2021 glomerular diseases guideline

> “In contrast, it is widely accepted that the recurrence rate of FSGS after transplantation is significantly low in genetic forms of the disease, with some studies reporting no individuals exhibiting recurrent disease after a kidney transplant.”
> “Furthermore, it has also been shown that APOL1 high-risk donor kidneys fail at higher rates than non-risk kidneys, and the recipient APOL1 genotype has not been demonstrated to”
> “have correlation with allograft survival.”
> “Therefore, in donors at high risk for APOL1 risk variants, genetic testing for APOL1 mutations may provide information for both the disease risk in the donor and allograft outcomes in the recipient.”

Source: [KDIGO (2021)](https://kdigo.org/wp-content/uploads/2017/02/KDIGO-Glomerular-Diseases-Guideline-2021-English.pdf)

<a id="topic-2.2.2.1.8-7"></a>

###### Implications for kidney transplantation: KDIGO 2025 APOL1 conference report

> “In the United States, living donors with APOL1 high-risk genotypes more often develop advanced CKD post donation”
> “but recipients with high-risk APOL1 genotypes may also have reduced graft survival.”
> “Agents must be shown to be safe in the transplant setting, including lack of interaction with immunosuppressive agents.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

<a id="topic-2.2.2.1.8-8"></a>

###### Monitoring for recurrent HIVAN after transplantation

> “Given the strong association between the APOL1 risk variants and HIVAN, HIV-positive recipients of African descent and those who receive an allograft from a donor of African descent should be monitored for recurrent HIVAN.”

Source: [Swanepoel et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5983378/)

<a id="heading-2.2.2.1.9"></a>

###### 2.2.2.1.9 Limitations of Current Therapies

<a id="topic-2.2.2.1.9-1"></a>

###### Summary: limitations of current therapies

No therapy directed at APOL1-mediated kidney disease is approved; the KDIGO 2025 conference report states that there are “no established treatments or treatment recommendations for APOL1 kidney disease”, and a 2021 Delphi consensus agreed that “No specific treatment is currently available”. KDIGO guidelines recommend RAS blockade, blood pressure control, and dietary salt restriction for adults with FSGS, and an SGLT2 inhibitor for adults with CKD who meet the criteria the guideline specifies. In AASK, the primary kidney outcome occurred in 58.1% of participants with a high-risk genotype and 36.6% of those with a low-risk genotype (hazard ratio 1.88), with no interaction between APOL1 status and the randomized blood-pressure goal or antihypertensive drug. In the FSGS Clinical Trial, APOL1 genotype did not affect proteinuria response to cyclosporine or mycophenolate mofetil with dexamethasone, but participants with the high-risk genotype were more likely to progress to ESRD. In DUPLEX, sparsentan reduced proteinuria more than irbesartan without a significant difference in eGFR slope at 108 weeks, and the APOL1 high-risk subgroup comprised 14 participants. In a real-world cohort of 1,332 people with AMKD, 35.7% had a RAAS inhibitor fill or administration and 10.5% an SGLT2 inhibitor, and 45.7% had CKD stage 4 or 5.

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/); [Freedman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8425659/); [Parsa et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3969022/); [Kopp et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4446865/); [Rheault et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37921461/); [Yee et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13065193/); [AJMC (2026)](https://www.ajmc.com/view/real-world-amkd-data-highlight-quick-progression-unmet-needs); [KDIGO (2021)](https://kdigo.org/wp-content/uploads/2017/02/KDIGO-Glomerular-Diseases-Guideline-2021-English.pdf); [KDIGO (2024)](https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf)

<a id="topic-2.2.2.1.9-2"></a>

###### No approved disease-directed therapy

> “There are no established treatments or treatment recommendations for APOL1 kidney disease, and APOL1 genotype results are not by themselves actionable for changing management.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

> “A24. No specific treatment is currently available for patients with APOL1-associated nephropathy”
> “There is currently no specific treatment or management protocol for APOL1-associated nephropathy, and so, the clinical value of APOL1 testing in routine clinical practice has not been established.”

Source: [Freedman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8425659/)

> “Although there is currently no approved treatment for AMKD, multiple therapeutic trials are ongoing.”

Source: [Hopper and Olabisi (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11462457/)

> “There are no therapies currently approved for AMKD.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="topic-2.2.2.1.9-3"></a>

###### Progression despite blood pressure control and RAS inhibition

> “In conclusion, renal high-risk variants in APOL1 were associated with an increased risk of progression of chronic kidney disease among black patients, even among those with well-controlled blood pressure.”
> “Currently, therapeutic options to retard disease progression are limited.”

Source: [Parsa et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3969022/)

> “As such, many patients with APOL1-associated nephropathy who present with subnephrotic proteinuria are misclassified as having unspecified CKD or hypertension-attributed CKD, although intensive BP control does not slow kidney disease progression.”

Source: [Freedman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8425659/)

<a id="topic-2.2.2.1.9-4"></a>

###### Residual disease burden and treatment utilization in real-world AMKD

> “Hypertension (88.9%), hyperlipidemia (42.3%), and chronic pulmonary disease (23.1%) were the most common comorbidities, and 45.7% of patients were in CKD stage 4 or 5.”
> “Variable treatment utilization and substantial residual disease burden underscore the significant unmet need for targeted therapies that address the underlying disease pathophysiology,”

Source: [AJMC (2026)](https://www.ajmc.com/view/real-world-amkd-data-highlight-quick-progression-unmet-needs)

<a id="heading-2.2.2.2"></a>

##### 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

###### Summary: anticipated place in therapy

Inaxaplin is investigational, and no labeled indication exists. The pivotal AMPLITUDE trial enrolls participants aged 10 to 65 years with two APOL1 variants (G1/G1, G2/G2, or G1/G2), a urine protein to creatinine ratio (UPCR) of 0.7 to less than 10 g/g, and an eGFR of 25 to less than 75 mL/min/1.73 m2, and excludes people with diabetes mellitus, a solid organ or bone marrow transplant, or another known cause of kidney disease. Inaxaplin is given as 45 mg once daily on top of standard of care. Vertex states that a positive AMPLITUDE interim analysis could form the basis for potential U.S. accelerated approval, and Vertex investor relations stated that AMPLITUDE could unlock a population of about 150,000 people in the U.S. and Europe. Vertex estimates approximately 100,000 further people with AMKD and comorbidities such as type 2 diabetes. The phase 2 AMPLIFIED study dosed 41 participants with modest proteinuria (cohort 1, n=23) or with type 2 diabetes (cohort 2, n=18), populations Vertex describes as not being studied in AMPLITUDE, and Fierce Biotech reported that an FDA label covering both cohorts would add about 100,000 people to the target population.

Use would depend on APOL1 genotyping. A Vertex-sponsored test describes a genetic test for two APOL1 risk variants as required for a definitive diagnosis of AMKD; trial eligibility used a Vertex-designated investigational assay, and the Vertex-sponsored Labcorp test states that it has not been cleared or approved by the FDA. A Delphi consensus panel agreed that nephrologists should counsel patients about APOL1 high-risk genotypes, order the test, and return results, and that if a treatment becomes available all patients suspected of having APOL1-associated nephropathy should be offered genetic testing with counseling. The KDIGO Controversies Conference report states that when treatments become available, “patient access to nephrologists with experience or knowledge of APOL1 kidney disease will be paramount”. In a U.S. real-world cohort of 1,332 people with AMKD, 45.7% had CKD stage 4 or 5 at a mean age of 45.6 years, 35.7% had at least one administration or fill of a RAAS inhibitor, and 10.5% of an SGLT2 inhibitor.

Source: [Chertow et al. (2024)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.20241x7qn0bv~amplitude-a-phase-23-adaptive-trial-of-inaxaplin-in); [ClinicalTrials.gov NCT05312879](https://clinicaltrials.gov/study/NCT05312879); [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study); [Vertex Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/vrtx-20251231.htm); [Fierce Biotech (2026)](https://www.fiercebiotech.com/biotech/vertexs-midstage-data-amplify-kidney-disease-market-opportunity); [ClinicalTrials.gov NCT06794996](https://clinicaltrials.gov/study/NCT06794996); [Labcorp](https://www.labcorp.com/tests/407154/apol1-genotyping); [Freedman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8425659/); [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/); [AJMC (2026)](https://www.ajmc.com/view/real-world-amkd-data-highlight-quick-progression-unmet-needs)

<a id="topic-2.2.2.2-2"></a>

###### Target population of the pivotal AMPLITUDE trial

> “Our Ph2/3, randomized, double-blind, placebo-controlled, adaptive trial is enrolling persons (Ph2:18-65yrs; Ph3:10-65yrs) with 2 APOL1 variants, UPCR≥0.7 to <10g/g, and eGFR≥25 to <75mL/min/1.73m2.”
> “Our Ph2/3 trial will evaluate the effects of IXP on preserving kidney function and reducing proteinuria in a broad AMKD population.”

Source: [Chertow et al. (2024)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.20241x7qn0bv~amplitude-a-phase-23-adaptive-trial-of-inaxaplin-in)

> “APOL1 genotype of G1/G1, G2/G2, or G1/G2”
> “Solid organ or bone marrow transplant”
> “Uncontrolled hypertension”
> “History of diabetes mellitus”
> “Known underlying cause of kidney disease including but not limited to sickle cell disease”

Source: [ClinicalTrials.gov NCT05312879](https://clinicaltrials.gov/study/NCT05312879)

<a id="topic-2.2.2.2-3"></a>

###### Manufacturer estimates of the AMKD population, including people with comorbidities

> “AMKD occurs in people with African ancestry, with an estimated patient population of approximately 150,000 people in the U.S. and Europe.”
> “In addition, we estimate that there are approximately 100,000 people with AMKD with comorbidities, such as type 2 diabetes, in the U.S. and Europe”
> “Our serial innovation strategy in AMKD focuses on indication expansion: evaluating inaxaplin in new populations of people with AMKD not included in the AMPLITUDE clinical trial.”

Source: [Vertex Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/vrtx-20251231.htm)

> “Vertex has completed full enrollment in the Phase 2/3 AMPLITUDE study of inaxaplin in people with severe proteinuria and no other kidney disease-causing comorbidities.”
> “If positive, the data could form the basis for potential accelerated approval in the U.S.”
> “AMKD affects approximately 150,000 people in the U.S. and Europe. There are no therapies currently approved for AMKD.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="topic-2.2.2.2-4"></a>

###### Populations evaluated beyond the pivotal trial: AMPLIFIED

> “Forty-one people were enrolled and dosed in two cohorts: 1) people with AMKD with modest proteinuria (UACR ≥0.1 g/g to <0.42 g/g) were eligible for cohort 1 (N=23), and 2) people with AMKD, type 2 diabetes and proteinuria (UACR ≥0.1 g/g to <6 g/g) were eligible for cohort 2 (N=18).”
> “AMPLIFIED is a Phase 2, single-arm, open-label study evaluating the effect of treatment with a 45 mg once-daily dose of inaxaplin for 13 weeks to reduce proteinuria in people with AMKD with modest proteinuria, and people with AMKD and type 2 diabetes”
> “populations not being studied in the AMPLITUDE trial.”
> “We look forward to discussing the AMPLIFIED results with regulators in the context of the AMPLITUDE pivotal study.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

> “Given the potential of IXP to treat AMKD, it is essential to assess its efficacy in a broader population, including many of whom have comorbidities that may independently contribute to chronic kidney disease and accelerate disease progression.”
> “AMPLIFIED is a phase 2, open-label study evaluating the efficacy of IXP to reduce proteinuria in 45 participants (ages 18-67yrs) with proteinuric AMKD who have none (Cohort 1,n=15) or one of the following significant comorbidities: type 2 diabetes mellitus (Cohort 2,n=15), sickle-cell disease (Cohort 3,n=5), human immunodeficiency virus (Cohort 3,n=5), or lupus nephritis (Cohort 3,n=5).”

Source: [Chertow et al. (2025b)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.20252q319dky~inaxaplin-for-a-broad-population-with-apol1-mediated-kidney)

<a id="topic-2.2.2.2-5"></a>

###### Size of the target population by scope of a future label

> “Amplitude could unlock a population with about 150,000 patients in the U.S. and Europe, Susie Lisa, senior vice president of investor relations at Vertex, said at a Wells Fargo event this week.”
> “An FDA label covering the two arms in Amplified would add about 100,000 patients to the target population.”

Source: [Fierce Biotech (2026)](https://www.fiercebiotech.com/biotech/vertexs-midstage-data-amplify-kidney-disease-market-opportunity)

<a id="topic-2.2.2.2-6"></a>

###### Use in addition to standard of care

> “Inaxaplin is being evaluated as a 45 mg once-daily oral dose compared to placebo, on top of standard of care.”
> “In this study, inaxaplin was evaluated as a 45 mg once-daily dose on top of optimized standard of care.”
> “These patients were already well treated with foundational chronic kidney disease therapies and treatment with inaxaplin led to additional reductions in proteinuria.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="topic-2.2.2.2-7"></a>

###### APOL1 genotyping as the gatekeeper to diagnosis and eligibility

> “A definitive diagnosis of AMKD requires a genetic test for the presence of two APOL1 risk variants”
> “This test is sponsored by Vertex and should only be ordered on eligible patients. Eligible patients include those of African ancestry who may self-identify as Black, African American, African or Afro-Caribbean, a diagnosis of chronic kidney disease, no history of kidney transplant, do not have diabetes and must not be currently treated with dialysis.”
> “This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.”

Source: [Labcorp](https://www.labcorp.com/tests/407154/apol1-genotyping)

> “Participant has an APOL1 genotype of G1/G1, G2/G2, or G1/G2 obtained with a Vertex designated investigational clinical study assay”

Source: [ClinicalTrials.gov NCT06794996](https://clinicaltrials.gov/study/NCT06794996)

> “The high prevalence of 2 APOL1 variants in participants with recent African ancestry and proteinuric CKD reinforces the importance of APOL1 genotyping to optimize kidney disease management and enable referral to clinical trials of APOL1-targeted therapies.”

Source: [Chertow et al. (2024)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.20241x7qn0bv~amplitude-a-phase-23-adaptive-trial-of-inaxaplin-in)

<a id="topic-2.2.2.2-8"></a>

###### Expert consensus on testing and treatment initiation once a treatment is available

> “If a treatment for APOL1-associated nephropathy becomes available, all patients suspected of having APOL1-associated nephropathy should be offered genetic testing with appropriate counseling”
> “If a treatment for APOL1-associated nephropathy becomes available, all Black people (or those with sub-Saharan African ancestry) with CKD should be offered genetic testing with appropriate counseling”
> “If a treatment for APOL1-associated nephropathy becomes available, intervention should begin as early as possible in patients with APOL1-associated nephropathy on the basis of data from clinical trials”
> “If a treatment for APOL1-associated nephropathy was available, a kidney biopsy should be performed to confirm the diagnosis in individuals with high-risk APOL1 genotypes”

Source: [Freedman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8425659/)

<a id="topic-2.2.2.2-9"></a>

###### Care setting: nephrology

> “Nephrologists should be responsible for counseling patients in their practice about the APOL1 high-risk genotypes as appropriate, ordering the APOL1 test, and returning results to patients”
> “APOL1 testing is not common in routine clinical practice; it is carried out in only a few specialist centers, often as part of APOL1 research”

Source: [Freedman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8425659/)

> “When treatments become available, patient access to nephrologists with experience or knowledge of APOL1 kidney disease will be paramount, as will affordability of any new therapies.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

<a id="topic-2.2.2.2-10"></a>

###### Current treatment and disease stage among people with AMKD

> “Patients with evidence of diabetes, autosomal dominant polycystic kidney disease, or IgA nephropathy were excluded, leaving 1332 patients with a mean (SD) age of 45.6 (15.4) years.”
> “Hypertension (88.9%), hyperlipidemia (42.3%), and chronic pulmonary disease (23.1%) were the most common comorbidities, and 45.7% of patients were in CKD stage 4 or 5.”
> “Within the study period, 35.7% of patients had at least 1 administration or fill of a RAAS inhibitor, 35% of a calcium channel blocker, 27.9% of a beta blocker, 10.5% of an SGLT2 inhibitor, and 4.4% of a GLP-1 receptor agonist.”

Source: [AJMC (2026)](https://www.ajmc.com/view/real-world-amkd-data-highlight-quick-progression-unmet-needs)

<a id="heading-2.2.2.3"></a>

##### 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

###### Summary: heterogeneity evidence for inaxaplin

The sources reviewed report no inaxaplin efficacy results stratified by APOL1 genotype. Of the 64 participants dosed in AMPLITUDE as of the 2024 abstract, 53.1% had the G1/G1, 37.5% the G1/G2, and 9.4% the G2/G2 genotype; efficacy results from that portion have not been published. The differences in response reported to date are by comorbidity and proteinuria level. In AMPLIFIED, the mean change in UACR at week 13 was -42.7% (95% CI -58.3% to -21.1%) in cohort 1 (modest proteinuria, most without diagnosed FSGS) and -17.3% (95% CI -36.3% to 7.2%) in cohort 2 (type 2 diabetes); the confidence intervals were generated post hoc, and the interval for cohort 2 includes no change. In the phase 2a study, the mean UPCR change was -47.7% in the 3 participants with nephrotic-range proteinuria and -47.5% in those with subnephrotic-range proteinuria, and 1 participant with 100% adherence had no reduction. In vitro, inaxaplin inhibited thallium flux in cells expressing G0, G1, and G2 APOL1; a 2026 abstract reports that inaxaplin partially reduced the cytotoxicity of full-length APOL1-G1 and did not rescue toxicity from a nuclear APOL1-G1 fragment produced by cathepsin S. For existing therapies, APOL1 genotype did not modify the effect of blood pressure target or ACE inhibitor treatment on CKD progression in AASK, and did not affect proteinuria response to cyclosporine or mycophenolate mofetil plus dexamethasone in the FSGS Clinical Trial; in AASK, strict blood pressure control was associated with 42% lower mortality in the high-risk genotype group only.

Source: [Chertow et al. (2024)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.20241x7qn0bv~amplitude-a-phase-23-adaptive-trial-of-inaxaplin-in); [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study); [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396); [Li et al. (2026b)](https://doi.org/10.1681/ASN.2026jtffd5vb); [Parsa et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3969022/); [Kopp et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4446865/); [Ku et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5237400/)

<a id="topic-2.2.2.3-2"></a>

###### Inaxaplin: response by cohort in AMPLIFIED (modest proteinuria and type 2 diabetes)

> “In cohort 1, treatment with inaxaplin administered on top of optimized standard of care led to a reduction of -42.7% (95% CI -58.3%, -21.1%) in UACR at Week 13 compared to baseline. UPCR decreased by -44.7% from baseline at Week 13.”
> “In this modest proteinuria cohort, most people were not diagnosed with FSGS.”
> “In cohort 2, treatment with inaxaplin administered on top of optimized standard of care led to a reduction in UACR at Week 13 of -17.3% (95% CI -36.3%, 7.2%) compared to baseline. UPCR decreased by -25.4% from baseline at Week 13.”
> “We are also excited with the treatment effect, though smaller in magnitude, in the type 2 diabetes cohort.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="topic-2.2.2.3-3"></a>

###### Inaxaplin: response by baseline proteinuria range in the phase 2a study

> “Reduction in proteinuria was seen in both the nephrotic- and subnephrotic-range groups (mean change in the urinary protein-to-creatinine ratio, −47.7% and −47.5%, respectively) (Table 2) and was unrelated to background standard-care medications.”
> “One participant with subnephrotic-range proteinuria did not have a decrease in proteinuria with inaxaplin therapy in our study. The adherence to treatment in this participant was 100%; neither the lead country investigator nor the treating nephrologist could identify any clinical characteristics that might have influenced the lack of treatment response.”
> “Although only three participants with nephrotic-range proteinuria were enrolled in this study, the results in these participants appeared to be consistent with those observed in participants who had less-severe proteinuria.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-2.2.2.3-4"></a>

###### Inaxaplin: APOL1 genotype distribution in the AMPLITUDE phase 2 portion

> “Among 64 participants dosed, 34(53.1%), 24(37.5%), and 6(9.4%) have G1/G1, G1/G2, or G2/G2 genotypes.”

Source: [Chertow et al. (2024)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.20241x7qn0bv~amplitude-a-phase-23-adaptive-trial-of-inaxaplin-in)

<a id="topic-2.2.2.3-5"></a>

###### Inaxaplin: in vitro activity against G0, G1, and G2 APOL1

> “Specifically, in cellular assays, inaxaplin blocked the channel function of APOL1 in a concentration-dependent manner, as shown by the reduced APOL1-induced thallium ion flux in tetracycline-inducible APOL1 HEK293 cells (Figure 1A).”
> “Panel A shows the percent inhibition of thallium ion flux in cell lines expressed by the apolipoprotein L1 (APOL1) reference sequence (G0) and disease-associated variants APOL1 G1 and APOL1 G2 as a function of inaxaplin concentration.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-2.2.2.3-6"></a>

###### Inaxaplin: preclinical APOL1-G1 fragments resistant to channel inhibition

> “Cytotoxicity assays were used to compare the effects of full-length APOL1-G1 and APOL1-G1 fragments, including their responses to the APOL1 channel inhibitor Inaxaplin.”
> “Notably, Inaxaplin partially reduced cytotoxicity induced by full-length APOL1-G1 but failed to rescue toxicity induced by the nuclear APOL1-G1 fragment.”
> “Our findings support a novel inflammatory mechanism in which IFN-γ promotes Cathepsin S–dependent processing of APOL1-G1 into toxic fragments that contribute to podocyte injury through membrane-independent pathways potentially resistant to current APOL1 channel inhibitors.”

Source: [Li et al. (2026b)](https://doi.org/10.1681/ASN.2026jtffd5vb)

<a id="topic-2.2.2.3-7"></a>

###### Inaxaplin: populations not yet studied

> “The effects of inaxaplin therapy in this short-term clinical study involving participants with two APOL1 variants and biopsy-proven focal segmental glomerulosclerosis (a severe, rapidly progressive form of proteinuric CKD) remain to be studied in persons with two APOL1 variants and other types of proteinuric CKD, such as hypertensive kidney disease.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-2.2.2.3-8"></a>

###### Genotype refinement: the p.N264K modifier of APOL1 G2

> “The APOL1 p.N264K variant was recently found to genetically and almost completely negate the effect of G2 risk alleles to levels comparable to G0, and this observation has been replicated in subsequent studies, making APOL1 p.N264K the most robust genetic modifier of APOL1 G2 to date.”
> “Increase utilization of p.N264K in inclusion criteria of clinical trials.”
> “Determine the effects of conventional therapies for FSGS and other glomerular diseases in those with APOL1 high-risk genotypes.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

<a id="topic-2.2.2.3-9"></a>

###### Blood pressure target and ACE inhibitor by APOL1 genotype: AASK

> “In the AASK study, the primary outcome occurred in 58.1% of the patients in the APOL1 high-risk group and in 36.6% of those in the APOL1 low-risk group (hazard ratio in the high-risk group, 1.88; P<0.001). There was no interaction between APOL1 status and trial interventions or the presence of baseline proteinuria.”
> “Although baseline proteinuria was a major predictor of disease progression, it did not significantly modify the effect of APOL1 on progression (P = 0.16 for interaction) (Fig. 1B). In addition, there was no significant interaction between APOL1 status and the randomized blood-pressure goal with respect to the progression of chronic kidney disease (P = 0.72 for interaction) (Fig. 1C), nor was there a significant interaction between APOL1 status and the randomized antihypertensive medication with respect to progression (P = 0.72 for interaction)”
> “The lack of significant interaction between APOL1 and treatment with an ACE inhibitor suggests that patients in the APOL1 high-risk group still benefit from this class of drugs.”

Source: [Parsa et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3969022/)

<a id="topic-2.2.2.3-10"></a>

###### Mortality with strict blood pressure control by APOL1 genotype: AASK

> “However, a significant interaction was detected between APOL1 risk group and blood pressure control strategy. In the APOL1 high-risk group, risk of death was 42% lower comparing strict versus usual blood pressure control (0.58 [0.35-0.97]). In the APOL1 low-risk group, risk of death comparing strict versus usual blood pressure control was not significantly different (1.09 [0.84-1.43]).”

Source: [Ku et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5237400/)

<a id="topic-2.2.2.3-11"></a>

###### Other modifiers of APOL1-associated progression: AASK

> “Sociodemographic factors and common risk factors for CKD progression do not seem to alter APOL1–related CKD progression. Additional investigation is needed to identify nontraditional factors that may affect the association between APOL1 and progressive CKD.”

Source: [Chen et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4670769/)

<a id="topic-2.2.2.3-12"></a>

###### Immunosuppression response by APOL1 genotype: FSGS Clinical Trial

> “APOL1 risk genotype did not affect response to either treatment regimen. Individuals with the risk genotype were more likely to progress to ESRD (P<0.01).”
> “The APOL1 risk genotype did not influence proteinuria responses to cyclosporin or mycophenolate mofetil/dexamethasone.”

Source: [Kopp et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4446865/)

<a id="topic-2.2.2.3-13"></a>

###### Baseline progression risk by diabetes status in proteinuric AMKD

> “Almost all subgroups, which were defined by diabetes status and baseline eGFR cutoffs, experienced eGFR decline faster than 3 mL/min per year, with faster declines in patients with diabetes. In the pooled cohort with baseline eGFR below 90 mL/min/1.73 m2, the mean annual eGFR slope was –3.0 mL/min/1.73 m2 (95% CI, –3.3 to –2.7) in patients without diabetes and –4.2 mL/min/1.73 m2 (95% CI, –4.5 to –3.9) in patients with type 2 diabetes.”

Source: [AJMC (2026)](https://www.ajmc.com/view/real-world-amkd-data-highlight-quick-progression-unmet-needs)

<a id="heading-2.2.2.4"></a>

##### 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

###### Delphi consensus: counseling before and after APOL1 testing

> “Patients should have a clear understanding of the purpose of the APOL1 test and the potential implications of the result before the test is taken”
> “When health care professionals discuss APOL1 testing with their patients, they should be honest and transparent about the current understanding of APOL1, take time to discuss APOL1 with patients, listen to their concerns, answer questions, and provide information sources that are balanced, easy to use and understand, and reliable”
> “After a patient with CKD is confirmed to have a high-risk APOL1 genotype, the clinician should:”
> “Encourage the patient to participate in clinical trials for which they are eligible”
> “Inform the patient about other modifiable risk factors and renoprotective measures (lifestyle changes, BP control)”
> “There is no established best practice for counseling patients about APOL1 testing; further research is required to define best practice”
> “Nephrology trainees need to be educated to be able to confidently deliver effective counseling to patients about APOL1 testing”

Source: [Freedman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8425659/)

<a id="topic-2.2.2.4-2"></a>

###### Delphi consensus: barriers to testing

> “Clinicians’ lack of confidence in communicating the findings from APOL1 testing to patients in a clear and effective way that minimizes patient confusion and misunderstanding is a major barrier to APOL1 testing in patients with nephropathy”
> “Low levels of trust in the medical establishment could be a barrier to APOL1 testing in the Black community”
> “The lack of specific treatment and concerns regarding insurance reimbursement for genetic testing and potential discrimination on the basis of APOL1 genotype (e.g., life insurance, health insurance, job security) may be barriers to physicians educating patients about APOL1-associated nephropathy”

Source: [Freedman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8425659/)

<a id="topic-2.2.2.4-3"></a>

###### Delphi consensus: disease awareness and community education

> “There are low levels of awareness of APOL1-associated nephropathy in the Black community”
> “Nephrologists, primary care providers, nurses, community leaders, and patient networks all have an important role to play in educating Black patients with nephropathy about the APOL1 gene”
> “To improve awareness of APOL1 among the patient community, health care professionals should work with community leaders and community groups and should provide education in a setting that is familiar and comfortable for patients”

Source: [Freedman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8425659/)

<a id="topic-2.2.2.4-4"></a>

###### KDIGO Controversies Conference: requirements for operating APOL1 testing and community engagement

> “For operationalizing genetic testing, the following are necessary: a validated test in a registered laboratory with appropriately trained staff; pre- and post-testing counseling; availability of co-designed educational material tailored to levels of health literacy; and a process for early surveillance and intervention, including in children. In high prevalence populations, community leaders, content experts, and faith leaders should be engaged to facilitate community education initiatives.”
> “Authentic community engagement is critical in designing and implementing APOL1 prevalence and research studies, testing in clinical care, as well as communicating how findings inform recommendations.”
> “Established guidance on disclosure of genetic test results to family members (cascade testing) should be followed.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

<a id="topic-2.2.2.4-5"></a>

###### KDIGO Controversies Conference: principles for deciding on APOL1 testing

> “Appropriately qualified counseling is available to support voluntary and informed decision-making about testing.”
> “CKD care and screening are available AND APOL1 test results could change management (e.g., an effective treatment for APOL1 is available OR results could lead to increased surveillance for CKD OR results would inform risk/benefit evaluation in decision-making about living kidney donation).”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

<a id="topic-2.2.2.4-6"></a>

###### KDIGO Controversies Conference: community outreach for clinical trial participation

> “To raise awareness about CKD and APOL1 kidney disease as well as encourage participation in clinical trials, community outreach is required to develop, strengthen, and sustain relationships with trusted community leaders and partners.”
> “As the understanding of and treatments for APOL1 kidney disease are further developed, engagement and education of communities and health care professionals, including those in primary care, will be key in improving patient health in all regions affected.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

<a id="topic-2.2.2.4-7"></a>

###### Genetic counseling and surveillance after a high-risk result

> “All individuals should receive genetic counseling before and after APOL1 genetic testing and be advised about potential for increased cost of health insurance that may be associated with detection of a high-risk APOL1 genotype. When individuals are noted to have a high-risk genotype, physicians may consider more frequent screening for reduced GFR and proteinuria to identify AMKD at an early stage.”

Source: [Hopper and Olabisi (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11462457/)

<a id="topic-2.2.2.4-8"></a>

###### KDIGO 2024 CKD guideline: genetic testing and counseling

> “Genetic testing is emerging as a valuable component for evaluation of cause.”
> “Access to genetic counseling and medical genetics is important for psychosocial support, appropriate use of genetic testing, and to limit costs.”

Source: [KDIGO (2024)](https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf)

<a id="topic-2.2.2.4-9"></a>

###### Manufacturer-sponsored no-cost APOL1 testing program

> “Through this program, Labcorp will perform testing using the lab-developed APOL1 Genotype Test. Each patient that meets the eligibility criteria will receive one Labcorp APOL1 Genotype Test and will have access to genetic results counseling included in the program at no cost to the patient.”
> “No patients, providers, and/or third-party payers (including commercial health plans and government health care programs) will be billed for the APOL1 testing covered under the program.”
> “Labcorp and Vertex Pharmaceuticals reserve the right to rescind, revoke or amend the program for any reason without notice.”

Source: [Labcorp](https://www.labcorp.com/tests/407154/apol1-genotyping)

<a id="topic-2.2.2.4-10"></a>

###### Returning APOL1 results to patients with hypertension: randomized trial

> “This pragmatic randomized clinical trial randomly assigned 2050 adults of African ancestry with hypertension and without existing chronic kidney disease in 2 US health care systems from November 1, 2014, through November 28, 2016; the final date of follow-up was January 16, 2018.”
> “At 3 months, the mean (SD) change in systolic blood pressure was significantly greater in patients with high-risk APOL1 genotypes vs those with low-risk APOL1 genotypes (6 [18] vs 3 [18] mm Hg; P = .004) and controls (6 [18] vs 3 [19] mm Hg; P = .01).”

Source: [Nadkarni et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8897752/)

<a id="topic-2.2.2.4-11"></a>

###### Manufacturer disease awareness campaign

> “an educational initiative aimed at raising awareness of APOL1-mediated kidney disease (AMKD), highlighting the importance of early diagnosis and genetic testing.”
> “Diagnosis depends on a urine test to detect proteinuria, and blood tests to detect reduced kidney function and the two APOL1 risk variants.”

Source: [Vertex Pharmaceuticals press release, AMKD awareness partnership (2022)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-partnership-basketball-hall-famer-alonzo)

<a id="topic-2.2.2.4-12"></a>

###### Transplant center APOL1 testing policies: Delphi panel

> “Key elements of consensus include the following: ask potential donors about African ancestry rather than race; make testing decisions only after discussion with donors; encourage disclosure of test results to blood relatives and organ recipients but do not require it; use test results to inform decision making, but never for unilateral decisions by transplant programs.”

Source: [McIntosh et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11020447/)

<a id="heading-2.2.2.5"></a>

##### 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

Not applicable.

<a id="heading-2.2.2.6"></a>

##### 2.2.2.6 Ongoing Post-approval Monitoring

Not applicable.

<a id="heading-2.2.2.7"></a>

##### 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

###### Summary: expected outcomes

AMPLITUDE is designed to assess the effect of inaxaplin on kidney function and proteinuria. In the phase 2a study, proteinuria decreased by day 15 and continued to decrease through week 13. The phase 2a study reported a mean UPCR change of -47.6% (95% CI -60.0 to -31.3) at week 13; its authors cite data from nearly 30,000 participants in which a 30% albuminuria reduction corresponded to a 27% lower risk of a composite kidney endpoint, and state as a hypothesis to be tested that a longer treatment period may prevent or slow progression to end-stage kidney disease. The AMPLITUDE final analysis uses eGFR slope after two years as the primary efficacy endpoint and time to a composite of a sustained eGFR decline of 30% or more, end-stage kidney disease, or death as the secondary endpoint, assessed when approximately 187 composite outcomes have occurred. Across CKD trials, each 30% reduction in albuminuria was associated with a 27% lower hazard of the clinical endpoint (41 treatment comparisons, 29,979 participants) or a 19% lower hazard (48 trials, 85,681 participants), and a 0.75 mL/min/1.73 m2 per year greater treatment effect on total GFR slope with a 23.3% lower hazard. In FSGS, a partial remission defined as a 40% proteinuria reduction with proteinuria below 1.5 g/g was associated with less progression (hazard ratio 0.30 at month 8), and a 2025 review found that further work is needed to define a treatment effect short of complete remission as an endpoint. The only AMKD-specific analysis found, a preprint of 128 participants, estimated that a 50% reduction in UACR at 12 months was associated with a 28% lower risk of a kidney composite endpoint. The sources reviewed give no estimate of the delay in kidney failure expected with inaxaplin; Vertex states that people with AMKD reach kidney failure at a median age of 45 years.

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396); [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study); [Vertex Pharmaceuticals press release, kidney portfolio advancements (2025)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-key-advancements-across-kidney-portfolio); [Heerspink et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30635226/); [Heerspink et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41198855/); [Inker et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13037386/); [Troost et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5967666/); [Mariani et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12014854/); [Mamak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13278290/); [Vertex Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/vrtx-20251231.htm)

<a id="topic-2.2.2.7-2"></a>

###### Inaxaplin: proteinuria reduction and the hypothesized effect on progression

> “For the 13 evaluable participants, the mean change in the urinary protein-to-creatinine ratio of −47.6% (95% confidence CI, −60.0 to −31.3) was observed at week 13.”
> “A reduction in proteinuria or albuminuria of more than 40% is considered to be clinically meaningful on the basis of data from nearly 30,000 patients, in whom a 30% reduction in albuminuria translated to a 27% reduction in the risk of a composite clinical end point of end-stage kidney disease, an estimated GFR below 15 ml per minute per 1.73 m2, or a doubling of the serum creatinine level (57% reduction in the estimated GFR).”
> “Collectively, these data provide a rationale to test the hypothesis that with a longer treatment period, inaxaplin therapy may prevent or slow progression to end-stage kidney disease.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-2.2.2.7-3"></a>

###### AMPLITUDE: endpoints that will measure clinical outcomes

> “The primary efficacy endpoint for the final analysis is estimated glomerular filtration rate (eGFR) slope in patients receiving inaxaplin compared to placebo after two years of treatment.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

> “The AMPLITUDE study is designed with an interim analysis at Week 48 in a pre-specified number of patients to assess percent change from baseline in proteinuria and eGFR slope in the inaxaplin arm versus placebo.”
> “The secondary efficacy endpoint is time to composite clinical outcome, which will also be assessed at the final analysis and is defined as a sustained decline of ≥30% from baseline in the eGFR, the onset of end-stage kidney disease or death. The final study analysis will occur when subjects have at least two years of eGFR data and when approximately 187 composite clinical outcomes have occurred.”

Source: [Vertex Pharmaceuticals press release, kidney portfolio advancements (2025)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-key-advancements-across-kidney-portfolio)

<a id="topic-2.2.2.7-4"></a>

###### Albuminuria change as a surrogate endpoint: meta-analysis of 41 treatment comparisons

> “We identified 41 eligible treatment comparisons from randomised trials (referred to as studies) that provided sufficient patient-level data on 29 979 participants (21 206 [71%] with diabetes).”
> “Across all studies, with a meta-regression slope of 0·89 (95% Bayesian credible interval [BCI] 0·13-1·70), each 30% decrease in geometric mean albuminuria by the treatment relative to the control was associated with an average 27% lower hazard for the clinical endpoint (95% BCI 5-45%; median R2 0·47, 95% BCI 0·02-0·96).”

Source: [Heerspink et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30635226/)

<a id="topic-2.2.2.7-5"></a>

###### Albuminuria change as a surrogate endpoint: meta-analysis of 48 trials

> “Here, in an individual participant data analysis of 48 randomized controlled trials (studies) involving 85,681 participants, we assessed the association between treatment effects on 6-month urinary albumin:creatinine ratio (UACR) change and the established clinical endpoint of kidney failure or doubling of serum creatinine concentrations.”
> “Across all trials, each 30% reduction in the geometric mean of the UACR in the treatment group relative to the control group was associated with an average of 19% lower hazard for the clinical endpoint (95% Bayesian credible interval (BCI): 5-30%); median coefficient of determination (R2) = 0.66 (95% BCI: 0.06-0.98). There was no clear evidence that this association varied by CKD etiology.”

Source: [Heerspink et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41198855/)

<a id="topic-2.2.2.7-6"></a>

###### GFR slope as a surrogate endpoint: meta-analysis of 66 studies

> “Treatment effects on the clinical endpoint were strongly associated with treatment effects on total slope (median R2=0.97 [95% Bayesian credible interval [BCI] 0.82 to 1.00]), and moderately associated with those on chronic slope (R2=0.55 [95% BCI 0.25 to 0.77]). There was no evidence of heterogeneity across disease. Our results support use of total slope as a primary endpoint for clinical trials of CKD progression.”
> “indicating that a 0.75 ml/min per 1.73 m2/year greater beneficial effect of the treatment on the total GFR slope is associated with an average 23.3% lower hazard ratio for the clinical end point (95% BCI 19.3% to 27.2%)”

Source: [Inker et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13037386/)

<a id="topic-2.2.2.7-7"></a>

###### Albuminuria and GFR slope as joint surrogate endpoints

> “The predicted probability of clinical benefit when considering both surrogates was determined primarily by estimated treatment effects on UACR when sample size was small (approximately 60 patients per treatment arm) and follow-up brief (approximately 1 year), with the importance of GFR slope increasing for larger sample sizes and longer follow-up.”

Source: [Heerspink et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10278784/)

<a id="topic-2.2.2.7-8"></a>

###### National Kidney Foundation, FDA, and EMA scientific workshop on surrogate endpoints

> “In March 2018, the National Kidney Foundation sponsored a scientific workshop in collaboration with the FDA and EMA to evaluate changes in albuminuria or GFR as candidate surrogate end points.”
> “We conclude that both early change in albuminuria and GFR slope fulfill criteria for surrogacy for use as end points in clinical trials for chronic kidney disease progression under certain conditions, with stronger support for change in GFR than albuminuria.”

Source: [Levey et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31473020/)

<a id="topic-2.2.2.7-9"></a>

###### Proteinuria remission and kidney survival in FSGS

> “A novel definition of partial remission (40% proteinuria reduction and proteinuria<1.5 g/g) on the basis of receiver operating curve analyses of 89 patients was identified (Sensitivity=0.70; Specificity=0.77).”
> “Propensity score–adjusted analyses showed the novel partial remission was associated with less progression at months 4 and 8 (month 4: hazard ratio, 0.50; P=0.01; month 8: hazard ratio, 0.30; P=0.002).”

Source: [Troost et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5967666/)

> “A 1 unit reduction in log-transformed urinary protein:creatinine ratio was associated with a 3.90 ml/year rise in eGFR (95% CI=2.01 to 5.79).”
> “There was an analogous relationship between time-varying proteinuria and time to end-stage kidney disease: the HR for ESKD or death per 1 unit reduction in log-transformed urinary protein-creatinine ratio was 0.23 (95% CI=0.12 to 0.44).”

Source: [Troost et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7854818/)

<a id="topic-2.2.2.7-10"></a>

###### Proteinuria endpoints in FSGS trials: Kidney Health Initiative review

> “Available data support the use of complete remission of proteinuria in patients with heavy proteinuria as a surrogate endpoint for progression to kidney failure. While substantial treatment effects on proteinuria that are short of a complete remission may also predict the effect of a treatment on progression to kidney failure, further work is needed to determine how such an endpoint should be defined.”

Source: [Mariani et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12014854/)

<a id="topic-2.2.2.7-11"></a>

###### Reasonably likely surrogate endpoints and accelerated approval

> “We conclude that data support the use of proteinuria reduction as a reasonably likely surrogate end point for a treatment’s effect on progression to ESKD in IgAN. In the United States, reasonably likely surrogate end points can be used as a basis for accelerated approval of therapies intended to treat serious or life-threatening conditions, such as IgAN. The clinical benefit of products approved under this program would need to be verified in a postmarketing confirmatory trial.”

Source: [Thompson et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6419287/)

<a id="topic-2.2.2.7-12"></a>

###### Albuminuria change as a surrogate endpoint in AMKD: real-world analysis (preprint)

> “Recently, proteinuria has been accepted as a surrogate end point for clinical trials in focal segmental glomerulosclerosis (FSGS) ang IgA nephropathy. However, proteinuria has not been evaluated in Apolipoprotein L1 (APOL1)-mediated kidney disease (AMKD).”
> “Real world data (RWD) analysis of 128 patients of African ancestry with APOL1 high risk genotypes, without diabetes, enrolled in the Million Veteran Program (MVP; n=109) or the biorepository at Vanderbilt University (BioVU; n=19), who had urine albumin-creatinine ratio (UACR) >= 420 mg/g (PCR~0.9 g/g) with a concurrent GFR value.”
> “It was estimated that a 50% reduction of UACR at 12 months was associated with a 28% reduction in the kidney composite endpoint (adjusted hazard ratio [aHR]=0.72; 95% confidence interval [CI]:0.59−0.88; p=0.002), and a 38% reduction in the risk of ESKD (aHR=0.62; 95% CI:0.49−0.80; p<0.001).”

Source: [Mamak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13278290/)

<a id="topic-2.2.2.7-13"></a>

###### Expected benefits of an APOL1-targeted treatment: expert consensus

> “Important potential benefits of a treatment for APOL1-associated nephropathy becoming available include:”
> “Slowing kidney disease progression”
> “Extending life expectancy”
> “Reducing the incidence of ESKD in the Black population”
> “Reducing the number of people requiring a kidney transplant”

Source: [Freedman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8425659/)

<a id="topic-2.2.2.7-14"></a>

###### Untreated course against which benefit would be measured

> “People with AMKD progress to end stage kidney disease at a faster rate than those with other forms of chronic kidney disease and reach kidney failure at a median age of 45 years old.”

Source: [Vertex Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/vrtx-20251231.htm)

> “For patients with baseline eGFR below 75 mL/min, the median time to a composite of a 30% or greater eGFR decline, end-stage kidney disease, or death ranged from 3 to 5 years across subgroups.”

Source: [AJMC (2026)](https://www.ajmc.com/view/real-world-amkd-data-highlight-quick-progression-unmet-needs)

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
